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Glucocorticoids	 are	 a	 class	 of	 steroid	 hormones	 which	 are	 highly	 relevant	 in	 human	 health	 and	
disease	as	they	are	involved	in	the	regulation	of	carbohydrate,	protein	and	fatty	acid	metabolism	and	
are	 instrumental	 in	 the	 onset	 or	 progression	 of	 various	 diseases	 including	 those	 associated	 with	
glucocorticoid	 deficiency	 or	 excess.	 Their	 importance	 is	 strengthened	 because	 of	 their	
pharmacological	 use	 in	 humans	 including	 in	 immune-mediated	 diseases,	 for	 example,	 the	 use	 of	
cortisol	 for	 the	 treatment	 of	 arthritis.	 The	 regulation	 of	 global	 metabolism	 through	 changes	 in	





application	 in	 untargeted	 metabolomic	 studies	 of	 healthy	 humans	 and	 those	 diagnosed	 with	
glucocorticoid-related	diseases	and	(2)	to	investigate	the	global	and	tissue-specific	metabolic	changes	
induced	 by	 glucocorticoid	 excess	 and	 deficiency	 and	 their	 integrated	 effects	 with	 the	 relevant	
hormone	insulin.		
A	 study	 of	 data	 pre-processing	methods	 applied	 for	 untargeted	 metabolomics	 including	 different	
normalisation,	missing	 value	 imputation,	 transformation	 and	 scaling	methods	were	 investigated	on	
an	 in-silico	modified	dataset.	The	results	showed	that	different	combinations	of	data	pre-processing	
methods	 influenced	 the	 results	 and	 different	 data	 pre-processing	 methods	 should	 be	 applied	 for	
univariate	and	multivariate	analysis.	Specifically,	for	a	non-targeted	metabolomics	study	I	recommend	
the	use	of	probabilistic	quotient	normalization	(PQN)	for	univariate	analysis,	the	use	of	normalization	
by	PQN,	 random	 forest	missing	 value	 imputation	 and	glog	 transformation	 for	principal	 component	
analysis	(PCA)	and	the	permutation	PQN,	k-nearest	neighbour	(KNN)	imputation	and	generalized	log	
transformation	for	partial	least	squares	discriminant	analysis	(PLS-DA).	
Untargeted	metabolomic	 studies	 of	 biofluids	were	 applied	 to	 investigate	 in-vivo	 global	 effects	 of	
glucocorticoids.	The	study	of	the	separate	and	integrated	effects	of	cortisol	and	insulin	showed	that	
insulin	may	have	negating	effects	on	the	 influence	of	cortisol	and	treatment	with	cortisol	should	be	
timed	 appropriately	 during	 the	 day	 to	 minimize	 the	 effect	 of	 insulin	 on	 the	 therapeutic	 effect	 of	
cortisol.	 Furthermore,	 cortisol	 administration	 displayed	 an	 upregulating	 effect	 on	 ceramides	 and	
sphingolipids.	 Whilst	 exposure	 to	 cortisol	 is	 associated	 to	 an	 increase	 in	 glycerophospholipids,	
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Figure	 1.	 Overview	 of	 steroid	 metabolic	 pathways23.	 Progestogens	 are	 highlighted	 in	 yellow,	






Figure	5.	A	generic	 study	workflow	 for	an	untargeted	metabolomics	 study.	The	 instrumental	 setup	
may	 vary	depending	on	 the	 analytical	 platform	as	discussed	 later.	Data	pre-treatment	 and	
data	analysis	methods	may	follow	many	and	diverse	procedures	as	defined	in	chapter	3.	....	46	
Figure	 6.	 Schematic	 representation	 of	 a	Q-Exactive	mass	 spectrometer	 equipped	with	 an	Orbitrap	
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Figure	7.	Schematic	representation	of	an	ESI	process209.	The	ions	that	are	present	in	the	capillary	are	
separated	 from	 ions	 with	 opposite	 charge	 through	 application	 of	 an	 electric	 field.	 In	 the	
central	part	of	the	picture	gas	steam	allows	the	evaporation	of	the	solution	until	creation	of	
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promote	 several	 anabolic	 or	 catabolic	 mechanisms	 such	 as	 the	 glycogenolytic	 actions	 of	
catecholamines	 and	 gluconeogenolytic	 actions	 of	 glucagon1.	 GCs	 also	 interact	 with	 insulin2-4,	
however	this	interaction	may	be	synergic	or	disruptive.	The	loss	of	the	regulatory	mechanisms	of	GCs	
plays	 important	 roles	 in	 a	 number	 of	 human	 diseases	 including	 type	 2	 diabetes	 (T2D)5,	 obesity6,	
Cushing’s	 syndrome7,	 adrenal	 insufficiency8	 and	 the	metabolic	 syndrome9.	 In	 fact,	 these	 disorders	
have	been	proven	to	be	partially	related	to	an	excess	or	deficiency	of	GCs.		Thus,	much	research	has	
focused	on	mechanistic	studies	in	order	to	understand	their	action	and	modulation	in	a	detailed	way.	
GCs	 have	 been	 proven	 to	 have	 an	 effect	 on	 the	 differentiation	 of	 pre-adipocytes	 into	 mature	
adipocytes10.	This	mechanism	is	 involved	 in	the	formation	of	adipose	deposits	and	obesity	which	 is	
also	related	to	insulin	resistance.	One	of	the	first	effects	of	heavy	GC	administration	(or	abnormally	
high	 levels	 of	 endogenous	 GCs)	 is	 Cushing’s	 syndrome.	 This	 condition	may	 easily	 degenerate	 into	
type	 2	 diabetes	which	 occurs	 as	 a	 consequence	of	 a	 long	 period	 of	 insulin-resistance.	 In	 fact,	GCs	
have	been	directly	linked	to	the	impairment	of	β–cells	and	the	inhibition	of	insulin	secretion11.	One	of	
the	mechanisms	which	 causes	 insulin	 sensitivity	 to	 decrease	 is	 the	 suppression	 of	 adiponectin	 by	
GCs.	 Adiponectin	 is	 secreted	 by	 adipocytes	 and	 has	 a	 role	 in	 insulin	 sensitisation.	 In	 2012,	 GC	
administration	was	also	related	to	the	inhibition	of	osteocalcin,	a	protein	which	is	produced	in	bones	
and	 suppresses	 adipose	 tissue	 formation12.	 It	 is	 also	 true	 that	 GCs	 have	 anti-inflammatory	 action;	
	
18	
therefore	 they	 are	 adopted	 in	 many	 therapies	 in	 order	 to	 treat	 immune-mediated	 diseases	 (e.g.	
asthma,	 arthritis,	 sepsis).	 As	 a	 consequence,	 the	 metabolism	 of	 GCs	 has	 been	 highlighted	 as	 an	










precursors	 for	 the	 formation	 of	 estrogens.	 They	 are	 characterized	 by	 a	 keto	 or	 hydroxyl	 group	 at	
carbon	C-1716.	An	androgen	which	has	a	main	role	in	steroid	biosynthesis	is	androstenedione	which	is	
a	nodal	metabolite	for	the	formation	of	more	potent	androgens	or	estrogens	via	17β-hydroxysteroid	
dehydrogenase	 and	 17β-hydroxysteroid	 aromatase	 enzymes.	 Conversely,	 estrogens	 are	 mainly	
involved	 in	 the	 regulation	 of	 female	 biological	 mechanisms	 such	 as	 menstrual	 and	 estrous	 cycles	
through	 different	 mechanisms	 including	 effects	 on	 plasma	 fibrinogen	 levels17	 and	 modulation	 of	
brain	activity18.	Progestogens	are	a	class	of	steroids	which	share	some	of	the	functions	undertaken	by	
estrogen,	 being	 involved	 in	 pregnancy	 and	 the	 menstrual	 cycle.	 Moreover,	 progestogens	 are	
synthesised	directly	from	cholesterol,	thus	acting	as	the	main	precursors	for	all	the	other	classes	of	
steroids	 (Figure	 1).	 Corticoids	 are	 generated	 in	 the	 adrenal	 cortex	 and	 are	 involved	 in	 various	
biological	processes	concerning	 immune	function,	 inflammation,	protein	synthesis	and	metabolism.	
They	can	be	subdivided	 in	 to	glucocorticoids	and	mineralocorticoids.	The	 former,	as	 stated	before,	
	
19	
have	many	 functions	 including	 regulation	of	 glucose,	 protein	 and	 lipid	metabolism	as	well	 as	 anti-
inflammatory	effects	through	up-regulation	of	specific	proteins	 in	the	cell	nucleus	(these	processes	
are	 mediated	 by	 GC	 receptors	 (GR)).	 Cortisol	 can	 be	 considered	 as	 the	 most	 important	 GC.	 It	 is	
involved	 in	 a	 plethora	 of	 metabolic,	 immunological	 and	 cardiovascular	 functions.	 For	 example,	
cortisol	has	been	proven	to	regulate	carbohydrate	metabolism	including	hepatic	glucose	production	
independent	 of	 insulin	 concentration19.	 Immune	 response	 has	 been	 shown	 to	 be	 modulated	 by	
cortisol	 as	 well,	 displaying	 a	 weakening	 trend	 on	 inflammatory	 responses	 through	 inactivation	 of	
interleukin-2	 (which	 produce	 T-cells)	 after	 cortisol	 administration20.	 Moreover,	 control	 of	
cardiovascular	 functions	 by	 cortisol	 is	 achieved	 through	 regulation	 of	 salt	 concentration	 (through	
sodium	uptake)	and	water	levels	influencing	blood	volume	and	pressure21.		





main	 precursor	 is	 cholesterol,	 which	 is	 consumed	 through	 diet	 and	 transported	 by	 low	 density	













and	 suitable	 for	 the	 drug	 market.	 Common	 synthetic	 GCs	 include	 prednisone,	 prednisolone,	









cardiovascular	 activity.	 The	 secretion	 of	 cortisol	 is	 regulated	 by	 the	 hypothalamopituitary-adrenal	




GC	 concentrations	 are	 regulated	 through	 different	 processes:	 synthesis,	 secretion,	 association	 to	
globulin	 and	negative-feedback.	 The	 free	 circulating	 fraction	of	GCs	 enter	 the	 cell	 through	passive	
diffusion	 across	 phospholipid	 membranes.	 In	 the	 cytosol,	 there	 are	 glucocorticoid	 receptors	 (GR)	
which	are	bound	 to	heat	 shock	proteins	and	display	 two	 isoforms:	α	and	β.	Only	 the	 former	binds	
tightly	to	the	GCs,	the	latter	can	act	as	a	negative	regulator.	Once	the	GCs	enter	the	cytosol,	the	GR	




glucocorticoid	 response	 elements	 (GREs)	 regulates	 the	 activation	 or	 inactivation	 of	 specific	 genes	
through	cofactors25,27	 including	cAMP	response	element	binding	protein	and	nuclear	factor-kappa	B	
(NF-kB)25.	 The	 main	 effects	 obtained	 in	 this	 step	 are	 the	 up-regulation	 of	 genes	 involved	 in	 the	
synthesis	 of	 anti-inflammatory	 proteins	 such	 as	 lipocortin-1	 and	 suppression	 of	 pro-inflammatory	
enzymes	 (e.g.	 phospholipase	 A2)28.	 Phospholipase	 A2	 has	 an	 essential	 role	 in	 the	 synthesis	 of	
eicosanoids	 (the	 precursors	 of	 prostaglandins),	 a	 process	 that	 directly	 results	 in	 the	 inflammatory	





effects,	 research	 has	 focused	 on	 the	 development	 of	 SElective	 GR	 Agonists	 (SEGRAs).	 These	
compounds	 trigger	 transcriptional	 activity	 that	 is	 selectively	exerted	on	anti-inflammatory	proteins	
while	 they	 have	 no	 effect	 on	 other	 transcriptional	 modifications	 responsible	 for	 global	 protein	
synthesis,	glucose	uptake,	glucose	transport	and	insulin	secretion28,30.	






IL-10	 is	 involved	 in	 strong	 anti-inflammatory	 responses	 and	 its	 absence	 has	 been	 linked	 with	 the	




as	Addison’s	 disease	 or	Waterhouse-Friderichsen	 syndrome,	may	 be	 administered	with	 exogenous	
GCs	 in	 order	 to	 rebalance	 steroid	 homeostasis.	 GCs	 have	 also	 been	 linked	 to	 suppression	 of	













Activity	 of	 isoform	 I	 is	 regulated	 by	 NADPH	while	 isoform	 II	 is	 regulated	 by	 NADH25.	 11β-HSD2	 is	
mainly	expressed	 in	 the	kidneys,	 colon,	 salivary	and	sweat	glands	 (all	 tissues	characterized	by	high	
concentrations	of	aldosterone	in	physiological	conditions)	and	its	absence	can	cause	hypertension	as	




gonads,	 heart	 and	 brain	 (in	 the	 endoplasmatic	 reticulum)35.	 The	 activity	 of	 11β-HSD1	 can	 be	
regulated	 by	 a	 number	 of	 factors.	 For	 example,	 GCs,	 peroxisome	 proliferator-activated	 receptor	 γ	
agonists	 and	 pro-inflammatory	 cytokines	 enhance	 the	 enzyme	 activity	 whereas	 growth	 hormones	
and	 liver	 X	 receptor	 agonists	 suppress	 it35.	 Also	 sex	 steroids	 regulate	 the	 expression	 of	 11β-HSD1,	
however	 their	 effect	 appears	 to	 be	 tissue-specific36.	 For	 example	 studies	 showed	 higher	
concentrations	of	11β-HSD1	in	adipose	tissue	in	women	compared	to	men37	and	suppression	of	11β-
HSD1	in	rat	liver	and	kidney	promoted	by	estradiol38.	
Due	 to	 the	 wide	 range	 of	 effects	 GCs	 achieve,	 the	 metabolic	 response	 is	 substantial.	 The	
identification	 of	 diseases	 regulated	 by	 GC	 concentration	 has	 driven	 research	 towards	 the	
investigation	of	GC	metabolism	and	the	effect	of	GCs	on	global	metabolism.	One	of	the	first	human	
models	to	investigate	GC	metabolism	was	offered	by	Cushing’s	syndrome;	subjects	display	high	levels	
of	 GCs	 and	 develop	 specific	 symptoms	 including	 immunosuppression,	 myopathy,	 hypertension,	
osteoporosis	and	hepatic	steatosis.	In	the	1930s	Cushing39	characterized	this	disease	and	started	the	
investigation	of	GC	metabolism.	Long,	 in	 two	separate	works,	 stated	 the	 relationship	between	GCs	
and	diabetes40	and	gluconeogenesis	associated	with	insulin	resistance41.	During	fasting,	GCs	increase	
circulating	glucose	and	free	fatty	acids	(FFA)	through	gluconeogenesis	and	 lipolysis	while	 in	the	fed	
state	they	promote	glucose	and	 lipid	storage	as	glycogen	and	triacylglycerides	 (TAGs),	 respectively.	
Cushing’s	syndrome	is	often	associated	with	metabolic	disorders	leading	to	type	2	diabetes.	Another	
crucial	metabolic	disorder	is	the	metabolic	syndrome,	which	is	characterized	by	increased	abdominal	
circumference	 and	 high	 levels	 of	 TAGs	 and	 glucose	 in	 the	 fasting	 state.	 Subjects	 affected	 by	 the	
metabolic	 syndrome	 are	 likely	 to	 develop	 diseases	 such	 as	 diabetes	 and	 cardiovascular	 diseases.	
Whilst	 the	 metabolic	 syndrome	 does	 not	 present	 higher	 levels	 of	 circulating	 GCs	 in	 blood,	
experiments	 have	 shown	 increased	metabolic	 activity	 involving	 GCs.	 Negative	 feedback	 sensitivity	




and	 11β-HSD1	 activity	 decreases,	 suggesting	 a	 decrease	 in	 cortisol	 concentration	 in	 the	 hepatic	
region	in	order	to	retain	insulin	sensitivity.		
1.3 The	role	of	glucocorticoids	in	endogenous	metabolism	




are	 not	 carbohydrates42.	 It	 occurs	 only	 occurs	 in	 the	 liver	 (Figure	 4).	 It	 generates	 glucose	 from	
pyruvate	 and	 other	 precursors	 through	 the	 same	 metabolic	 steps	 observed	 in	 glycolysis	 (which	
generates	 pyruvate	 from	 glucose).	 However,	 when	 compared	 to	 glycolysis	 the	 direction	 of	 the	
metabolic	reaction	of	gluconeogenesis	is	inverted.	This	is	possible	thanks	to	the	double	functionality	
of	 the	 enzyme	 phosphofructokinase	 2	 (PFK2)/fructose	 bisphosphatase	 2	 (FBPase2)43.	 During	
glycolysis	mainly	PFK2	activates	phosphofructokinase	1,	an	enzyme	with	glycolytic	 functions.	When	
glucose	levels	are	low	(during	starvation	or	fasting)	PFK2	functions	are	suppressed	through	glucagon	








skeletal	muscle.	Glucose	 is	 the	primary	metabolic	substrate	 for	energy	production	 in	 the	brain	and	
GCs	 are	 essential	 for	 maintaining	 high	 glucose	 levels	 in	 the	 brain	 in	 the	 fasted	 state	 and	 during	
starvation.	The	contribution	of	GCs	to	gluconeogenesis	also	involves	other	mechanisms:	including	(1)	
protein	 breakdown	 in	 skeletal	 muscle	 which	 provides	 amino	 acids	 that	 can	 be	 converted	 in	 to	
oxaloacetate	 and	 enter	 the	 pathway44	 and	 (2)	 lipolysis	 in	 white	 adipose	 tissue	 which	 produces	
glycerol	and	fatty	acids45	(which	provide	energy	for	gluconeogenesis).	











to	 suppress	 glucagon	 secretion46	 at	 high	 levels	 of	 GCs.	 As	 already	 stated,	 glucagon	 promotes	
gluconeogenesis	 and	 glycogenolysis,	 hence	 chronic	 overexpression	 of	 glucagon	 eventually	 leads	 to	
hyperglycemia47.	It	must	be	noted	that	after	administration	of	GCs	hepatic	tissues	do	not	display	any	
change	from	the	physiological	ratio	of	insulin/glucagon	that	are	measured	in	the	fasted	and	fed	state.	





showed	 glycogen	 accumulation	 in	 the	 liver	 after	 GC	 administration48.	 This	 mechanism	 operates	
through	 activation	 of	 glycogen	 synthase	 by	 GCs49.	 Activity	 of	 glycogen	 synthase	 depends	 on	 its	
phosphorylation.	In	fact	some	enzymes	have	an	effect	on	its	activity	acting	through	phosphorylation	
or	 dephosphorylation.	 Protein	 kinase	 A	 (PKA)	 and	 glycogen	 synthase	 kinase	 3	 inactivate	 glycogen	
synthase	through	phosphorylation50,	while	protein	phosphatase	1	(PP1)	enhances	glycogen	synthase	
activity	by	removing	the	phosphate	group	from	its	structure51.	This	action	is	contrasted	by	glycogen	
phosphorylase	 a	 through	 two	 mechanisms.	 On	 one	 hand	 it	 inhibits	 the	 dephosphorylation	 of	
glycogen	 synthase	operated	by	PP1	and	on	 the	other	hand	 it	 breaks	down	glycogen	 in	 to	 glucose.	
Studies52,53	have	reported	a	correlation	between	GC	 levels	and	overexpression	of	PP1	although	the	
mechanisms	underlying	such	outcomes	are	still	unclear.	
Skeletal	muscle	 displays	 a	 different	 phenotype.	 Indeed	 epinephrine,	 a	 hormone	 that	 is	 present	 in	
skeletal	muscle	is	able	to	change	PP1	activity.	Adrenalectomised	rats	with	a	lack	of	endogenous	GCs	
display	increased	PP1	activity	and	impaired	suppression	operated	by	epinephrine54.	Administration	of	
cortisol	 in	 these	 rats	 restored	 the	 original	 inhibiting	 effect	 of	 epinephrine	 ultimately	 suppressing	
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glycogen	 synthesis.	 Inhibition	 of	 glycogen	 synthesis	 in	 skeletal	 muscle	 by	 GCs	 is	 caused	 also	 by	
interference	 with	 insulin-mediated	 production	 of	 glycogen55.	 Notably,	 one	 study55	 reported	 an	
increase	of	glycogen	storage	despite	decreased	glycogen	synthase	activity.	
Cardiac	muscle	 displays	 a	 decrease	 in	 epinephrine-activated	 glycogenolysis	 after	 adrenalectomy56.	
However,	administration	of	GCs	enhances	glycogen	storage	 in	 this	case.	 It	 seems	that	 this	effect	 is	
obtained	 through	 GC-induced	 overexpression	 of	 AMP-activated	 protein	 kinase	 which	 enhances	





them	 down	 in	 to	 free	 fatty	 acids	 (FFA).	 These	 FFA	 can	 reach	 the	 cell	 through	 specific	 transport	








are	 negatively	 charged,	 they	 need	 prior	 transformation	 in	 order	 to	 traverse	 the	 mitochondrial	
membrane.	 This	 step	 is	 operated	 through	 carnitine	 acyltransferase	 that	 synthesise	 acyl-carnitines	




the	 citric	 acid	 cycle.	 Moreover	 fatty	 acids	 may	 also	 act	 as	 building	 blocks	 for	 sphingolipids,	
glycerophospholipids	and	eicosanoids60.		





Adipose	 tissue	 contains	 triacylglycerides	 (TAGs)	 that	 can	 be	 broken	 down	 via	 lipolysis	 in	 order	 to	
release	 fatty	 acids	 during	 periods	 of	 fasting.	 TAGs	 are	 converted	 to	 diacylglycerides	 (DAGs)	 and	 a	
fatty	 acid	 by	 adipose	 triglyceride	 lipase	 (ATGL).	 DAGs	 are	 then	 converted	 to	 monoacylglycerides	
(MAGs)	and	a	fatty	acid	by	hormone-sensitive	lipase	(HSL).	Finally	MGs	are	converted	to	glycerol	and	
a	 fatty	acid	by	monoglyceride	 lipase60.	GCs	are	known	to	enhance	 the	activity	of	 the	enzymes	that	
catalyse	 lipolysis	 in	peripheral	 adipose	depots	 through	 interaction	with	 gene	 transcription	of	ATGL	






showed	 no	 effect	 on	 β-oxidation	 after	 GC	 administration	 in	 the	 Chub-S7	 adipose	 cell	 line2.	 At	 a	
biochemical	 level,	 GC	 administration	 may	 promote	 lipolysis	 in	 peripheral	 adipose	 tissue	 through	
inactivation	 of	 lipogenesis	 and	 fatty	 acid	 re-esterification	 with	 glycerol	 to	 TAGs,	 leading	 to	 an	
increase	 of	 circulating	 free	 fatty	 acids	 (FFA)2,69.	 Surprisingly,	 when	 GCs	 are	 administrated	 with	
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starts	 with	 the	 reaction	 of	 acetyl-CoA	 (which	 can	 be	 obtained	 from	 conversion	 of	 glucose	 in	 to	










restoration	 after	 GC	 replacement	 therapy75.	 GCs	 also	 appear	 to	 promote	 fatty	 acid	 β-oxidation	 in	
adipose	 tissue.	 The	 mechanism	 is	 mediated	 by	 Tribbles-homologue	 3	 (TRIB3),	 a	 protein	 which	 is	
produced	 during	 fasting	 periods	 and	 which	 has	 been	 correlated	 with	 high	 rates	 of	 fatty	 acid	
oxidation76.	 TRIB3	 has	 been	 reported	 to	 activate	 degradation	 of	 ACC	 thus	 presenting	 a	 pathway	
which	opposes	the	lipogenic	effect	of	GCs	previously	described.	
Apart	from	fatty	acid	uptake,	the	liver	can	act	to	provide	distribution	of	 lipids	to	peripheral	tissues.	





induced	 stimulation	 of	 lipogenesis	 (and	 thus	 increased	 synthesis	 of	 triglycerides)	 triggers	 the	
secretion	of	VLDL79.	This	effect	seems	to	be	assisted	by	an	imbalance	of	lipoprotein	lipase	activity	in	
dexamethasone-treated	 rats.	 Cushing’s	 syndrome	 is	 characterised	 by	 increased	 secretion	 of	 VLDL	
that	 is	 not	 counterbalanced	 by	 enhanced	 peripheral	 clearance80.	 GCs	 appear	 to	 suppress	 the	
degradation	of	triglycerides	derived	from	lipoproteins81.	In	fact,	high	levels	of	TAGs	were	reported	in	
individuals	 affected	 by	 the	 metabolic	 syndrome	 with	 enhanced	 activity	 of	 the	 HPA81.	 It	 has	 been	
suggested	 that	 GCs	 may	 act	 on	 lipoprotein	 clearance	 through	 a	 direct	 interaction	 with	 receptors	
rather	than	with	the	TAGs.	
Muscle	 tissue	 also	 displays	 lipogenesis.	 Chickens	 undergoing	 dexamethasone	 administration	
displayed	 fat	 accumulation	on	muscle	 tissue	due	 to	 inhibition	of	AMPK82.	However	 this	effect	 is	 in	
contrast	 with	 in	 vitro	 studies.	 Indeed	 C2C12	 myotubes	 have	 displayed	 the	 inhibition	 of	 genes	
expressing	 proteins	 involved	 in	 the	 lipogenic	 pathway	 after	 dexamethasone	 administration83.	






adipocytes	 to	 insulin	which	enhances	 the	actual	production	of	adipose	 tissue.	This	 is	accomplished	
through	activation	of	 transcriptional	 adipogenic	 factors85.	However	 it	must	be	noted	 that	different	
adipose	cells	respond	differently	to	high	levels	of	GCs.	Visceral	fat	for	example	shows	an	increase	in	








influenced	 by	 the	 presence	 of	 GCs,	 including	 glucose	 uptake	 and	 protein	 synthesis.	 Both	 of	 these	
pathways	 seem	 to	be	 inhibited	by	a	high	 concentration	of	GCs	 and	both	 are	 regulated	by	 a	 signal	
cascade	 that	 involves	 insulin/IGF1	 receptors,	 PI3	 kinase	 and	 Akt	 kinase.	 Their	 role	 is	 to	 promote	




Other	 considerations	 are	 required	 when	 investigating	 protein	 synthesis.	 Apart	 from	 Akt	 kinase	
signaling,	 GC	 exposure	 decreases	 the	 levels	 of	 free	 amino	 acids	 in	 musculoskeletal	 cells	 through	
uptake	 inhibition91.	 Protein	 degradation	 is	 enhanced	 after	 external	 administration	 of	 GCs.	
Corticosterone	 treatment	 administered	 in	 high	 doses	 caused	 higher	 rates	 of	 protein	 degradation	
compared	to	lower	doses92.	Another	study,	conducted	on	normal	and	adrenalectomised	rats	showed	
reduced	 proteolysis	 in	 adrenalectomized	 rats,	 due	 to	 the	 lack	 of	 endogenous	 GCs93.	 This	 effect	 is	








The	highest	concentration	of	the	enzyme	11β-HSD1	has	been	observed	 in	the	 liver	 (ten-fold	higher	
than	 in	adipose	 tissue).	Hepatic	 lipid	accumulation	 is	a	marker	 for	metabolic	 syndrome	and	 insulin	
resistance	although	such	an	effect	is	not	always	linked	with	an	over-expression	of	11β-HSD1.	Indeed	
while	 some	 studies	 have	 reported	 an	 increased	 11β-HSD1	 concentration	 in	 liver	 for	 patients	with	
metabolic	disease94,	other	studies	did	not	report	a	significant	difference	in	hepatic	expression	of	11β-
HSD1	 between	 healthy	 patients	 and	 patients	 affected	 by	 non-alcoholic	 fatty	 liver	 disease	which	 is	
characterised	by	hepatic	 lipid	accumulation95.	 Indeed	 fat	accumulation	 imbalances	 insulin	 signaling	
affecting	 protein	 kinase	 C	 (PKC)	 and	 jun	 N-terminal	 kinase	 1	 (JNK1)	 pathways	 with	 a	 consequent	
decrease	of	phosphorylation	of	 insulin	 receptor	substrate	1	 (IRS1)96.	Comparisons	between	healthy	
patients	 and	patients	 affected	by	 the	metabolic	 syndrome	 reported	different	 results,	 sometimes	 a	
significant	 difference	 in	 concentrations	 of	 11β-HSD1	 and	 H6PDH	 in	 the	 liver	 were	 observed94	 and	
sometimes	 no	 difference	 was	 observed95.	 It	 has	 been	 hypothesized	 that	 changes	 in	 enzyme	
concentrations	can	occur	during	disease	progression26.		Overexpression	of	11β-HSD1	causes	hepatic	
steatosis,	 dyslipidemia	 and	hypertension	 although	 the	effects	 on	 insulin	 resistance	 are	 limited97.	 It	
has	been	suggested	that	overexpression	of	11β-HSD1	in	adipose	tissue	may	be	sufficient	in	itself	to	
provide	hepatic	steatosis	with	the	transport	of	cortisol	to	the	liver	possible.	Activity	of	hepatic	11β-
HSD1	 has	 been	 assessed	 through	measurement	 of	 urinary	 steroid	metabolites	 and	 active	 cortisol	
circulating	in	serum98.	This	experiment	highlighted	a	drop	in	activity	of	the	enzyme	in	obese	subjects.	
11β-HSD1	is	present	in	high	concentrations	in	adipose	tissue.	While	the	enzyme	itself	does	not	show	
any	 particular	 difference	 in	 concentration	 between	 visceral	 and	 subcutaneous	 adipose	 tissue37,99,	





The	obese	phenotype	 is	unexpectedly	 related	 to	 low	 levels	of	 circulating	GCs	 suggesting	 that	11β-
HSD1	plays	an	essential	 role.	 In	 fact,	an	overexpression	of	 this	dehydrogenase	would	decrease	 the	
circulating	GC101	and,	at	the	same	time,	would	increase	GC	activity	locally	in	adipose	tissue	probably	
due	to	intra-adipose	metabolism26,101.	As	a	result,	11β-HSD1	overexpression	and	high	levels	of	GC	in	
adipose	 tissue	 induce	 the	 same	 phenotype	 of	 abdominal	 obesity,	 glucose	 intolerance	 and	
hyperglycemia.		





















The	PhD	 research	programme	 I	 undertook	had	 an	objective	 to	 assess	 the	 effects	 of	 glucocorticoid	
deficiency	and	excess	on	 tissue-specific	and	global	metabolism	and	to	understand	the	mechanisms	
underlying	those	processes.	 In	fact,	many	contrasting	opinions	still	characterise	the	investigation	of	
GC	 mechanisms	 on	 global	 and	 tissue-specific	 metabolism.	 The	 experiments	 performed	 had	 the	
objective	to	elucidate	the	effect	of	GC	administration	(at	 low	and	high	insulin	levels)	on	the	human	
metabolome	with	 tissue-specific	 considerations.	 In	 order	 to	 investigate	 the	 endogenous	metabolic	
perturbations	 induced	 by	 glucocorticoid	 administration,	 non-targeted	 ultra	 performance	 liquid	






















While	GCs	 inhibit	glucose	uptake	and	oxidation	 in	skeletal	muscle	and	white	adipose	tissue,	 insulin	
stimulates	glucose	uptake	and	oxidation105.	Administration	of	GCs	has	shown	suppression	of	insulin-
induced	 glucose	 uptake	 through	 inactivation	 of	 the	 transport	 of	 GLUT4	 to	 the	 cell	 membrane106.	
Conversely	low	levels	of	GCs	have	been	shown	to	enhance	the	effect	of	insulin	on	glucose	uptake	in	




on	 the	 cell	 surface.	 IR	 then	phosphorylates	 the	 insulin	 receptor	 substrate	 (IRS1)109.	Hence,	 IRS	and	
IRS1	 trigger	 a	 series	 of	 signals	 that	 also	 involve	 phosphoinositide-3-kinase	 (PI3K)	 and	 Akt.	
Administration	of	GCs	 in	mice	decreased	 the	phosphorylation	 levels	 for	 IR	 and	 the	activity	of	PI3K	
and	 Akt4,107.	 This	 inhibition	 has	 been	 studied	 in	 mice	 C2C12	 myotubes110	 and	 allowed	 the	
identification	of	 the	target	gene	Pik3r1	which	also	 involves	 the	synthesis	of	proteins	regulating	the	
insulin	signal	downstream.	
Insulin	 release	 from	 β-cells	 in	 the	 pancreas	 is	 regulated	 by	 glucose	 in	 an	 eight	 step	 mechanism	
involving	calcium	uptake	as	a	signal	for	insulin	vesicle	exocytosis.	Different	studies	involving	GCs	and	
islet	 cells	 have	 been	 performed,	 revealing	 conflicting	 outcomes.	 GCs	 have	 been	 demonstrated	 to	





high	 levels	 of	 glucose,	 prolonged	 periods	 of	 insulin	 resistance	 cannot	 be	 counterbalanced	 by	




the	 treatment	 and	may	 be	 reversible	 after	 short-term	 acute	 exposure116.	 β-cell	 activity	 is	 a	 direct	
consequence	 of	 cellular	 respiration	 as	 it	 is	 dependent	 on	 the	 glucose	 concentration	 and	 ADP/ATP	
ratios.	
In	 vivo	 and	 in	 vitro	 studies	 on	 pancreatic	 islets	with	GC	 administration	 have	 displayed	 contrasting	
outcomes.	 In	 vitro	 reports	 on	 pancreatic	 islets	 exposed	 to	 high	 levels	 of	 dexamethasone	 show	
degradation	of	the	GLUT2	transporter	and	impairment	of	insulin	secretion	triggered	by	glucose117.	In	
specific	 cell	 lines	 dexamethasone	 also	 appears	 to	 suppress	 glucokinase	 transcription	 factors118.	 It	
must	be	noted	that	GCs	have	been	reported	to	directly	affect	the	pancreas	at	both	the	genetic119	and	
transcriptional120	 levels.	 Indeed	 in	 vitro	 GCs	 administration	 in	 pancreatic	 islets	 inhibited	 genes	
associated	with	 insulin	production	and	 transcriptional	 factors	 responsible	 for	 the	actual	generation	
and	growth	of	β-cells.	As	already	mentioned,	these	results	contrast	with	the	 in	vivo	studies.	 Indeed	
pancreatic	 islets	 obtained	 from	mice	 that	 underwent	heavy	GC	 administration	displayed	 increased	
glucose	uptake,	 improved	insulin	secretion	and	enhanced	oxidative	metabolism121,122.	This	outcome	
is	likely	to	be	caused	by	β-cell	response	after	short-term	high	GC	exposure.	As	stated	before,	GCs	can	












(which	 is	 a	 known	 inhibitor	 of	 serine	 palmitoyltransferase,	 involved	 in	 the	 metabolic	 pathway	 of	
ceramides)	 administered	 in	 conjunction	 with	 GCs	 markedly	 suppressed	 the	 effects	 of	 GCs	 on	
insulin129.	Furthermore,	the	presence	of	GCs	has	been	linked	with	overexpression	of	enzymes	directly	
involved	 in	 ceramide	metabolism.	 It	 is	 possible	 that	 ceramides	 and	other	 lipid	mediators	 linked	 to	
insulin	 resistance	 (e.g.	 diacylglycerols)	may	be	 transported	 to	 skeletal	muscle	 as	 a	 consequence	of	
GC-induced	lipolysis	in	white	adipose	tissue	131.	
Glucose	 metabolism	 in	 other	 tissues	 is	 affected	 by	 administration	 of	 GCs.	 Mouse	 adipocytes	 for	
example	showed	severe	impairment	of	insulin-mediated	glucose	uptake	after	GC	administration132.	It	
must	be	noted	that	human	adipocytes	have	also	been	adopted	for	studies	on	the	effects	of	GCs	on	
glucose	 metabolism	 leading	 to	 an	 interesting	 differentiation.	 Omental	 adipocytes	 displayed	 the	
typical	 outcome	 of	 inhibited	 glucose	 uptake	 in	 conjunction	with	 high	 levels	 of	 GCs,	 subcutaneous	
adipocytes	 showed	 a	 synergistic	 effect	 between	 GCs	 and	 insulin87.	 In	 fact	 GC	 administration	
enhanced	 insulin-induced	 glucose	 uptake	 in	 those	 tissues.	 Brain	 glucose	 levels	 (especially	 in	 the	
hypothalamus	 and	 hippocampus)	 appear	 to	 be	 regulated	 by	 the	 level	 of	 circulating	 GCs133.	 Again	
impaired	glucose	oxidation	and	uptake	appear	to	be	inhibited	by	high	levels	of	GCs.	
The	 effect	 of	 GC	 administration	 on	 impaired	 insulin	 secretion	 acts	 through	 β-cell	 dysfunction	 and	
down-regulation	 of	 the	 glucose	 type	 2	 transporter	 and	 glucokinase,	which	 ultimately	 reduces	 ATP	
synthesis	 leading	 to	 imbalanced	 insulin	 secretion	 from	 β-cells.	 Acute	 effects	 of	 GC	 administration	
include	inhibition	of	GLP1134	which	contributes	to	β-cell	physiological	function	(i.e.	insulin	secretion).	
In	 the	 long	 term,	 hypercortisolism	 can	 lead	 to	 hyperinsulinaemia116	 (β-cells)	 and	
hyperglucagonaemia135	(α-cells).	






of	GCs	on	 insulin-regulated	mechanisms	 is	 controlled	 through	down-regulation	of	 IRS1	and	 IRS2126.	
Moreover,	 insulin	 sensitivity	 has	 been	 more	 directly	 linked	 to	 expression	 of	 11-βHSD1,	 which	
converts	cortisone	 into	cortisol.	 In	fact	 this	enzyme	has	been	found	to	be	severely	unbalanced	 in	a	








mechanisms.	 The	 expected	 phenotypes	 include	 weight	 gain,	 hypertension,	 polyuria	 and	 insulin	
resistance136.	Notably,	insulin	resistance	can	be	cured	in	the	early	stages	of	Cushing’s	syndrome	but	
may	later	develop	(20-47%	of	cases86)	into	T2D.	
A	 general	 mechanism	 underlies	 this	 group	 of	 diseases	 although	 slight	 differences	 may	 arise	
depending	 on	 the	 specific	 type	 of	 disease.	 In	 physiological	 condition	 the	 hypothalamus	 produces	
corticotropin-releasing	 hormone	 (CRH)	 which	 in	 turn	 leads	 to	 the	 release	 of	 corticotropin	 (ACTH)	







can	 be	 eventually	 ascribed	 to	 exogenous	 or	 endogenous	 reasons.	 Exogenous	 causes	 are	 the	most	
common138.	 In	 this	 case,	 high	 cortisol	 levels	 are	 reached	due	 to	 cortisol	 prescription	 to	patients	 in	




Cushing’s	although	 in	 this	 case	 this	 is	due	 to	endocrine	 impairment	of	 the	adrenal	gland	 (e.g.	by	a	




been	 applied	 as	 an	 important	 biological	 research	 tool.	 	 Metabolites	 are	 low	 molecular	 weight	
biochemicals	present	in	living	organisms	which	have	a	role	as	precursors,	intermediates	or	products	
in	 enzymatic	 reactions146	 observed	 in	 metabolism.	 Importantly,	 metabolites	 are	 studied	 to	
interrogate	metabolism	but	also	to	understand	the	regulatory	and	structural	roles	metabolites	play.	
In	 fact,	many	metabolites	are	 involved	 in	a	number	of	biological	pathways	and	they	can	act	as	 the	
rate-limiting	step	for	some	of	those	processes.	For	example	mammalian	metabolomics	often	involves	
the	 detection	 of	 metabolites	 participating	 in	 glycolysis,	 TCA	 cycle,	 β-oxidation	 and	 many	 other	
metabolic	pathways.	 Some	metabolites	may	also	hold	a	 structural	 role;	 some	cholesterol	 lipids	 for	
instance	can	merge	into	the	phospholipid	cell	membrane	acting	through	weak	chemical	interactions.	
The	majority	of	metabolites	are	organic	compounds	(e.g.	carbohydrates,	amines,	organic	acids,	fatty	
acids.	 Biochemicals	 involved	 in	metabolism	 are	 defined	 as	metabolites.	 The	 chemical	 structure	 of	
each	 metabolite	 allows	 sub-grouping	 of	 compounds	 into	 classes	 sharing	 similar	 biological	 and	
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physical-chemical	 properties.	 For	 example,	 hexadecanoic	 acid	 is	 an	 essential	 metabolite	 in	
mammalian	systems	and	can	be	defined	as	a	fatty	acid.	The	molecular	weight	of	metabolites	ranges	
from	1	(proton)	to	greater	than	1500	Dalton147	 (e.g.	TAGs)	and	their	chemical	 (pKa,	LogP,	H-bonds)	
and	 physical	 (boiling	 point,	 solubility)	 properties	 encompass	 a	wide	 range	 of	 diversities.	 The	 total	
number	 of	 endogenous	 and	 exogenous	 metabolites	 in	 a	 biological	 system	 is	 defined	 as	 the	
metabolome148.	 The	 same	organism	 can	 be	 constructed	with	 different	metabolomes,	 for	 example,	
mammals	are	composed	of	many	different	metabolomes	associated	with	biofluids,	cells	and	tissues.	
The	 Human	Metabolome	 Database	 (HMDB)	 as	 of	 April	 2017	 reports	 that	 41,514	 metabolites	 are	
present	 in	 the	 human	body149.	 Plant	metabolomics	 report	 a	 broader	 variety	 and	 larger	 number	 of	
metabolites	when	 compared	with	mammalian	metabolomes146.	 Resources	 to	 define	metabolomes	







genetic	 modification”154.	 In	 the	 early	 development	 of	 both	 disciplines,	 metabolomics	 was	 mainly	
related	 to	 microbial	 and	 plant	 research	 through	 the	 use	 of	 mass	 spectrometry	 (MS),	 while	
metabonomics	 studied	 mammalian	 systems	 applying	 nuclear	 magnetic	 resonance	 (NMR)	
spectroscopy.	
Metabolomics	 has	 developed	 in	 the	 last	 15	 years	 as	 an	 acknowledged	 new	 field	 of	 study.	 The	
development	 of	 new	 analytical	 techniques	 has	 driven	 the	 field	 forward;	 for	 example,	 new	




1999,	 focused	on	NMR	analysis	 of	 human	biofluids154,	 and	of	 “metabolomics”	 in	 2000,	 focused	on	
GC-MS	analysis	for	metabolic	studies	of	plants157.	These	developments	occurred	in	conjunction	with	
advances	 in	 analytical	 techniques	 such	 as	mass	 spectrometry	 and	NMR	 spectroscopy	 (and	 related	




transcriptomics	 is	 the	 study	 of	 transcription	 of	 biological	 information	 codified	 by	 genes	 and	
proteomics	concerns	the	analysis	of	proteins	in	an	organism,	their	structure	and	how	this	relates	to	
their	functions.	There	is	a	logical	relationship	between	every	‘omics	area	and	a	slight	perturbation	in	
one	 biological	 level	may	 affect	 the	 others.	 For	 example,	metabolites	 are	 not	 just	 end	 products	 of	
biological	 processes	 but	 can	 also	 act	 as	 active	 regulators	 of	 metabolism.	 Αlpha-keto	 acids	 for	
instance,	 have	 a	 significant	 effect	 on	 transcriptional	 factors	 through	 inhibition	 of	 cyclic	 AMP158.	
Furthermore,	a	deficiency	of	a	specific	metabolite	will	cause	the	activation	or	inactivation	of	specific	
enzymatic	 processes	 in	 order	 to	 increase	 or	 maintain	 a	 specific	 metabolite	 concentration.	
Metabolites	 can	 interact	 with	 proteins	 through	 post-translational	 modifications	 (PTMs),	 chemical	
modifications	 to	 the	 amino	 acidic	 side	 chains	 or	 to	 the	 terminal	 ends	 of	 the	 protein.	 Specifically,	
some	metabolites	 are	 covalently	 bound	 to	 the	 protein	 structure	 after	 enzymatic	 activation	 of	 the	
process159.	 Such	 enzymatic	 activity	 may	 be	 triggered	 by	 other	 metabolites	 binding	 to	 allosteric	
sites160.	 Therefore	 the	 role	 of	 metabolites	 appears	 to	 allow	 a	 rapid	 response	 to	 environmental	
changes.	Given	this	tight	interconnection,	the	study	of	a	specific	level,	for	example	metabolism,	can	
provide	 information	 about	 perturbations	 occurring	 in	 other	 levels	 such	 as	 the	 proteome	 or	
transcriptome.	 Indeed,	 some	metabolites	 like	 glucose161	 and	acetyl	 CoA162	 are	 involved	 in	PTMs	of	
histone	 and	 non-histone	 proteins.	 Hence,	while	 genomics	 and	 proteomics	 give	 us	 the	 information	
about	what	may	 occur	 or	 is	 occurring,	metabolomics	 give	 us	 a	 description	 of	what	 is	 occurring	 or	
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what	has	 just	occurred.	A	metabolic	snapshot	of	a	biological	 system	corresponds	 to	 its	phenotype,	
the	 result	 of	 genome	 and	 environmental	 interactions147.	 Genetic	 and	 environmental	 perturbations	
can	 be	 monitored	 through	 metabolomics,	 as	 the	 metabolite	 concentration	 can	 be	 very	 sensitive	
compared	to	the	observed	transcriptional	or	proteomic	changes163.	Despite	the	fact	that	the	global	
analysis	of	the	entire	metabolome	is	not	achievable,	metabolomics	shows	clear	advantages	in	some	
studies.	 It	 takes	 advantage	 of	 high-throughput	 techniques	 (which	 are	 time-efficient	 and	 cost-




complexity.	 The	human	metabolome	 is	 one	of	 the	most	 complex	 systems	 to	 study	 and	 is	 typically	




disease	diagnosis	or	 risk	 stratification.	An	early	diagnosis	 can	be	extremely	 important	dealing	with	
diseases	such	as	heart	failure	or	diabetes	since	a	precautionary	therapy	can	be	adopted	preventing	
invasive	 and	 intensive	 interventions.	 Identification	 of	 biomarkers	 for	 disease	 progression	 or	
treatment	monitoring	and	phenotype	characterization	is	also	performed	applying	metabolomics.		
Stratified	 or	 personalized	 medicine	 aims	 to	 investigate	 groups	 of	 patients	 affected	 by	 the	 same	
disease	and	to	find	multiple	common	traits	(in	this	case	metabolome	changes)	to	allow	stratification,	
which	would	 allow	 treatment	 in	 a	 specific	 and	personalised	way.	 Furthermore	metabolomics	 is	 an	











has	 implemented	 a	 method	 to	 distinguish	 between	 the	 metabolomes	 of	 doped	 and	 non-doped	
athletes177.		
In	 optimal	 conditions	 a	 metabolomics	 experiment	 would	 allow	 identification	 and	 absolute	
quantifications	of	all	metabolites	present	in	the	biological	sample.	However	this	is	rarely	the	case.	In	
order	 to	 obtain	 absolute	 quantification	 the	 calibration	 curves	 of	 all	 the	 metabolites	 involved	 are	
needed.	 While	 it	 is	 possible	 to	 obtain	 standards	 for	 some	 metabolites,	 this	 task	 becomes	
unachievable	when	the	sample	contains	thousands	of	metabolites.	Another	problem	that	may	arise	
is	the	failed	detection	of	some	metabolites.	In	fact,	depending	on	the	analytical	method	adopted,	the	
metabolites	 need	 to	undergo	physico-chemical	modifications	 in	 order	 to	be	detected.	While	 some	
metabolites	 may	 be	 prone	 to	 certain	 modifications	 (e.g.	 ionization,	 vaporization),	 they	 can	 be	
resistant	to	others	and	therefore	they	will	fail	to	be	detected.		
There	 are	 various	 strategies	 to	 analyze	 the	 metabolic	 content	 of	 samples	 and	 in	 general	 we	 can	
define	 three	main	approaches.	Non-targeted	analysis	 is	defined	as	 the	holistic	detection	of	 a	wide	
range	 of	metabolites	 following	minimal	 sample	 preparation.	 Targeted	 studies	 are	 applied	 when	 a	
limited	number	of	metabolites	of	 known	biological	 importance	are	 to	be	 studied	 (Table	2).	A	new	
approach	 has	 emerged	 in	 recent	 years	 called	 semi-targeted	 analysis.	 This	 strategy	 provides	
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quantitative	 information	 on	 a	 larger	 number	 of	 metabolites	 (usually	 belonging	 to	 specific	
biochemical	classes)	compared	to	targeted	assays	but	detects	fewer	metabolites	compared	to	non-




its	own	constraints;	one	 is	 that	 the	number	of	compounds	analyzed	 is	 restricted	by	 the	number	of	
chemical	standards	commercially	available.	For	targeted	and	semi-targeted	assays,	the	identity	of	all	
























are	 robust	 and	 include	 no	 biases	 that	 will	 negatively	 influence	 the	 biological	 conclusions.	 Many	
biases	can	be	introduced	including	gender,	age,	BMI	and	drug	treatment.	The	experimental	design	is	
dependent	on	 the	objective	of	 the	experiment	 itself.	One	of	 the	main	aspects	of	 the	experimental	
design	 is	 the	reproducibility	of	 the	data.	Several	procedures	have	been	developed	to	contribute	 to	
this.	 First	 of	 all,	 it	 is	 recommended	 that	 the	 experiment	 is	 performed	 according	 to	 a	 standard	
operating	 procedure	 (SOP).	 This	 way,	 the	 bias	 that	 may	 occur	 due	 to	 different	 researchers	
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performing	 the	 same	experiment	 in	a	different	way	 is	minimized.	 If	 the	 sample	 size	 is	 large	 (more	
than	200),	then	samples	should	be	split	in	to	batches	of	100-150	units	which	are	analysed	separately.	
This	 is	particularly	 true	 for	mass	spectrometry	experiments	where	a	decrease	 in	sensitivity	 is	often	
displayed	after	~150	injections182.	Randomisation	is	another	important	step	in	experimental	design.	It	
allows	 the	 minimization	 of	 unwanted	 correlation	 in	 the	 analysis.	 If	 samples	 are	 collected	 with	 a	
certain	 order	 related	 to	 a	 factor	 (e.g.	 age,	 sex,	 BMI,	 treatment),	 the	 variation	 of	 the	 instrumental	
response	 over	 time	 could	 be	 falsely	 associated	 with	 one	 of	 these	 factors	 leading	 to	 flawed	 data	
analysis183.	 In	 order	 to	 achieve	 better	 results	 it	 is	 often	 appropriate	 to	 stratify	 the	 randomization	
across	 different	 experimental	 stages	 (e.g.	 sample	 extraction,	 sample	 reconstitution,	 analysis).	 The	





The	 sample	 preparation	 depends	 on	 the	 purpose	 of	 the	 experiment.	 If	 an	 untargeted	 study	 is	
performed,	 the	 samples	 will	 require	 minimal	 preparation	 so	 not	 to	 exclude	 potential	 analytes	 of	
interest	 from	detection	while	with	 targeted	 analysis,	 the	preparation	 is	 developed	 for	 the	optimal	










a	 sample	matrix	 that	 is	 relatively	 easy	 to	 extract.	 It	 can	 be	 analysed	 after	 removal	 of	 particulates	
(through	centrifugation	or	filtration)	and	dilution187.	Further	sample	treatment	may	include	removal	
of	proteins	through	the	addition	of	methanol.	However,	urine	has	the	advantage	of	containing	 low	
concentrations	 of	 proteins	 therefore	 simplifying	 preparation	 steps168,176,177,188	 as	 no	 quenching	 is	
required.	 Serum	 and	 plasma	 samples	 undergo	 the	 same	 extraction	 procedures.	 Due	 to	 their	 high	
protein	 content,	 they	 require	deproteinisation	 through	addition	of	methanol	 or	 acetonitrile	 as	 the	
most	frequently	applied	organic	solvents189.	While	monophasic	extractions	adopting	water/methanol	
solutions	provide	a	broad	recovery	of	compounds,	biphasic	extractions	which	involve	the	addition	of	
chloroform	 or	 MTBE190,	 provide	 aliquots	 which	 are	 specifically	 tailored	 towards	 one	 side	 of	 the	
polarity	spectrum	(polar	and	non-polar	fractions).		




metabolites	 that	 are	 present	 in	 the	metabolome	 two	main	 steps	will	 be	 required:	 quenching	 (for	
samples	 with	 high	 enzymatic	 activity	 only)	 and	 extraction	 (for	 all	 samples	 except	 where	 direct	
imaging	 is	 performed).	 Cells	 undergo	 different	 quenching	 procedures	 depending	 on	 their	 culture	
mode.	Suspended	cells	(grown	in	suspension)	are	quenched	by	placing	in	organic	solvents	at	low	or	
high	temperatures.	Examples	include	use	of	60	%	methanol	solutions	at	-40	°C191.	The	supernatant	is	
then	 removed	 through	 centrifugation	 or	 filtration.	 Conversely,	 adherent	 cells	 are	washed	 in	 saline	
solution	after	removal	of	the	growth	medium	and	quenched	in	the	same	solution	were	extraction	is	
performed189.	The	use	trypsin	to	remove	adherent	cells	is	still	debated192.	Extraction	usually	involves	





Tissue	 analysis	 is	 also	 performed	 but	 sampling	 techniques	 are	 highly	 demanding.	 The	metabolites	
have	to	be	released	from	the	intracellular	environment	through	extraction	processes	and	blood	has	
to	 be	 washed	 from	 the	 tissues	 to	 eliminate	 contamination.	 Usually	 blood	 washing	 is	 achieved	
through	the	use	with	saline	solutions	at	4	°C.	The	tissue	needs	to	be	homogenized	in	solution	using	
homogenisers196	 or	 precellys	 tubes197.	 The	 sample	 is	 then	 extracted	 in	 a	 monophasic	 or	 biphasic	
solution.	
1.9 Analytical	technologies	
Metabolomics	 studies	 are	 performed	 with	 a	 range	 of	 analytical	 techniques	 although	 the	 most	
common	 are	 Nuclear	 Magnetic	 Resonance	 (NMR)	 spectroscopy	 and	 Mass	 Spectrometry	 (MS),	
typically	 but	 not	 always	 coupled	 with	 separation	 techniques	 including	 electrophoresis	 and	
chromatography.	 Direct	 Infusion	 Mass	 Spectrometry	 (DIMS),	 which	 does	 not	 involve	 a	 separation	
technique	 is	 applied	 less	 frequently.	 	 A	 PubMed	 search	 led	 in	October	 2016	 querying	 the	 terms	
“direct	 infusion	mass	 spectrometry”	 produced	 543	 results	while	 the	 query	 “liquid	 chromatography	
mass	spectrometry”	produced	103081	results.	Each	technique	has	its	advantages	and	disadvantages	
encompassing	 sensitivity,	 reproducibility,	 sample	 pre-treatment,	 range	 of	 detected	 compounds,	






















of	 olive	 oil	 through	 the	 use	 of	 chemometrics	 tools200	 and	 the	 assessments	 of	 solvent	 effects	 on	
protein	recovery	in	crude	cell	extracts201.	
DIMS	data	collection	 is	a	complex	process	and	 it	 is	characterized	by	numerous	 issues	arising	 in	 the	
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workflow.	 As	 already	 stated,	 the	 metabolites	 are	 introduced	 in	 the	 mass	 spectrometer	 with	 no	
separation,	therefore	the	sample	matrix	 is	often	complex	and	multiple	metabolites	can	be	detected	
as	 a	 single	 signal.	 This	 is	 especially	 true	 for	 untargeted	 studies.	 DIMS	 techniques	 also	 display	
impediments	concerning	metabolite	identification,	as	it	will	be	later	discussed.	
This	 series	 of	 issues	 promoted	 the	 widespread	 use	 of	 chromatographic	 techniques	 in	
metabolomics203-205	 in	 order	 to	 obtain	 simpler	 data	 matrices	 and	more	 parameters	 (e.g.	 retention	
time)	to	compare	during	the	metabolite	identification	phase.	
1.9.2.1 Chromatography	
While	 the	 interpretation	 of	 a	 MS	 spectrum	 can	 be	 extremely	 challenging,	 especially	 for	 complex	
samples	populated	by	many	metabolites,	the	use	of	separation	methods	can	ease	the	detection	and	
identification	 of	 metabolites	 in	 a	 complex	 mixture.	 Chromatography	 can	 separate	 different	
compounds	 over	 a	 time	 span.	 The	 main	 principle	 involves	 a	 stream	 of	 solvent	 (when	 liquid	
chromatography	is	applied)	containing	the	analytes	(mobile	phase)	passing	through	a	column	packed	
with	 a	 solid	 support	 (stationary	 phase).	 Chromatography	 takes	 advantage	 of	 different	 chemical	
interactions	between	the	analytes	and	the	stationary	phase	whose	chemical	nature	can	vary.	In	this	
way	the	analytes	can	be	retained	or	pass	through	the	column	with	no	interaction	with	the	stationary	
phase.	 The	 use	 of	 different	 solvents	 in	 the	mobile	 phase	 can	 vary	 the	 solubility	 and	 the	 chemical	
interaction	 of	 specific	 metabolites	 with	 the	 stationary	 phase,	 thus	 allowing	 the	 detection	 of	
particular	 classes	 of	 compounds	 in	 certain	 spectral	 areas.	 This	 technique,	when	 coupled	with	MS,	
allows	the	analysis	of	metabolites	distributed	over	chromatographic	time	(retention	time).	Moreover	
it	 allows	 the	 potential	 separation	 of	 isobaric	 compounds	 due	 to	 possible	 chemical	 structure	






observed	 for	 GC.	 Due	 to	 its	 nature,	 LC	 detects	 many	 high	 boiling	 point	 compounds	 that	 are	 not	
detected	with	GC	and	therefore	GC	and	LC	are	complementary	analytical	techniques.	Originally,	the	
stationary	phase	was	 silica	or	alumina,	 thus	offering	a	hydrophilic	 surface	 that	 interacted	with	 the	
analytes.	 Polar	 compounds	 were	 retained	 on	 the	 column	 while	 apolar	 compounds	 were	 rapidly	




by	 non-polar	 stationary	 phase	 which	 interacts	 strongly	 with	 non-polar	 metabolites	 therefore	


















Nowadays,	 a	 typical	 UPLC	 setup	 include	 pumps	 that	 operate	 between	 600	 and	 1200	 bar,	 column	
lengths	 that	vary	between	30	and	150	mm,	column	 internal	diameter	 ranging	between	2.1	and	4.5	
mm,	particles	diameter	under	2	µm	and	flow	rates	between	50	and	1000	µL/min.	Depending	on	the	
method,	peak	separation	and	shape	need	to	be	optimized	fine	tuning	numerous	parameters.	Solvent	
composition	 and	 gradient	 modifications	 are	 the	 primary	 instruments	 to	 optimize	 the	
chromatographic	 method.	 Flow	 rate	 also	 plays	 an	 important	 role,	 as	 a	 non-optimal	 flow	 rate	 can	
prove	detrimental	for	the	peak	shape.	Usually	optimal	flow	rates	can	be	calculated	depending	on	the	
internal	 diameter	 of	 the	 column.	UPLC	 techniques	 coupled	 with	mass	 spectrometry	 generated	 an	
extremely	 successful	 instrumental	 platform	 which	 is	 widely	 used	 nowadays	 for	 a	 large	 variety	 of	
analysis.	Taking	advantage	of	the	precision	and	accuracy	achieved	by	modern	mass	analysers	like	the	
Orbitrap	(accuracy	<	5	ppm	and	resolving	power	up	to	240,000	at	m/z	400),	UPLC-MS	analysis	 turn	
out	 to	 be	 extremely	 reliable.	 As	 already	 mentioned,	 nowadays	 mass	 spectrometers	 manage	 to	
achieve	 high	 resolution.	 It	 must	 be	 noted	 though,	 that	 higher	 the	 resolution,	 slower	 will	 be	 the	
number	 of	 scans	 per	 second.	 Hence	 the	 analytical	 method	 is	 usually	 a	 matter	 of	 compromise	
between	mass	resolution	and	scan	speed.		
1.9.2.3 Ionisation	
The	metabolites	must	be	 ionised	before	being	analysed	as	 the	charge	 is	 applied	 to	manipulate	 the	
flight	path	of	ions	and	separate	ions	based	on	their	m/z	ratio.	Therefore	ionization	of	metabolites	is	
required	 and	 can	 be	 performed	 according	 to	 different	 techniques	 with	 two	 common	 ionization	
techniques	being	Electron	ionisation	(EI)	and	Electrospray	ionization	(ESI).		




electric	 field.	 The	 addition	 of	 acid	 species	 in	 solution	 facilitates	 the	 formation	 of	 protonated	 ions.	
Subsequently,	 the	 charged	analytes	 flow	 through	a	charged	capillary	bearing	a	potential	 difference	
with	a	counterelectrode	between	3000	and	4500	V209.	Such	a	difference	can	be	regulated	intervening	
on	the	distance	between	the	capillary	and	the	electrode.	The	analytes	exit	the	capillary	and	through	
the	 use	 of	 heat	 and	 gas	 stream,	 the	 solvent	 gradually	 evaporates	 generating	 nebulized	 charged	
droplets.	 In	 this	 way	 droplets	 containing	 ions	 with	 the	 same	 charge	 reduce	 their	 volume	 until	
exploding	 in	a	coulomb	effect.	Hence	the	analytes	enter	the	mass	analyser	with	no	trace	of	solvent	
(Figure	7).		
ESI	 mainly	 produces	 [M+H]+,	 [M-H]-	 and	 [M+NH4]+	 ions;	 nevertheless	 it	 is	 common	 to	 detect	 ion	
adducts	 with	 K+	 and	 Na+	 formed	 by	 thermal	 ion	 attachment.	 While	 this	 process	 can	 hinder	 the	
detection	 of	 the	 [M+H]+	 and	 [M-H]-	 ion	 forms,	 it	 can	 also	 prove	 useful	 when	 the	 analytes	 do	 not	
produce	 simple	 protonated	 or	 deprotonated	 ion	 forms.	 The	 use	 of	 specific	 salts	 in	 solution	 can	






from	 ions	 with	 opposite	 charge	 through	 application	 of	 an	 electric	 field.	 In	 the	 central	 part	 of	 the	
picture	 gas	 steam	 allows	 the	 evaporation	of	 the	 solution	 until	 creation	 of	 charged	 droplet	 through	
Coulomb	effect.	These	droplets	are	ready	to	enter	the	mass	spectrometer.	
	
The	 ESI	 source	 may	 suffer	 from	 poor	 ionization	 when	 the	 solvent	 composition	 is	 rich	 in	 water.	
Ionization	efficiency	has	also	proved	 to	be	dependent	on	physical	 chemical	properties	as	 LogP	and	
pKa.	For	example	aromatic	molecules	rich	in	N-hetero	atoms	produce	a	larger	quantity	of	[M+H]+	ions	
when	 compared	 to	 oxidized	 aromatic	 compounds211.	 It	 is	 particularly	 important	 when	 using	 ESI	


























4-20	 2-10	 4-6	 104-105	
Orthogonal	Time	
of	Flight	(oToF)	




5-500	 >7.5	 >10	 >3	 105-106	
Qq-TOF	 1-5	 >60	 >100	 >40	 104-105	
Orbitrap	 1-3	 100-240	 >18	 >4	 103-104	
FT-ICR	 0.3-1	 750−2500	 0.5-2	 4-10	 104	
Table	3.	Specifications	of	widely	used	mass	analysers212	
	
Given	 the	 broad	 range	 of	 mass	 analysers	 that	 are	 available	 nowadays	 some	 trends	 developed	 in	
terms	 of	 untargeted	 and	 targeted	 metabolomics.	 Reproducible	 and	 sensitive	 mass	 analysers	 (e.g.	
triple	 quadrupole,	 FT-ICR)	 are	 the	 instruments	 of	 choice	 when	 performing	 targeted	 studies	 while	
mass	analysers	with	higher	resolving	power	and	scan	rate	(e.g.	Orbitrap,	Q-TOF)	are	preferred	when	
performing	 untargeted	metabolomics.	 Untargeted	 studies	 are	 performed	 on	 samples	 that	 undergo	
minimal	sample	preparation;	therefore	the	mass	spectrum	is	often	complex	displaying	a	plethora	of	




detect	 different	 ions	having	 the	 same	nominal	mass	but	different	monoisotopic	mass.	 Indeed,	 it	 is	
possible	 that	 even	 after	 chromatographic	 separation	 two	 ions	 having	 the	 same	 nominal	 mass	 are	
eluted	at	 the	 same	 retention	 time.	Overlapping	peaks	 can	 in	 fact	appear	as	a	unique	peak	 causing	




accuracy,	 scan	 rate	 and	 resolution.	 In	 2015	 and	 2016	 for	 example,	 an	 untargeted	 screening	 for	
toxicants	in	urine	was	performed	using	an	Orbitrap	mass	analyser213,	a	GC-TOF	approach	detected	13	
statistically	 significant	 metabolites	 in	 saliva	 that	 differentiate	 smokers	 from	 non-smokers214,	 the	
complementary	 use	 of	QTOF	 and	 hybrid	 quadruple	 Orbitrap	 (QExactive)	 allowed	 the	 detection	 of	




to	ensure	a	 long	mean	free	path	 for	 the	 ions.	The	 ions	 that	enter	 the	analyser	are	attracted	to	 the	
inner	electrode	but	oscillate	around	 it	due	to	centrifugal	 force.	A	voltage	(5	kV)	 is	applied	between	
the	 outer	 and	 inner	 electrodes	 thus	 creating	 a	 linear	 electromagnetic	 field216.	 The	 molecules	 are	
injected	in	the	analyser	with	a	certain	tangential	velocity.	The	radial	electromagnetic	field	deflects	the	
analytes	towards	the	inner	electrode	but	the	tangential	velocity	provides	centrifugal	force.	Given	the	












where	 t	 is	 the	 independent	variable	and	the	angular	 frequency	ω	depends	on	 the	m/z	ratio.	While	


















The	 obtained	 raw	 data	 requires	 several	 processing	 steps	 (Figure	 8)	 prior	 to	 univariate	 and/or	
multivariate	 analysis	and	 the	 raw	 data	 format	 is	 heavily	 dependent	 on	 the	manufacturer	 of	 each	
instrument.	As	already	 stated,	 these	data	 can	be	presented	 in	different	 formats	and	much	effort	 is	
spent	 to	 unify	 different	 formats	 into	 a	 single	 and	 universally	 accepted	 file	 format.	 An	 example	 is	
the	 .mzML	 file	 format	 which	 is	 now	 available	 in	 many	 conversion	 and	 analysis	 tools	 (e.g.	
ProteoWizard218).	Once	data	are	converted	in	to	a	standardized	file	format,	they	need	to	be	aligned	
and	 subsequently	 converted	 into	 a	 format	 that	may	 be	 handled	 and	 modified	 easily.	 There	 are	
specific	 software	 whose	 purpose	 is	 to	 convert	 different	 .mzML	 data	 files	 into	 a	 unique	 file	 (often	
a	 .csv)	 represented	 by	 a	 matrix	 reporting	 samples	 in	 rows	 and	 different	 metabolites	 in	 columns.	
Examples	 include	 freely	 available	 software	 like	 XCMS219	 ,	 commercial	 software	 like	 Progenesis	






performed	 to	 characterise	 the	 different	 types	 of	 variation	 introduced	 in	 a	 metabolomics	 study.	
Sample	 preparation	 and	 data	 acquisition	 can	 introduce	 sources	 of	 variation.	 The	 sample	 physically	
interacts	 with	 the	 LC	 and	 MS	 instruments	 in	 LC-MS	 metabolomics	 studies	 and	 this	 can	 lead	 to	
changes	 in	 the	 retention	 time	 and	 measured	 response	 across	 an	 analytical	 batch.	 For	 example,	
research	by	Zelena	et	al.	have	shown	how	data	for	LC-MS	can	change	across	an	analytical	batch	and	
defined	 that	 for	 LC-MS	 a	 specific	 number	 of	 injections	 should	 be	 performed	 and	 then	 routine	
instrument	 maintenance	 should	 be	 performed182.	 Earlier	 research	 demonstrated	 that	 instrument	
sensitivity	 can	 change	 significantly	 after	 routine	 instrument	 maintenance	 and	 that	 non-important	








measurements.	 In	 order	 to	quantify	 technical	 variation	 in	 LC-MS	metabolomics	 studies,	 the	 use	 of	
Quality	Control	(QC)	samples	has	been	strongly	recommended184.	QC	samples	are	usually	replicates	
of	 a	 pooled	 sample	 produced	 from	mixing	 aliquots	of	 all	 the	biological	 samples,	 thus	 producing	 a	
representation	of	all	the	qualitative	variability	in	the	study205.	Aliquots	of	the	pooled	sample	undergo	
the	 same	 technical	 procedure	 as	 the	 biological	 samples	 and	 it	 is	 assumed	 any	 technical	 variation	
introduced	will	be	equivalent	for	QC	and	biological	samples.	Three	reasons	justify	the	use	of	QCs:		
(1)	 the	 injection	 of	 a	 series	 of	 QCs	 at	 the	 beginning	 of	 the	 analytical	 batch	 guarantees	 the	
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conditioning	of	 the	column	 (in	experiments	 involving	chromatography)	with	a	sample	type	which	 is	
extremely	similar	to	the	one	soon	to	be	analysed205;		
(2)	the	injection	of	a	QC	replicate	every	nth	injection	allows	the	monitoring,	filtering	and	reporting	of	
technical	 variation.	 As	QC	 samples	 are	 identical	 replicates,	 the	 removal	 of	 features	with	 a	 relative	
standard	deviation	(RSD)	above	a	certain	threshold	gives	a	quantitative	measure	of	the	instrumental	
stability	and	ability	to	remove	features	of	high	technical	variance182.	
(3)	 the	 injection	of	a	QC	 replicate	every	nth	 injection	allows	 for	 correction	of	drift	 in	 the	measured	
response184,222.		
1.12 			Normalisation,	scaling	and	transformation	
Further	 procedures	 provide	 the	 reduction	 of	 the	 impact	 of	 technical	 variation.	 For	 example,	
normalisation	takes	into	account	and	nullifies	the	effect	of	samples	of	different	dilution	(for	example,	
for	 urine).	 Technical	 variation	due	 to	 instrumental	 nuisance	may	 lead	 to	 the	occurrence	of	missing	
values	 that	 therefore	 need	 to	 be	 imputed	 according	 to	 different	 methods.	 This	 aspect	 plays	 an	
important	part	 in	multivariate	analysis	 since	many	procedures	do	not	operate	 robustly	 for	datasets	
with	 missing	 values.	 Successively	 in	 the	 workflow,	 scaling	 and/or	 transformation	 is	 often	 applied;	
scaling	 is	applied	to	remove	heteroscedasticity	from	the	dataset	(after	scaling	the	variance	for	each	
metabolite	to	a	constant	value)	while	transformation	is	applied	to	minimise	the	differences	between	
high	abundance	and	 low	abundance	metabolite	 features	as	 the	 relative	change	 in	concentration	of	
metabolites	is	more	informative	than	their	absolute	concentration.	This	feature	assumes	a	major	role	
in	multivariate	analysis	since	all	 the	variation,	 if	 the	data	are	not	transformed,	will	be	addressed	to	
the	 most	 abundant	 metabolites.	 In	 chapter	 3,	 an	 assessment	 will	 be	 performed	 on	 LC-MS	
metabolomics	datasets	acquired	on	different	manufacturer’s	platforms	 in	order	to	 identify	 the	best	
‘fit-for-purpose’	missing	 values	 imputation	method	 and	 data	 pre-processing	workflow	 (in	 this	 case	
normalisation,	 scaling	 and	 transformation)	 method	 to	 apply	 for	 metabolomic	 experiments.	
Surprisingly,	 limited	 research	 has	 been	 published	 on	 the	 most	 appropriate	 data	 pre-processing	
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steps223,	 therefore	 a	 thorough	 analysis	 in	 this	 direction	 will	 fill	 a	 significant	 gap	 in	 LC-MS	 driven	
experiments.	
1.13 					Univariate	and	multivariate	data	analysis	




the	 analysis	 is	 to	 identify	 biological	 variation	 in	 the	 concentration	 of	 metabolites	 related	 to	 the	
biological	 question	 and	 statistical	 methods	 provide	 the	mathematic	 tools	 to	 accomplish	 this	 task.	
Univariate	methods	that	are	commonly	applied	to	metabolomics	studies	are	the	Student’s	t-test	and	




classes,	 respectively).	Non-parametric	methods	are	more	conservative	and	are	valid	 in	most	 cases.	
While	univariate	analysis	considers	the	variation	of	a	single	variable	(metabolite)	at	a	time,	it	must	be	
noted	 that	 metabolomics	 datasets	 are	 composed	 by	 numerous	 variables	 that	 are	 often	 inter-
dependent.	 To	 this	 regard,	 multivariate	 analysis	 instead	 of	 focusing	 on	 the	 variation	 of	 a	 single	
metabolite	 at	 the	 time,	 considers	 the	 global	 trend	 of	 the	 metabolic	 profile	 (through	 principal	
components,	decision	trees	etc.)	and	displays	it	in	a	synthetic	fashion	(e.g.	two-dimensional	plots)226.	
For	 example,	metabolites	 detected	with	 a	weak	 signal	may	 not	 appear	 as	 significant	 in	 univariate	
analysis	but	may	contribute	to	the	biology	of	the	system	and	that	would	be	displayed	in	multivariate	







from	various	areas)	or	 time	 ranges	 (samples	 collected	and/or	analysed	 in	different	days)	making	 it	
difficult	for	univariate	analysis	to	show	differences	due	to	diverse	conditions	of	sampling	or	analysis	
while	 a	 simple	 Principal	 Component	 Analysis	 (PCA)	 analysis	 may	 point	 out	 a	 difference	 which	 is	




The	 use	 of	 multivariate	 analysis	 can	 detect	 such	 variations	 and	 visually	 highlight	 them	 through	
techniques	including	PCA	and	Partial	Least	Squares	–	Discriminant	Analysis	(PLS-DA)	227.	




the	 principal	 components	 to	 a	 response	 variable	 a	 Partial	 Least	 Squares	 (PLS)	 computation	 is	
performed	 and	 through	 loadings	 plots	 or	 Variable	 Important	 in	 Projections	 (VIP)	 scores	 the	
discriminating	variables	are	identified226.	In	general,	methods	that	use	the	response	variable	to	build	
a	 model	 are	 called	 supervised,	 otherwise	 they	 are	 called	 unsupervised.	 PCA	 is	 an	 unsupervised	
method	 commonly	 applied	 to	 visualize	 data	 and	 assess	 outliers.	 Supervised	 methods	 are	 very	




set	 for	 cross-validation.	 Recently,	 this	 aim	has	 been	 pursued	 through	machine	 learning	 algorithms	
using	Artificial	Neural	Networks	(ANNs)228.	
1.14 			Metabolite	identification	
Univariate	 and	 multivariate	 methods	 identify	 the	 metabolites	 whose	 biological	 variation	 is	
significantly	 different	 between	 samples	 and	 classes.	 The	 next	 step	 is	 then	 the	 annotation	 or	
identification	of	metabolites.	Metabolite	annotation	and	identification	is	one	of	the	most	challenging	
steps	in	the	workflow	due	to	the	complexity	of	the	data,	the	number	of	biological	isomers	detected	
and	 the	 unavailability	 of	 a	 resource	 defining	 all	metabolites	 that	 are	 expected	 to	 be	 present	 in	 a	
specific	sample	type.		
The	Metabolic	 Standard	 Initiative	 (MSI)	 is	 a	 consortium	 that	 started	 operating	 in	 2005	 in	 order	 to	
define	 objective	 standards	 for	 the	 research	 quality	 in	 the	 metabolomics	 community	 including	
metabolite	 identification.	Four	 levels	were	proposed229.	The	 levels	decrease	by	order	of	confidence	
and	 are:	 identified	 metabolites	 (1),	 putatively	 annotated	 compounds	 (2),	 putatively	 characterized	
compound	 classes	 (3),	 unidentified	 compounds	 (4).	 Level	 1	 is	 reached	 for	 non-novel	 metabolites	
when	a	minimum	of	two	orthogonal	measurements	 (e.g.	 retention	time	and	m/z)	 is	collected	for	a	
standard	 in	 the	 same	 instrumental	 conditions	 and	 compared	 with	 the	 experimental	 data.	 Novel	
metabolites	need	to	be	fully	described	in	elemental	composition	and	stereochemistry	hence	entailing	
extraction,	isolation	and	purification,	accurate	mass	determination	and	ion	fragmentation.	Level	2	is	
reached	 when	 the	 metabolites	 are	 annotated	 by	 comparison	 with	 spectral	 libraries	 but	 with	 no	
standard	 comparison.	 Similarly	 level	 3	 is	 reached	 when	 physical	 chemical	 properties	 of	 a	 specific	
chemical	 class	 are	 compared	 against	 a	 library.	 At	 the	 current	 stage	 metabolite	 identification	 still	
actively	requires	the	researcher’s	biochemical	knowledge164.	The	creation	of	databases	for	definitive	
identification	is	an	admirable	initiative;	however	analysis	performed	on	different	platforms	(multiple	
models	 of	 spectrometers	 and	 chromatography)	 contrast	 with	 the	 standardization	 of	 a	 unique	
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database.	Although	research	 is	struggling	 in	this	direction,	a	database	for	definitive	 identification	 is	
not	available	as	of	yet.	
The	 typical	 identification	workflow	 for	 a	UPLC-MS	 study	uses	 accurate	m/z	and	 retention	 times	 to	
map	 the	 detected	 features	 against	 libraries.	 PUTMEDID	 is	 an	 automated	 tool	 dedicated	 to	 such	
task147.	Mean	or	median	peak	area	 is	frequently	used	to	detect	 isotopic	patterns.	A	deeper	 level	of	
identification	can	be	reached	through	the	study	of	metabolite	fragments.	The	use	of	subsequent	ion	
fragmentation	 (MSn	 where	 n	 is	 the	 number	 of	 fragmentation	 cycles)	 allows	 the	 facilitated	
identification	of	the	analytes.	Chemical	fragments	deriving	from	the	same	molecule	can	be	combined	
together	 in	 order	 to	 address	 with	 more	 confidence	 the	 chemical	 structure	 of	 the	 precursor	
compound.		
Occasionally	 these	 procedures	 do	 not	 ensure	 the	 identification	 of	 a	 metabolite:	 in	 such	 cases	
fractionation	and	isolation	of	the	metabolite	is	required.		
1.15 			Research	objectives	
The	 application	 of	 untargeted	 and	 targeted	 metabolomics	 studies	 offers	 many	 advantages	 as	










1.	To	 investigate	 the	 impact	of	different	data	pre-processing	methods	on	the	quality	and	validity	of	
untargeted	LC-MS	datasets	and	to	define	an	appropriate	data	pre-processing	workflow	(see	Chapter	
3).	
2.	 To	 investigate	 the	 effect	 of	 cortisol	 administration	 at	 low	 and	 high	 insulin	 levels	 on	 global	



















datasets	 and	 the	 one	 presented	 in	 section	 2.2.1	were	 collected	 within	 Dr.	 Dunn	 research	 group,	
although	the	PhD	candidate	did	not	participate	in	the	data	collection.	
	(1)	Mouse	serum	(MS)	from	a	study	of	ischemia	following	stroke	acquired	in	negative	ion	mode.	The	




(2)	 Placental	 tissue	 extract	 (PT)	 from	 a	 study	 of	 normal	 and	 pre-eclamptic	 pregnancy	 as	 published	
previously233.	Data	for	24	samples	were	acquired	in	negative	ion	mode	and	RP	chromatography	with	
3412	metabolite	 features.	 The	m/z	 range	was	 100-1000Da	 and	 data	were	 acquired	 on	 a	 UPLC-MS	
system	operating	with	RP	chromatography	(Waters	Acquity	UPLC	system	and	Thermo	Scientific	LTQ-
Orbitrap	XL).	




MS	 system	 operating	 with	 HILIC	 chromatography	 (Thermo	 Scientific	 Dionex	 Ultimate	 3000	 UPLC	
system	and	Thermo	Scientific	Q-Exactive).	These	data	are	unpublished.	
	(4)	 Intracellular	 metabolome	 dataset	 (FP)	 obtained	 from	 an	 arthritis	 study	 involving	 88	 fibroblast	





The	 .RAW	 files	 produced	 were	 converted	 to	 .mzML	 applying	 ProteoWizard	 2.1218	 followed	 by	
deconvolution	 and	 peak	 alignment	 applying	 XCMS	 as	 described	 previously234.	 The	 noise	 threshold	
applied	was	set	to	3	and	the	bandwidth	applied	for	grouping	was	set	to	10.	
2.1.3 Feature	pre-treatment	
	Peak	 filtering	was	performed.	 Specifically,	 if	 a	 single	 feature	 in	 a	 single	 class	was	 completely	 filled	
with	missing	values,	it	was	replaced	by	a	small	value	(defined	as	the	half	of	the	minimum	value	in	the	




values	 of	 each	metabolite	 feature,	missing	 values	 occurrence	 vs.	m/z	 values	 and	 missing	 values	











3. Median	 replacement	 (MD):	 for	 every	 metabolite	 the	 missing	 values	 were	 replaced	 by	 the	
median	of	the	specific	metabolite	across	all	samples236.	
4. K-nearest	neighbour	imputation	(KNN):	the	missing	values	are	replaced	by	the	average	of	the	
corresponding	 (sample	 specific)	 non-missing	 values	 in	 the	 k	 (here	 k=10)	 closest	 columns	 in	
terms	 of	 Euclidean	 distance	 of	 the	 abundances	 across	 all	 the	 samples.	 Therefore	 every	
imputed	value	is	unique	across	the	samples	or	across	the	metabolite	features236,237.	
5. Bayesian	principal	component	analysis	replacement	(BPCA):	the	missing	values	are	replaced	
by	 the	 values	 obtained	 through	 principal	 component	 analysis	 regression	 with	 Bayesian	
method.	Therefore	every	 imputed	missing	value	 is	unique	across	 the	samples	or	across	 the	
metabolite	features237,238.	
6. Random	forests	(RF):	missing	values	are	iteratively	imputed	using	as	a	decisional	criterion	the	













follows:	 only	 the	 features	 with	 no	 missing	 values	 were	 retained,	 missing	 values	 were	 assigned	
randomly	 until	 reaching	 a	 missing	 value	 frequency	 of	 10%.	 This	 value	 was	 acknowledged	 as	 a	
representative	 estimate	 of	 the	 number	 of	missing	 values	which	 are	 present	 in	 a	 UPLC-MS	 dataset	
before	any	data	treatment	stage	as	confirmed	by	other	studies223,237.	This	value	was	consistent	with	
six	publicly	available	datasets	collected	on	different	UPLC-MS	instruments	(Agilent	and	Waters).	The	





known,	 it	 was	 possible	 to	 compare	 the	 imputed	 values	 to	 the	 original	 values	 through	 different	
methods.	 For	 this	 purpose	 normalised	 root	mean	 squared	 error	 (NRMSE)	was	 calculated	 for	 every	







One	 UPLC-MS	 dataset	 was	 used	 to	 assess	 the	 effect	 of	 different	 combinations	 of	 pre-processing	
methods,	absolute	response	and	fold	change.	Human	serum	(HS)	was	acquired	in	positive	ion	mode	
for	77	samples.	The	total	number	of	detected	metabolite	features	was	3837.	The	m/z	range	applied	













vector	of	coefficients.	This	method	was	adapted	by	Dieterle	et	al.246.	 Its	purpose	 is	 to	 take	
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into	 account	 the	 concentration	 changes	 of	 some	 metabolites	 which	 affect	 just	 limited	
regions	of	the	spectrum.	





















• Autoscaling:	 every	metabolite	 feature	 is	 centered	and	divided	by	 the	 standard	deviation	of	
the	column.	This	treatment	ensures	the	standard	deviation	of	each	metabolite	is	equal	to	1.	
Autoscaling,	along	with	range	scaling,	is	not	affected	by	the	feature	abundance250.		














The	QC	 samples	were	 labelled	 as	QC.	 Two	biological	 classes	were	 randomly	 assigned	 to	 the	 other	
samples	so	that	no	statistical	difference	(applying	Mann-Whitney	U	test)	was	reported	between	the	
two	classes.		
The	 dataset	was	 normalised	 applying	 normalisation	 by	 sum	 and	 PQN	 according	 to	 section	 2.3.4.	
Subsequently,	after	checking	for	consistency	of	fold	change	between	the	two	classes	(median	values	
ranged	between	0.8	and	1.2),	the	features	were	split	 in	to	three	blocks	based	on	mean	abundance:	
specifically,	 the	mean	 abundance	was	 calculated	 for	 each	metabolite	 feature;	hence	 the	 vector	 of	




multiplication	 factor	 (only	 one	 class	 was	multiplied	 and	 the	 other	 left	 unmodified).	Multiplication	
factors	0.1,	0.2	and	5-10	were	considered	as	 inducing	high	variation;	factors	0.3-0.5	and	2-4.5	were	
considered	as	inducing	medium	variation.		
Table	4.	32	metabolite	 features	 from	 each	 abundance	 block	were	multiplied	 (class	 1	 only)	 according	 to	 32	
different	 factors.	These	 factors	were	 classified	 as	 high,	medium,	medium/low	 and	 low	 fold	 change	
inducers.	
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normalisation,	 scaling	 and	 transformation).	 The	 total	 number	 of	 statistically	 significant	metabolite	
features	(p<0.05	after	FDR	correction)	was	recorded	along	with	the	number	of	statistically	significant	




features	 from	 the	 total	 number	 of	 significant	metabolite	 features.	 Here,	 by	 “false	 positives”	 we	























between	 23	 and	 47	 were	 recruited	 and	 studied	 in	 two	 separate	 visits	 via	 a	 double-blinded,	




















microcentrifuge	 tubes	 (Eppendorf,	 Cambridge,	 U.K.)	 and	 placed	 on	 ice.	 300	 µL	 of	 HPLC	 grade	
methanol	 were	 added	 followed	 by	 vortex	 mixing	 for	 15	 s	 and	 centrifugation	 at	 13,000	 g	 for	 15	
minutes	at	 3	 °C.	 330	µL	 of	 supernatant	were	 transferred	 to	 2	mL	microcentrifuge	 tubes	and	were	
dried	by	speed	vacuum	concentration	(Thermo	Scientific	Savant	SpeedVac	Concentrator	SPD111V)	at	
room	 temperature	 for	 4	 h	 and	 stored	 at	 -	 80	 °C	 until	 analysis.	 Just	 before	 analysis,	 samples	were	
reconstituted	in	100	µL	of	HPLC	grade	methanol/water	(50:50	v/v),	vortexed	for	30	s	and	centrifuged	
at	13,0	00	g	for	15	minutes	at	3	°C.	The	supernatant	was	then	transferred	to	HPLC	vials	and	analysed.	
Simultaneously	 a	 single	 pooled	 QC	 sample	was	 prepared	 by	 combining	 80	 µL	 aliquots	 from	 each	






















The	 .RAW	 files	 produced	 by	 the	 software	 Xcalibur	 3.0.63	 were	 converted	 to	 .mzML	 with	
ProteoWizard	 2.1	 followed	 by	 deconvolution	 and	 peak	 alignment	 applying	 XCMS	 as	 described	
previously234.	 Metabolite	 features	 (a	 m/z-RT	 pair)	 showing	 greater	 than	 30%	missing	 values	 were	
removed	from	the	dataset.	 If	an	entire	class	of	a	metabolite	 feature	was	still	populated	by	missing	
values	 those	were	 substituted	 by	 a	 small	 value	 identified	 as	 half	 of	 the	minimum	 intensity	 of	 the	
dataset.	Subsequently	a	quality	assessment	was	performed.	All	of	the	metabolite	features	reporting	
a	relative	standard	deviation	greater	than	20%	on	all	QC	samples	(starting	from	QC	8)	were	removed.	
The	 dataset	 was	 normalised	 to	 total	 peak	 area	 for	 each	 sample	 and	 univariate	 analysis	 was	
performed	 through	 paired	Mann-Whitney	U	 tests.	 No	 FDR	 (Benjamini	 –	Hochberg)	 correction	was	













Ten	 samples	were	 collected	 from	each	 subject:	 cortisol	 infusion	on	 the	 evening	 of	 day	 1	 between	
21:00	and	22:00	(fed	state;	HCE),	cortisol	 infusion	on	the	morning	of	day	2	between	6:00	and	8:00	
(fasted	state;	HCM),	cortisol	 infusion	at	basal	 level	of	 insulin	 (HC1),	cortisol	 infusion	at	 low	 level	of	
insulin	(HC2),	cortisol	 infusion	at	high	 level	of	 insulin	(HC3),	saline	 infusion	on	the	evening	of	day	1	
between	21:00	and	22:00	(fed	state;	HCE),	saline	infusion	on	the	morning	of	day	2	between	6:00	and	





















The	 lowest	quality	 injection	out	of	 the	 four	 replicates	 (calculated	as	 the	outlying	 total	 ion	current)	
was	 removed	 from	further	analysis.	The	 .RAW	files	produced	by	 the	software	Xcalibur	3.0.63	were	









Whitney	 U	 tests.	 No	 FDR	 correction	 (Benjamini	 –	 Hochberg)	 was	 applied	 as	 no	 feature	 was	




Metabolite	 annotation	 was	 performed	 using	 the	 PUTMEDID_LCMS	 workflow147	 implemented	 on	
Taverna	 2.5257	 to	 MSI	 level	 2	 (putatively	 annotated	 compounds)258	 and	 the	 software	 MI-Pack	








period)	 randomised	 across	 arms.	 A	 7-day	washout	 period	 occurred	 between	 different	 treatments.	










3. Assessment	 of	 the	 effect	 of	 hydrocortisone	 capsules	 administration;	 patients	 were	
admitted	at	13:00	on	day	1.	1	mg	of	dexamethasone	was	administered	at	22:00	on	day	1,	
06:00	and	12:00	(fasted	state)	on	day	2	in	order	to	suppress	endogenous	production	of	
cortisol.	 At	 07:00	 on	 day	 2	 they	 received	 a	 hydrocortisone	 capsule	 (20	mg).	 A	 plasma	
sample	was	taken	at	7:00	(3-pre)	and	another	at	19:00	on	day	2	(3-post).	





cortisol.	 At	 07:00	 on	 day	 2	 they	 received	 a	 hydrocortisone	 tablet	 (20	 mg).	 A	 plasma	
sample	was	taken	at	07:00	(4-pre)	and	another	at	19:00	on	day	2	(4-post).	
5. Assessment	 of	 the	 effect	 of	 hydrocortisone	 injection	 administration;	 patients	 were	
admitted	at	13:00	on	day	1.	1	mg	of	dexamethasone	was	administered	at	22:00	on	day	1,	
06:00	and	12:00	(fasted	state)	on	day	2	in	order	to	suppress	endogenous	production	of	





Figure	 10.	 Experimental	 design	 for	 the	 dexamethasone	 and	 cortisol	 study.	 Dex:	 administration	 of	 1	mg	 of	
dexamethasone.	HC	capsule:	administration	of	20	mg	of	cortisol	in	capsules.	HC	tablet:	administration	




Plasma	 samples	 were	 extracted,	 analysed	 and	 processed	 in	 two	 batches	 following	 an	 identical	












Figure	 11.	 Experimental	 design	 for	 assessment	 of	 the	 effects	 of	 finasteride	 and	 dutasteride	 on	 the	 human	
serum	metabolome.	
Each	subject	was	admitted	 to	 the	 research	 facility	at	17:00	and	a	spot	urine	 sample	was	collected.	






above.	 In	total	4	serum	samples	were	collected	for	each	subject	(visit	1-pre	 insulin	 infusion;	visit	1-

















(01GL)	 from	 the	 study.	 Serum	 samples	 were	 extracted	 following	 two	 different	 procedures:	
monophasic	extraction	and	biphasic	extraction.		
The	monophasic	extraction	was	performed	as	 follows.	Samples	were	thawed	at	 room	temperature.	
100	µL	of	 serum	was	 transferred	 to	a	2	mL	microcentrifuge	 tube	 (Eppendorf,	Cambridge,	U.K.)	and	
placed	on	 ice.	300	µL	of	HPLC	grade	methanol	were	added	 followed	by	vortex	mixing	 for	15	 s	and	
centrifugation	at	13,000	g	for	15	minutes	at	3	°C.	330	µL	of	supernatant	was	then	transferred	to	a	2	
mL	 microcentrifuge	 tube.	 Samples	were	 dried	 by	 speed	 vacuum	 concentration	 (Thermo	 Scientific	
Savant	SpeedVac	Concentrator	SPD111V)	at	room	temperature	for	4	hours	and	stored	at	-80°C	until	





Biphasic	 extraction	was	performed	as	 follows.	 Samples	were	 thawed	at	 room	 temperature.	 200	µL	
was	 then	 transferred	 to	 a	 2	 mL	 microcentrifuge	 tube	 and	 placed	 on	 ice.	 600	 µL	 of	 HPLC	 grade	









80	 °C	 until	 analysis.	 Just	 before	 analysis	 samples	 were	 reconstituted	 in	 100	 µL	 of	 HPLC	 grade	
methanol/water	 (50:50),	 vortexed	 for	 30	 s	 and	 centrifuged	 at	 13,000	 g	 for	 15	 minutes	 at	 3	 °C.	
Simultaneously,	a	single	pooled	QC	sample	was	prepared	by	aliquoting	and	mixing	120	µL	from	each	
biological	 sample.	 This	 sample	 was	 aliquoted	 into	 48	 different	 QC	 samples	which	 underwent	 the	
same	extraction	procedures	as	described	above.	
Urine	samples	were	extracted	through	deproteinisation.	Samples	were	thawed	at	room	temperature.	
100	µL	of	urine	was	 then	 transferred	 to	a	2	mL	microcentrifuge	 tube	and	placed	on	 ice.	300	µL	of	
HPLC	grade	methanol	were	added	followed	by	vortex	mixing	for	15	s	and	centrifugation	at	13,000	g	
for	15	minutes	at	3	°C.	330	µL	of	supernatant	was	then	transferred	to	a	2	mL	microcentrifuge	tube.	
Samples	were	dried	 by	 speed	 vacuum	 concentration	 at	 room	 temperature	 for	 4	 h	 and	 stored	 at	 -	
80	 °C	until	 analysis.	 Just	before	analysis	 samples	were	 reconstituted	 in	50	µL	of	HPLC	grade	water,	
vortexed	for	30	s	and	stored	at	room	temperature	for	10	minutes.	Samples	were	then	vortexed	mixed	
and	 50	 µL	 of	 HPLC	 grade	 acetonitrile	 was	 added.	 Subsequently	 samples	 were	 vortex	 mixed	 and	
centrifuged	at	13,000	g	for	15	minutes	at	3	°C.	The	supernatant	was	then	transferred	to	a	HPLC	vial	
and	 analysed.	 Simultaneously	 a	 single	 pooled	 QC	 sample	 sample	 was	 prepared	 by	 aliquoting	 and	
mixing		100	µL	from	each	biological	sample.	This	sample	was	aliquoted	into	20	different	QC	samples	
which	underwent	the	same	extraction	procedure	as	described	above.		
Serum	 monophasic	 extracts	 and	 biphasic	 extracts	 were	 analysed	 on	 a	 UPLC-MS	 system	 (Dionex	
Ultimate	 3000	 and	 Thermo	 Scientific	Q-Exactive,	Thermo	 Scientific	Hemel	Hempstead,	UK)	 using	 a	
reversed	phase	C18	method	 (Thermo	Scientific	Hypersil	GOLD	100	x	2.1	mm	1.9	μm).	Solvent	A	was	
water	 +	 0.1%	 formic	 acid	 and	 solvent	 B	was	methanol	 +	 0.1%	 formic	 acid.	 The	 gradient	 elution	
conditions	were:	from	0	to	1	minute	(A	was	constant	at	100%),	from	1	to	4	minutes	(B	increased	from	
0	 to	100%);	 from	4	 to	7	minutes	 (B	was	kept	 constant	at	100%);	 from	7	 to	8	minutes	 (A	 increased	
from	 0	 to	 100%);	 from	 8	 to	 10	 minutes	 (A	 was	 constant	 at	 100%).	 All	 of	 the	 column	 eluent	 was	











Scientific	 Accucore	 150-Amide	 100x2.1	 mm	 1.9	 µm).	 Solvent	 A	 was	 95%	 acetonitrile	 +	 5mM	
ammonium	 formate	 at	 pH	 3	 and	 solvent	 B	 was	 water	 +	 5mM	 ammonium	 formate	 at	 pH	 3.	 	 The	
gradient	elution	conditions	were:	from	0	to	1	minutes	(A	was	constant	at	95%);	from	1	to	12	minutes	
(B	 increased	 from	5	 to	45%);	 from	12	 to	15	minutes	 (B	was	 kept	 constant	 at	 45%);	 from	15	 to	16	
minutes	(A	increased	from	55%	to	95%);	from	16	to	21	minutes	(A	was	constant	at	95%).	All	of	the	
column	 eluent	was	 introduced	 in	 to	 the	 electrospray	 source	 of	 the	mass	 spectrometer.	 The	mass	
spectrometer	 operating	 conditions	 were	 identical	 to	 the	 ones	 applied	 for	 the	 analysis	 of	 serum	
samples.	 Ten	 conditioning	 QC	 samples	 were	 injected	 at	 the	 start	 of	 the	 run.	 Four	 of	 those	 were	
analysed	with	a	HCD	MS/MS	data	dependent	analysis	method	exploring	different	m/z	ranges	 (100-
300Da;	 300-500Da;	 500-750Da;	 750-1000Da)	with	 a	 stepped	 collision	 energy	 of	 30-80%.	 After	 the	
first	ten	QC	samples	a	QC	sample	was	injected	after	every	6th	biological	sample.	
The	 .RAW	 files	 produced	 by	 the	 software	 Xcalibur	 3.0.63	 were	 converted	 to	 .mzML	 files	 with	
ProteoWizard	 2.1	 followed	 by	 deconvolution	 and	 peak	 alignment	 applying	 XCMS	 as	 described	
previously234.	 Metabolite	 features	 (m/z-RT	 pair)	 bearing	 more	 than	 30%	 missing	 values	 were	
removed	 from	the	dataset.	 If	 the	biological	class	of	a	 feature	was	still	populated	by	missing	values	






applying	paired	Mann-Whitney	U	 tests	 using	 the	base	 stats	package	 in	R261.	 Subsequently,	missing	
values	were	imputed	by	Random	Forest	(RF)	replacement	for	PCA	and	by	KNN	replacement	for	PLS-








CHAPTER	 3	 -	 Assessment	 of	 normalization,	 missing	 value	





Mass	 spectrometry	 (MS)	 is,	 the	 most	 frequently	 applied	 analytical	 technique	 in	 metabolomics	
experiments	 for	 non-targeted	 analysis164,262.	 A	 Pubmed	 search	 for	 example,	 retrieved	 1100	 results	
using	 the	words	 “metabolomics”	 AND	 “NMR”	 for	 the	period	 from	 January	 2013	 to	 June	 2016	and	
retrieved	2314	 results	 using	 the	words	 “metabolomics”	 AND	 “chromatography”	 for	 the	 same	 time	
period.	In	fact,	the	expansion	of	MS	as	the	main	technique	for	non-targeted	metabolomics	studies	is	
witnessed	 by	 1013	 papers	 published	 in	 2015	 browsed	 on	 the	 PubMed	 database	 typing	 “mass	
spectrometry”	 AND	 “metabolomics”	 and	 464	 papers	 browsed	 typing	 “mass	 spectrometry”	 AND	
“metabolomics”	AND	“liquid	chromatography”.		
Chromatographic	 techniques	have	contributed	 to	 this	prevalence	with	significant	benefits	providing	
enhanced	 sensitivity	 and	 metabolome	 coverage.	 The	 development	 of	 UPLC,	 coupled	 with	 the	
constant	advances	in	MS	sensitivity	and	mass	resolution,	has	provided	significant	advantages	to	non-
targeted	metabolomics	studies.	Moreover,	the	use	of	chromatography	allows	the	potential	separation	
of	 isomeric	 compounds	 and	 provides	 a	 unique	 signature	 for	 every	 metabolite	 (m/z	 and	 retention	
time)	 that	 can	ease	 the	metabolite	 identification	process.	The	use	of	 ionisation	 techniques	 such	as	
MALDI	 opened	 new	 research	 pathways	 allowing	 the	 imaging	 of	 samples	 with	 high	 spatial	















which	 usually	 comply	with	 the	 XML	 standard,	 can	 then	 be	 processed	 in	 order	 to	 identify	 genuine	
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metabolite	 feature	 peaks	 within	 and	 across	 different	 samples.	 Several	 software	 are	 available	 to	
perform	this	process:	MetAlign265,	MZmine266,267	and	XCMS268.	XCMS	for	example,	produces	a	matrix	
containing	m/z	values,	retention	times	and	chromatographic	peak	 intensities.	The	primary	objective	
of	 XCMS	 is	 to	 detect,	 align	 and	 group	 peaks	 which	 are	 present	 in	 different	 samples.	 The	 peak	
alignment	and	grouping	in	XCMS	can	be	tuned	with	a	variety	of	parameters	and	different	groups	have	
performed	 studies	 in	 order	 to	 optimise	 the	 appropriate	 parameters	 for	 different	 experiments;	 for	
example,	 IPO,	 an	 automated	 tool	 for	 optimisation	 of	 metabolite	 detection,	 has	 also	 been	
published269.	 Alternatively,	 dilution	 series	 have	 been	 analysed	 with	 varying	 parameters	 and	
correlations	between	peaks	have	been	assessed	 to	 identify	 the	optimal	 conditions	 that	 lead	 to	 the	
integration	 of	 genuine	 peaks270.	 Once	 the	 data	 have	 been	 processed	 through	 XCMS,	 a	 matrix	
describing	the	dataset	is	obtained.	This	matrix	reports	all	the	metabolite	features	detected	along	with	
their	retention	time,	m/z and	chromatographic	peak	intensity.		Metabolite	features	do	not	necessarily	
correspond	 to	 unique	metabolites	 since	 they	 could	 include	multiple	 features	 all	 generated	 by	 the	
same	metabolite.	Furthermore,	multiple	metabolite	feature	peaks	may	refer	to	the	same	compound	
as	different	 isotopes,	adducts	and	 fragments;	hence	 they	need	 to	be	 identified	and	 integrated	 to	a	
unique	metabolite;	this	process	is	known	as	deconvolution.	The	high	instrument	sensitivity,	medium	
throughput	 and	 complexity	 of	 samples	 mean	 the	 obtained	 datasets	 are	 often	 large	 (1000s	 of	
metabolite	features	and	100s	of	samples).		
	
The	dataset	obtained	 can	 contain	 a	high	percentage	of	missing	 values	depending	on	 the	 threshold	
used	 to	 identify	and	 report	a	peak	across	 samples.	Peaks	with	a	high	percentage	of	missing	values	
could	be	interpreted	as	not	being	robustly	detected	and	are	often	removed	from	the	dataset.	
The	 use	 of	 QC	 data	 (technical	 replicates)	 allows	 for	 the	 measurement	 and	 reporting	 of	 the	
reproducibility	of	the	analytical	processes	for	each	peak.	For	example,	peaks	with	a	relative	standard	














of	 the	values	 for	 that	sample	and	 (2)	probabilistic	quotient	normalisation	 (PQN)	where	a	 reference	
sample	is	used	to	produce	a	normalisation	coefficient	for	all	the	other	samples246.		
The	effect	of	dilution	(and	thus	the	need	of	normalisation)	becomes	more	critical	in	cases	such	as	the	
analysis	 of	 urine	 samples.	 In	 fact,	 the	 urine	 water	 concentration	 in	 a	 human	 subject	 can	 be	 very	
variable	 depending	 on	 hydration	 level.	 Moreover,	 urine	 displays	 different	 biological	 responses	
depending	 on	 the	 dilution	 factor;	 for	 instance,	 calcium	 oxalate	 crystallisation	 has	 been	 proven	 to	
occur	more	in	concentrated	urine272.	A	study	by	Lusczek	et	al.273	tested	seven	different	normalisation	









One	of	 the	major	 issues	encountered	during	data	pre-treatment	 is	 the	presence	of	missing	 values.	
Some	peak	processing	software	can	 impute	 the	missing	values	present	 in	 the	dataset	although	 the	
values	 are	 usually	 replaced	by	a	 value	 representative	 of	 the	noise	 signal.	Missing	 values	may	have	




• The	 analyte	 may	 be	 present	 in	 the	 sample	 but	 at	 a	 concentration	 which	 is	 below	 the	
analytical	LOD	thus	will	not	be	detected	
• The	analyte	may	not	be	present	at	any	concentration	in	the	sample	(biological	reason).	
• The	 analyte	 is	detected	 by	 the	 UPLC-MS	 assay	but	 is	not	 reported	by	 the	 data	 processing	
software.		
It	 is	worth	noting	missing	values	can	be	classified	 in	three	classes276:	missing	completely	at	random	
(MCAR)	 when	 the	 occurrence	 of	 missing	 values	 is	 not	 related	 to	 any	 other	 variable,	 missing	 at	






or	 MCAR	 depending	 on	 the	 case.	 Different	 treatment	 methods	 would	 imply	 different	 biological	
interpretations	and	more	importantly	different	statistical	outcomes.	Some	studies	report	filtering	of	
all	 features	displaying	more	 than	a	certain	percentage	of	missing	values,	 the	percentage	of	missing	
values	threshold	varies237,277,278.			The	issue	associated	with	missing	values	is	also	connected	with	the	




to	 this	 problem,	 several	missing	 value	 imputation	 (MVI)	methods	 have	 been	 applied	 in	 the	 ‘omics	
area.	Probabilistic	principal	component	analysis	 (PPCA)	was	evaluated	as	a	valid	method	to	process	








other	 processing	 steps	 (normalisation,	 scaling,	 transformation).	 A	 common	 practice	 is	 to	 perform	
imputation	 right	 after	 normalisation	 and	 before	 any	 data	 transformation.	 It	 is	 also	 important	 to	
define	 whether	 missing	 value	 imputation	 should	 be	 performed	 before	 univariate	 analysis.	 The	
present	chapter	discusses	these	issues.	As	the	missing	value	imputation	affects	all	the	latter	steps	of	
the	metabolomics	pipeline	it	 is	extremely	useful	to	 identify	the	best	method	to	perform	in	order	to	
obtain	 the	most	 reliable	 analysis.	 Hrydziuszko	et	 al.237	 compared	 different	 commonly	 used	missing	
values	 imputation	 methods	 for	 Direct	 Infusion	 Fourier	 Transform	 Ion	 Cyclotron	 Resonance-Mass	
Spectrometry	 (DI	 FTICR-MS).	 Similarity	 between	 outcomes	 produced	 by	 different	 imputation	
methods	applied	to	dummy	datasets	was	evaluated.	The	results	pointed	out	k-nearest	neighbour	as	
the	most	reliable	imputation	method	for	DIMS	metabolomic	datasets.	As	far	as	we	know,	this	is	the	
only	work	 reporting	 a	 thorough	 comparison	between	different	missing	 values	 imputation	methods	
concerning	DIMS	metabolomics.	A	study	by	Gromski	et	al.223	explored	the	effects	of	different	missing	
value	imputation	methods	on	classification	performance	in	GC-MS	studies.	In	fact,	the	issue	of	coping	
with	 missing	 value	 imputation	 has	 been	 investigated	 in	 other	 ‘omics	 areas	 such	 as	 genomics	 and	
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proteomics.	 Troyanskaya	 et	 al.285	 examined	 the	 impact	 of	 missing	 values	 in	 genomics	 studies	 on	
statistical	 parameter	 evaluation,	 while	 the	 effect	 of	 missing	 values	 handling	 on	 univariate	 and	
multivariate	 statistics	 was	 studied	 by	 Scheel	 et	 al.288	 for	 genomics	 and	 Pedreschi	 et	 al.289	 for	
proteomics,	respectively.	
The	 final	 step	 in	 data	 pre-processing	 of	 non-targeted	 metabolomics	 datasets	 manages	 the	 large	
differences	 in	 abundance	 of	 different	 metabolites.	 Indeed	 multivariate	 analysis	 can	 be	 heavily	
influenced	 by	 abundant	 metabolites	 while	 minor	 compounds	 (that	 might	 well	 have	 biological	
relevance)	 may	 not	 be	 reported	 as	 discriminant	 in	 the	 analysis	 preventing	 the	 identification	 of	









Despite	 some	studies	having	been	published	 regarding	 the	best	 fit-for-purpose	method	 for	missing	
value	 imputation223,237,296	 (DIMS	 untargeted	 metabolomics	 and	 GC-MS	 untargeted	 metabolomics),	
scaling247	 (GC-MS	untargeted	metabolomics)	and	normalisation297	 (simulated	data)	no	holistic	study	
has	 ever	 been	 performed	 in	 order	 to	 investigate	 and	 propose	 the	 best	 data	 treatment	 pipeline	
involving	all	processes	for	UPLC-MS	non-targeted	metabolomics.	
Indeed	a	 random	query	of	papers	 (a	selection	of	51)	published	 in	2014	and	2015	using	 the search	
terms	 	 ‘metabolomics’	 AND	 ‘liquid’	 AND	 ‘chromatography’	 revealed	 extreme	 diversity	 between	
workflows	adopted	by	different	 research	groups	 in	metabolomics.	However	 the	majority	of	papers	
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Table	 5.	 Different	 pre-processing	 methods	 applied	 in	 a	 selection	 of	 51	 papers	 retrieved	 through	
Pubmed	 using	 search	 terms:	 ‘metabolomics’	 AND	 ‘liquid’	 AND	 ‘chromatography’.	 PQN:	
probabilistic	 quotient	 normalisation,	 IS:	 internal	 standard,	 SUM:	 total	 sum	 normalisation,	
KNN:	k-nearest	neighbour.	
	
The	present	 PhD	project	 relies	 solely	 on	UPLC-MS	methods	and	 therefore	 an	assessment	 study	on	
UPLC-MS	 pre-treatment	 routines	 was	 performed	 in	 order	 to	 define	 the	 most	 appropriate	 data	
processing	methods	 to	 apply	 throughout	 the	 PhD	 project.	 The	 aim	 of	 this	 work	 is	 to	 provide	 a	


























































































The	 Pearson	 coefficient	 related	 to	 the	 missing	 values	 occurrence	 vs.	 the	 mean	 abundance	 of	 the	
metabolite	 features	 showed	no	particular	pattern	or	 recurrence	 for	any	of	 the	analysed	datasets	 (-
0.05	for	AS	dataset,	-0.12	for	PT	dataset,	-0.05	for	UR	dataset	and	-0.08	for	the	FP	dataset).	The	same	
outcome	was	observed	 for	 the	 relationship	between	missing	value	occurrence	and	m/z	value	 (0.07	
for	 AS	 dataset,	 -0.02	 for	 PT	 dataset,	 0.30	 for	UR	 dataset	 and	 0.35	 for	 the	 FP	 dataset)	and	missing	
value	occurrence	and	retention	time	 (0.02	 for	AS	dataset,	 -0.11	 for	PT	dataset,	0.03	 for	UR	dataset	
and	 -0.07	 for	 the	 FP	 dataset)	 (Table	 6).	 Although	 the	 Pearson	 correlation	 did	 not	 highlight	 any	













Figure	 13.	 Plots	 correlating	 occurrences	 of	 missing	 values	 with	 retention	 time	 for	 PT	 dataset	 (top)	 and	 FP	
dataset	(right)	










root	 square	 error;	MS:	 mouse	 serum;	 PT:	 placental	 tissue;	 UR:	 urine;	 FP:	 fibroblast	 fingerprint;	 SV:	
small	 value	 replacement;	 MN:	 mean	 replacement;	 MD:	 median	 replacement;	 KNN:	 k-nearest	
neighbour	replacement;	BPCA:	Bayesian	principal	component	analysis;	RF:	random	forest.	
The	 results	 were	 consistent	 with	 the	 conclusions	 reported	 by	 Hrydziuszko293	 for	 DIMS	 data.	 SV	
achieved	 the	worst	 performance	 (highest	 NRMSE)	 among	 the	methods	 tested.	 The	 reason	 for	 the	
poor	performance	of	SV	is	to	be	assumed	that	the	missing	values	occurring	in	the	dataset	were	due	
uniquely	 to	 low	 concentration	 metabolites.	 This	 assumption	 does	 not	 reflect	 real	 experimental	
conditions,	 as	missing	 values	will	occur	 because	 of	 technical	 or	 biological	 reasons.	 In	 fact	 the	 only	
case	in	which	SV	could	perform	efficiently	would	be	in	datasets	in	which	missing	values	are	correlated	
with	the	mean	response.	However	the	correlation	data	reported	above	excludes	such	a	hypothesis.	
Conversely,	 RF	 achieved	 the	 lowest	NRMSE	error	 in	 all	 datasets	 proving	 to	 be	 the	 best	 imputation	
method	when	dealing	with	MCAR.	This	result	complies	with	the	findings	shown	by	Gromski	et	al.223	
for	 GC-MS.	 Indeed,	 the	KNN	method	 generated	 low	NMRSE	 values	 (Table	 7)	 between	original	 and	
predicted	values.	Although	RF	 is	 the	best	 imputation	method	 tested,	one	of	 its	major	drawbacks	 is	
the	computational	time.	For	instance,	the	application	of	such	a	method	in	the	present	study	took	15	
minutes	 per	 dataset.	 Hence,	 when	 dealing	 with	 data	 analysis	 that	 is	 required	 to	 be	 fast,	 other	
methods	should	be	preferred.	Specifically,	KNN	replacement	seems	to	perform	markedly	better	than	
other	 methods	 (excluding	 RF)	 in	 all	 four	 datasets.	 Although	 the	 results	 showed	 BPCA	 and	 KNN	
NMRSE	 MS	dataset	 PT	dataset	 UR	dataset	 FP	dataset		
SV	 9.99	 3.64	 7.66	 5.53	
MN	 1.82	 0.66	 1.47	 1.01	
MD	 1.60	 0.68	 1.49	 1.01	
KNN	 1.29	 0.58	 1.44	 0.54	
BPCA	 1.30	 0.62	 1.49	 1.12	
RF	 0.75	 0.45	 1.16	 0.37	
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performances	 as	 similar,	 it	 must	 be	 highlighted	 that	 in	 general	 the	 computation	 time	 for	 BPCA	 is	
consistently	higher	when	compared	to	KNN.	Therefore	the	application	of	RF	is	strongly	recommended	
in	general	case	scenarios,	however,	KNN	is	recommended	when	the	analysis	is	heavily	dependent	on	
time	 (e.g.	multiple	 analysis	 in	which	 some	parameters	 are	 slightly	 changed).	 Also,	 the	 use	 of	 SV	 is	
highly	 discouraged.	On	 a	 final	 note,	 this	 assessment	 dealt	 primarily	with	missing	 value	 imputation	
methods	 for	UPLC-MS	 experiments	 affected	 by	 technical	 nuisance	 caused	 by	 software	 inability	 to	





The	 46	biological	 samples	 from	 the	 dataset	described	 in	 section	 2.2.8	were	 assigned	 to	 a	 random	
class	as	described.	This	process	produced	22	samples	assigned	to	class	A	and	24	to	class	B.	Before	any	
further	modification	of	the	dataset,	Mann	Whitney	U	tests	and	Benjamini	Hochberg	correction	were	







Figure	 14.	 PCA	 of	 the	 dataset	 used	 for	 the	 pre-processing	 study	 before	 applying	 any	 modifications	 to	 the	
randomly	assigned	classes.	Class	1	samples	are	reported	as	X	and	class	2	samples	are	reported	as	O.	
QC	samples	are	in	green.	
The	 metabolite	 features	 were	 then	 ordered	 according	 to	 mean	 response	 and	 divided	 in	 to	 three	
blocks	 (low,	medium	 and	 high	 response).	 From	 each	 block	 32	metabolite	 features	 were	 randomly	
chosen.	Each	of	the	32	metabolite	features	was	then	multiplied	by	a	factor	ranging	between	0.1	and	
10	 (class	 A	 only).	 This	 procedure	 generated	 96	 metabolite	 features	 belonging	 to	 three	 different	
equally	populated	response	blocks.	Three	metabolite	features	(one	for	each	block)	bore	a	fold	change	
of	0.1	between	class	A	and	class	B,	three	bore	a	fold	change	of	0.2	and	so	on.	The	dataset	obtained	
contained	 7.8	 %	 missing	 values	 with	 65.3	 %	 of	 features	 bearing	 at	 least	 one	 missing	 value.	 The	
dataset	underwent	assessment	 for	 a	normal	distribution	applying	 the	Shapiro-Wilk	 test	 in	order	 to	
choose	 the	 appropriate	 univariate	 method	 to	 apply	 (parametric	 or	 non-parametric).	 The	 high	
percentage	 of	 non-normally	 distributed	 metabolite	 features	 even	 after	 logarithmic	 transformation	
(Table	9)	demonstrated	 that	 the	non-parametric	Mann	Whitney	U	 test	 is	 the	method	of	 choice	 for	
univariate	 analysis.	 It	 must	 be	 highlighted	 that	 parametric	 statistical	 methods	 are	 widely	 used	 in	
research;	 however,	 these	 methods	 require	 an	 underlying	 normal	 distribution	 of	 the	 data.	 This	
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condition	 is	 not	 always	 tested	before	performing	parametric	methods.	Table	8	 shows	 that	 it	 is	 not	
appropriate	to	assume	this	assumption	even	when	the	sample	size	is	not	small	(77	samples).		
Table	8.	Percentage	of	normally	distributed	metabolite	features	following	different	pre-processing	procedures	






















medium	 and	 high	 fold	 change	metabolite	 features	 gradually	 decreased,	 respectively	 (i.e.	 became	













none	 80	 80	 0	
SV	 77	 77	 0	
MN	 79	 79	 0	
MD	 79	 79	 0	
KNN	[1]	 81	 84	 3	
KNN	[2]	 81	 84	 3	
BPCA	[1]	 81	 82	 1	
BPCA	[2]	 81	 84	 3	
BPCA	[3]	 81	 84	 3	
RF	 81	 81	 0	
PQN	
none	 81	 81	 0	
SV	 77	 77	 0	
MN	 80	 80	 0	
MD	 80	 80	 0	
KNN	 82	 87	 5	
BPCA	[1]	 82	 88	 6	
BPCA	[2]	 82	 88	 6	
RF	 81	 81	 0	
Table	9.	 Summary	 of	 the	 univariate	 analysis.	 The	 third	 column	 indicates	 the	 number	 of	 imputed	metabolite	
features	detected	as	 significant	 (p<0.05	 following	FDR	correction)	while	 the	 fourth	displays	 the	 total	
number	of	significantly	changing	metabolite	features	detected.		
The	 univariate	 outcome	was	 affected	 by	 the	 normalisation	 method	 and	 missing	 value	 imputation	
method	applied	but	very	limited	effect	was	observed	caused	by	scaling	or	transformation.	Indeed	the	
univariate	 analysis	 performed	 on	 datasets	 normalised	 by	 PQN	 (and	 subsequent	 missing	 value	
imputation	 methods)	 produced	 identical	 outcomes	 regardless	 of	 the	 transformation	 or	 scaling	
method	applied.	The	only	exception	 is	 represented	by	 the	BPCA	MVI	method	which	generates	 two	
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different	 outcomes:	 [1]	produced	 after	nlog	 transformation	 (regardless	 of	 scaling	method	 applied);	
[2]	generated	by	all	the	other	transformation	and	scaling	methods.		
The	 results	 are	 slightly	 different	 concerning	 SUM	 normalisation.	 In	 fact,	 there	 is	 no	 scaling	 or	
transformation	effect	 for	 five	missing	values	 imputation	methods	(none,	SV,	MN,	MD	and	RF)	while	
KNN	 and	 BPCA	produced	diverse	 outcomes	dependant	on	 transformation	 and	 scaling.	 Specifically,	
KNN	imputation	generates	two	different	sets	of	p-values:	[1]	for	glog	and	nlog	transformation	and	[2]	
for	 all	 the	 other	 transformation	methods.	Conversely,	 BPCA	 replacement	 generates	 three	 different	
results:	 [1]	obtained	after	glog	and	subsequent	range	scaling	or	autoscaling	or	vast	scaling;	 [2]	nlog	
transformation	 followed	 by	 no	 scaling/Pareto	 scaling/range	 scaling/autoscaling	 or	 glog	 and	
subsequent	no	scaling/Pareto	scaling	and	[3]	for	all	the	other	transformation	methods.	
Following	 SV,	MN,	MD	 and	 RF	 the	 statistically	 significant	metabolite	 features	 were	 picked	 entirely	




has	been	described298	 that	SUM	normalisation	does	not	 cope	well	with	 large	differences	bore	by	a	
few	 high	 intensity	 metabolites	 therefore	 indicating	 PQN	 as	 the	 optimal	 normalisation	 method	 to	
apply	in	univariate	analysis.	
Regarding	the	missing	value	imputation	methods	which	do	not	generate	false	positive	results	(none,	
SV,	MN,	MD	and	 RF).	The	 highest	 number	 of	 correctly	 identified	 statistically	 significant	metabolite	
features	was	achieved	by	no	missing	value	imputation	and	RF	while	the	lowest	number	was	achieved	
through	SV	(Table	9).	It	is	notable	that	following	SUM	normalisation,	RF	performed	even	better	than	
no	 imputation	 (although	 presenting	 just	 one	 more	 true	 positive).	 In	 conclusion,	 it	 seems	 that	




rather	 offers	 guidance	 to	 the	 user	 since	 the	 treatment	 performed	 for	 univariate	 analysis	 is	 heavily	
affected	by	the	purpose	of	the	study.																																																																																																																																																																																																																																																																															
Commonly,	if	a	dataset	presents	a	high	percentage	of	features	not	following	normal	distribution	it	is	
assumed	 (sometimes	 falsely	 as	Table	8	 shows)	 that	 logarithm	 transformation	 is	 able	 to	modify	 the	





In	 fact,	 the	 features	with	a	multiplication	 factor	between	0.8	and	1.2	were	still	observed	 to	not	be	
statistically	 significant	 in	 all	 three	 response	 blocks.	 Furthermore,	 KNN	 and	BPCA	 still	 produced	 the	
highest	 number	 of	 false	 positives	 while	 no	 missing	 value	 imputation	 achieved	 80-81	 significant	
metabolite	 features	 for	 SUM	 normalisation	 and	 81-82	metabolite	 features	 for	 PQN	 always	 while	
keeping	the	false	positive	rate	at	0	%.	 
RF	 achieved	 similar	 results	 compared	 to	 no	missing	 value	 imputation	 although	 the	 combination	of	
SUM	 normalisation	 and	 nlog	 transformation	 produced	 a	 false	 positive.	 Therefore,	 the	 same	
conclusions	 described	 before	 for	 use	 of	 non-parametric	 statistical	 methods	 can	 be	 described	 for	
parametric	 statistics.	 Hence	 for	 both	 parametric	 and	 non-parametric	 univariate	 methods	 it	 is	




















































































































































































































































































































































































































































































The	overall	 purpose	 of	 this	 study	was	 to	 identify	 data	 treatment	methods	 affected	 by	 fold	 change	
alone,	by	abundance	alone	and	by	a	combination	of	both.	Every	permutation	was	recorded	in	terms	

















































































































The	 treatments	 occupying	 the	 first	 positions	 all	 contained	 transformation	 followed	 by	 no	 further	




separation	 for	PC1.	PCA	on	datasets	 that	did	not	undergo	missing	value	 imputation	was	computed	
through	 the	 NIPALS	 algorithm.	 This	 algorithm	 effectively	 provides	 an	 alternative	 method	 for	
imputation,	 which	 is	 required	 for	 PCA.	 Although	 this	 method	 appeared	 to	 work	 well	 with	 PCA,	 it	
presents	 its	own	drawbacks.	 Firstly,	 computation	 time	 for	PCA	 is	much	 longer	 if	 compared	with	an	
already	 imputed	dataset;	secondly,	 it	 is	often	essential	to	relate	a	PCA	model	with	a	PLS-DA	model,	
however	 PLS-DA	 computation	 on	 non-imputed	 datasets	 is	 often	 difficult	 (cross-validation	 presents	
several	 impediments).	Hence,	 imputation	methods	 like	RF,	KNN	and	BPCA,	which	 still	 achieve	good	
separation	on	PC1	and	PC2,	appear	to	be	a	valid	alternative.	Generally,	permutations	including	RF	as	
the	MVI	method	and	 transformation	 followed	by	no	scaling	appear	as	 the	optimal	combination	 for	
PCA.	Notably,	the	only	MVI	method	that	does	not	appear	in	the	first	20	positions	is	SV.	Looking	at	the	
p-values	 related	with	 separation	along	PC1	and	PC2,	 glog	 transformation	appears	 to	achieve	 lower	
and	more	statistically	significant	p-values	compared	to	nlog	or	IHS	and	therefore	better	separation	on	
PC1.	 Comparing	 the	 two	 normalisation	 methods,	 SUM	 seems	 to	 generate	 lower	 p-values	 on	 PC1	
while	PQN	is	associated	with	lower	p-values	on	PC2.		
In	 order	 to	 analyse	 the	 treatments	 affected	 by	 abundance	 alone	 on	 PC1,	 the	 permutations	 were	
selected	 according	 to	 an	 effect	 of	 abundance	 of	 PCA	 and	 no	 effect	 of	 fold	 change.	 The	 resulting	
permutations	are	all	characterised	by	PQN	and	range	scaling	(apart	 from	a	 few	exceptions)	with	no	
particular	effect	of	transformation	applied.	Strangely	the	methods	which	are	affected	by	abundance	
alone	 on	 a	 combination	 of	 PC1	 and	 PC2	 are	 different.	 In	 fact	 SUM	 normalisation	 followed	 by	 no	
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transformation	 and	 no	 scaling	 or	 by	 IHS	 transformation	 and	 no	 scaling	 appears	 to	 be	 affected	 by	




“high	 fold	change”	class	contains	 the	higher	number	of	metabolite	 features	meaning	 that	even	 if	a	
treatment	 is	 recorded	 as	 not	 affected	 by	 fold	 change	 (the	 “high	 fold	 change”	metabolite	 features	
must	be	at	least	8)	it	may	still	show	some	dependence	from	fold	changes.	
Conversely,	 treatments	 affected	 by	 concentration	 and	 fold	 change	 simultaneously	 on	 PC1	 and	 a	
combination	 of	 PC1	 and	 PC2	 are	 all	 characterised	 by	Pareto	 scaling.	 These	 permutations	 are	 SUM	
normalisation	 followed	by	 IHS	or	no	 transformation	 and	 subsequent	Pareto	 scaling	or	 alternatively	
PQN	 followed	by	no	 transformation	and	 subsequent	Pareto	 scaling.	Notably,	 these	 treatments	 also	
achieve	 a	 good	 PCA	 separation	 on	 both	 PC1	 and	 PC2,	 the	 overall	 ranking	 first	 positions	 for	 PCA	
loadings	 are	 mainly	 occupied	 by	 metabolite	 features	 representing	 the	 96	 imputed	 metabolite	
features.	
Another	remark	has	to	be	stated.	Although	different	MVI	methods	do	not	heavily	influence	the	effect	









by	abundance	and	 fold	 change	 together	 should	 consider	 the	use	of	normalisation	by	SUM	or	PQN	
(there	is	no	marked	difference)	and	Pareto	scaling	without	any	transformation.	
3.1.2.2.2	PLS-DA	outcome	




In	 fact,	 PQN	 followed	 by	 KNN	 imputation	 and	 ihs	 or	 nlog	 (the	 scaling	 has	 no	 effect)	 are	 the	 only	
permutations	 being	 affected	 by	 fold	 change	 ratio	 and	 abundance	 on	 variable	 1.	 Conversely,	 on	
variable	2	the	majority	of	permutations	does	not	seem	to	be	affected	by	abundance	or	by	fold	change	
although	 some	 combinations	 present	 an	exception	 displaying	 an	abundance	 effect.	 Precisely	 these	
combinations	 are:	 all	 the	 permutations	 including	 SV	 replacement;	 SUM	 normalisation	 followed	 by	
MN	replacement	and	IHS	transformation	(scaling	has	no	effect);	SUM	normalisation	followed	by	MD	
replacement	and	ihs	or	glog	transformation	(scaling	has	no	effect).		
Normalisation	 MVI	 Transformation	 Scaling	 R2	 Q2	 R2-Q2	
PQN	 BPCA	 nlog	 Pareto	 0.63	 0.47	 0.16	
PQN	 KNN	 glog	 none	 0.61		 0.46	 0.15	
PQN	 BPCA	 nlog	 none	 0.59		 0.44	 0.15	
SUM	 KNN	 glog	 none	 0.59		 0.51	 0.08	
SUM	 BPCA	 nlog	 none	 0.57		 0.40	 0.16	
PQN	 BPCA	 nlog	 none	 0.56		 0.38	 0.18	
PQN	 BPCA	 glog	 Rg	 0.56		 0.55	 0.01	




values	(first	 level)	and	the	difference	between	R2	and	Q2	being	 less	than	0.20	(Table	12).	 It	 is	worth	
mentioning	that	the	highest	R2	and	Q2	scores	are	obtained	by	applying	KNN	and	BPCA	replacement	
with	no	particular	effect	of	normalisation.	Such	models	though,	hardly	exceed	values	of	0.5.	It	is	likely	
that	 models	 constructed	 on	 a	 dataset	 characterised	 by	 a	 limited	 number	 of	 changing	metabolite	
features	may	not	produce	a	robust	validation.	
It	 must	 be	 noted	 that	 while	 the	 PCA	 outcome	might	 point	 out	 the	use	 of	 glog	 transformation	 as	
convenient	 in	 order	 to	 highlight	 the	 fold	 change	 effect	 (the	 first	 positions	 all	 contain	 glog	
transformation),	the	PLS-DA	analysis	provides	the	same	conclusion.		
The	main	recommendation	concerning	PLS-DA	would	be	to	avoid	the	combination	of	PQN,	KNN	and	
ihs	 (or	nlog)	 and	avoid	all	 permutations	applying	SV	 if	 the	experiment	 is	designed	 to	highlight	 fold	
changes.	Conversely,	the	permutations	applying	SV,	SUM,	MN	and	ihs	and	SUM,	MD	and	ihs	(or	glog)	
provide	an	abundance	and	fold	change	effect	of	the	second	variable	of	the	PLS-DA	model.	It	has	to	be	




is	 likely	 that	 the	 limited	 investigation	of	 the	 topic	 is	due	 to	 technical	difficulties	 in	 reproducing	 the	
pre-processing	steps	(lack	of	statistical	programming	knowledge,	lack	of	dedicated	software).	In	order	
to	facilitate	the	investigation	of	different	pre-processing	methods	and	promote	the	standardisation	of	








One	 of	 the	major	 concerns	 of	 scientific	 research	 is	 the	 reproducibility	 of	 the	 data	 processing	 and	




different	 normalisation	 methods	 not	 involving	 the	 use	 of	 an	 internal	 standards	 have	 been	
reported273.	 While	 this	 limitation	 can	 somehow	 be	 overcome	 in	 some	 scientific	 areas	 where	 no	
complex	data	handling	is	required,	it	becomes	absolutely	necessary	for	‘omics	studies	which	operate	
with	datasets	consisting	of	several	thousands	of	metabolite	features.	Therefore	the	standardisation	
of	data	 treatment	procedures	 inside	research	groups	and	 inside	scientific	communities	 is	essential.	
To	this	extent	an	online	platform	named	Galaxy	has	been	developed299-301.	The	purpose	of	Galaxy	is	
to	 provide	 a	 common	 repository	 to	 store	 and	 share	 computational	 procedures	 and	 to	 allow	
computationally	 intensive	 steps	 to	 be	 performed	 on	 an	 online	 or	 local	 server	 through	 dedicated	
routines.	Once	the	input	of	a	processing	step	is	uploaded	in	to	the	system	and	the	output	has	been	
produced,	 this	 result	 can	 be	 published	 and	 shared	 online	 for	 other	 researchers.	 In	 this	 way	 the	
experimental	data	and	the	related	computation	can	be	observed	by	the	scientific	community	leading	
to	a	high	 level	of	 reproducibility.	Moreover,	Galaxy	allows	the	users	 to	connect	different	 tools	one	
after	 the	 other	 to	 obtain	 a	 comprehensive	 and	 coherent	 workflow	which	 can	 also	 be	 shared	 and	





The	main	 instance	 of	 Galaxy302	 is	 suited	 for	 general	 purpose	 computational	 analysis	 and	 common	
tasks	for	genomics	analysis	such	as	mapping	against	genome	libraries	and	RNA	analysis.	Conversely,	
tasks	 more	 specific	 to	 proteomics	 or	 metabolomics	 are	 almost	 totally	 absent.	 While	 the	 main	
instance	 of	 Galaxy	 is	 thoroughly	 debugged	 and	 well	 presented,	 it	 is	 possible	 to	 run	 instances	 of	
Galaxy	 on	 any	 server	 (hence	 on	 local	 machines	 as	 well).	 Different	 groups	 across	 the	 globe	 have	
developed	 their	 own	 instance	 of	 Galaxy	 with	 specific	 tools.	 In	 fact	 it	 is	 possible	 to	 upload	 user-
developed	tools	on	private	and	public	instances	of	Galaxy,	although	before	a	tool	is	approved	on	the	
public	 instance	 it	 must	 be	 thoroughly	 tested	 and	 debugged.	 Tools	 can	 be	 written	 in	 a	 variety	 of	
programming	 languages	which	are	 interpreted	by	Galaxy	such	as	Python,	R,	 Java,	C	and	Perl.	Some	
languages	which	are	not	open-source	(sometimes	called	proprietary	languages)	can	also	be	adopted	
to	 build	 tools	 but	 in	 this	 case	 an	 executable	 must	 be	 directly	 available.	 It	 must	 be	 noted	 that	
“private”	 instances	 can	 be	made	 publicly	 available;	 the	 word	 “private”	 just	 denotes	 that	 such	 an	
instance	is	not	developed	by	the	Galaxy	team.	
The	possibility	of	writing	your	own	tools	makes	such	platform	extremely	flexible	and	powerful	at	the	
same	 time.	 In	 fact	 numerous	 instances	 are	 currently	 being	 developed	 for	 specific	 ‘omics	 areas,	
Galaxy-P303	for	example	 is	a	well-established	instance	for	proteomics	analysis.	The	majority	of	tools	





workflow.	 Workflow4Metabolomics304	 is	 a	 computational	 infrastructure	 for	 metabolomics	 which	
uses	 Galaxy	 to	 serve	 tools	 which	 are	 commonly	 used	 in	 LC-MS,	 GC-MS	 and	 NMR	 based	


















Galaxy-M	 is	 a	 platform	 for	metabolomics	 data	 processing	 hosted	 on	Galaxy	 and	 developed	 at	 the	
University	 of	Birmingham305.	 Its	 purpose	 is	 to	provide	 a	 standardised	workflow	 for	 both	DIMS	and	
UPLC-MS	untargeted	metabolomics	experiments.	While	 the	main	 focus	of	 the	project	 is	 towards	a	
unique	 processing	 platform	 which	 can	 be	 adopted	 by	 the	 entire	 research	 group,	 it	 can	 easily	 be	
shared	with	the	metabolomics	community.	The	workflow	is	publically	available	in	Github306.	Once	the	






through	 virtual	 machines.	 It	 relies	 on	 Python,	 R	 and	 a	 standalone	 application	 which	 allows	 the	
execution	of	Matlab	binaries	on	machines	which	do	not	have	Matlab	installed.	This	is	due	to	the	fact	
that	Matlab	is	a	proprietary	language;	hence	tools	written	in	such	languages	cannot	be	run	directly	






The	 first	 steps	 of	 the	 LC-MS	 pipeline	 heavily	 rely	 on	 XCMS,	 an	 open	 source	 package	 written	 in	 R	
which	 includes	numerous	functions	 for	the	extraction	of	data	 from	chromatographic	and	mass	raw	
data	files.	This	package	accepts	.mzML	or	.mzXML	data	as	an	input	and	produces	a	.csv	output	with	
the	complete	experimental	data	matrix.	Different	tasks	can	be	performed	with	XCMS	including	peak	











will	 then	 be	 filtered.	 After	 this	 step	 peaks	 less	 than	 a	 defined	 S/N	 ratio	 are	 removed.	 In	 this	 case	
noise	is	calculated	as	the	average	signal	of	non-filtered	peaks.	
The	 “centwave”	algorithm	 is	best	 suited	 for	data	 collected	 in	 centroid	mode.	 It	 identifies	 so-called	








After	 peak	 detection	 and	 integration,	 features	must	 be	 grouped	 across	 all	 samples.	 The	 grouping	
algorithm	implemented	by	XCMS	is	based	on	the	division	of	the	m/z	range	in	overlapping	bins	so	that	
groups	 of	 signals	 belonging	 to	 the	 same	 peak	 are	 not	 split.	 Filtering	 is	 then	 applied	 in	 order	 to	
remove	 peaks	 which	 are	 counted	 twice.	 Hence	 the	 algorithm	 calculates	 the	 peak	 distribution	












dataset	 which	 have	 a	 low	 number	 of	 samples	 with	 missing	 peaks	 or	 more	 than	 one	 peak.	 These	
features	 which	 are	 usually	 evenly	 distributed	 across	 the	 retention	 time	 range	 are	 used	 as	
“standards”.	For	each	standard	the	median	retention	time	is	calculated	and	the	deviation	for	every	
sample	 is	 noted.	 Hence	 for	 each	 sample	 we	 can	 plot	 an	 interpolation	 function	 based	 on	 these	




use	of	 the	tool	 is	often	discarded	 in	 favour	of	missing	value	 imputation	 in	subsequent	steps	of	 the	
workflow	described	here.	
(e) Compound	extraction	
Another	R	package	named	CAMERA	was	developed	 to	 carry	out	metabolite	 annotation307	 and	 it	 is	




repeated	 until	 all	 features	 are	 included	 in	 a	 compound	 spectrum.	 Subsequently,	 within	 the	 same	
compound	spectrum	the	13C	isotopic	pattern	is	searched	for	using	an	m/z	difference	of	1.0033.	Hence	
correlations	between	 features	 in	 the	 same	compound	 spectrum	are	 calculated	using	extracted	 ion	
chromatograms.	A	 score	matrix	 is	 then	obtained	as	 it	describes	 the	 relationship	between	different	




a	 hypothesis	 on	 the	 nature	 of	 a	 peak	 and	 if	 several	 hypothesis	 are	 coherent	 the	 peak	 is	 finally	
annotated.	
At	this	point	a	.csv	file	is	created	with	samples	as	rows	and	features	as	columns.	Additional	files	are	
created	bearing	 information	 about	m/z	 values	 collected	 and	 sample	names.	 In	order	 to	undertake	














of	 the	 metabolite	 feature.	 Also,	 a	 high	 percentage	 of	 missing	 values	 in	 a	 sample	 may	 indicate	










feature.	 Before	 doing	 so	 any	 QC	 sample	 used	 to	 condition	 the	 chromatographic	 column	must	 be	




When	 analysing	 biological	 samples	 it	 is	 common	 to	 cope	 with	 samples	 characterised	 by	 different	
concentrations.	 In	 this	 case	 statistics	might	 indicate	metabolite	 features	which	appear	 significantly	
different	simply	due	to	a	different	dilution	factor.	In	order	to	overcome	this	problem	a	normalisation	
step	is	often	required	in	a	metabolomics	workflow.	It	is	possible	to	apply	two	methods:	normalisation	




At	 this	 stage,	 if	 no	peak	 filling	was	performed	 there	 are	 still	 features	with	missing	 values	present.	
Although	 some	 multivariate	 algorithms	 are	 able	 to	 cope	 with	 datasets	 with	 missing	 values	 (e.g.	
NIPALS308)	it	is	much	easier	to	process	these	data	prior	to	multivariate	analysis.	Furthermore	it	must	
be	 considered	 that	 missing	 values	 may	 arise	 due	 to	 different	 causes.	 They	 may	 be	 caused	 by	 a	
metabolite	which	is	effectively	absent,	by	a	metabolite	below	the	detection	limit,	by	problems	with	
the	 peak	 picking	 algorithm	 etc..	 A	 correct	 imputation	 of	 such	 values	 is	 therefore	 desirable.	 The	
imputation	 methods	 implemented	 are:	 small	 value	 replacement,	 mean	 replacement,	 median	
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data	 heteroscedasticity	 (different	 variance	 for	 each	 feature).	 This	 may	 lead	 to	 abundant	 features	
heavily	 affecting	multivariate	models	without	 any	 regard	 to	 their	 effective	 change	 across	 samples.	
Usually	 a	 transformation	 step	 is	 required.	 In	 this	 case	 the	 generalised	 logarithm	 transformation248	
was	 implemented.	 The	 operating	 equation	 can	 be	 found	 in	 paragraph	 2.2.6.	 The	 algorithm	 first	
isolates	the	QC	samples	in	the	dataset.	 It	then	iteratively	varies	the	λ	parameter	and	computes	the	
glog	transformation	on	the	 filtered	dataset	keeping	track	of	 the	sum	of	 the	squared	error	 for	each	




This	 study	 has	 highlighted	 relationships	 between	 normalisation,	 missing	 value	 imputation,	 scaling	
and	 transformation	 methods	 and	 the	 validity	 and	 information	 provided	 by	 univariate	 and	
multivariate	 analysis	 methods.	 Specifically,	 univariate	 analysis	 (regardless	 of	 parametric	 or	 non-
parametric	 methods)	 should	 be	 performed	 after	 RF	 imputation	 or	 no	 imputation	 at	 all	 as	 other	
methods	 may	 produce	 false	 positives	 or	 be	 too	 conservative.	 The	 choice	 concerning	 other	
treatments	 (normalisation,	 scaling	 and	 transformation)	 is	 not	 crucial	 as	 these	 other	 steps	 did	 not	




It	 has	 been	 found	 for	 PCA	 that	 SUM	or	 PQN	 normalisation,	 in	 combination	with	 RF	missing	 value	
imputation,	glog	transformation,	and	no	scaling	highlights	the	metabolite	features	with	a	significant	
fold	 change	 between	 classes	 regardless	 of	 the	metabolite	 feature	 response.	 For	 PLS-DA,	 KNN	 and	
BPCA	missing	value	 imputation	operate	more	effectively	 than	other	 imputation	methods,	 including	
RF.	 The	 highest	 ranked	 permutations	 with	 the	 smallest	 R2	−	Q2	 difference	 were	 (1)	 PQN	











As	 discussed	 in	 chapter	 one,	 the	 interaction	 between	 glucocorticoids	 (GCs)	 and	 insulin	 is	 a	 crucial	
step	 for	 understanding	 the	 biochemical	 mechanisms	 operating	 in	 a	 variety	 of	 metabolic	 diseases	
including	the	metabolic	syndrome	(including	obesity	and	diabetes)	and	Cushing’s	syndrome.	Schilling	
et	 al.309	 showed	 that	 insulin	 has	 an	 effect	 on	 cerebral	 blood	 flow	 regulating	 appetite	 on	 humans	
while	the	effect	of	GCs	was	not	detected.	Griffin	and	Wildenthal310	showed	that	hydrocortisone	can	
have	opposite	effects	on	cardiac	protein	synthesis	depending	on	the	presence	or	absence	of	insulin,	
while	 hydrocortisone	 infusion	 alone	 at	 low	 insulin	 levels	 displayed	 severe	 reduction	 of	 protein	
synthesis	 and	 hydrocortisone	 in	 conjunction	 with	 insulin	 increased	 protein	 synthesis	 rate	 and	
significantly	decreased	protein	degradation.	This	suggests	that	endogenous	hydrocortisone	may	have	
an	 essential	 role	 in	 regulation	 of	 cardiac	 protein	 synthesis.	 Long	 demonstrated	 that	 GC	
administration	is	related	to	lipolysis	and	gluconeogenesis	during	the	fasted	state	(absence	of	insulin)	
and	 to	 lipid	 storage	during	 the	 fed	 state	 (presence	of	 insulin)41.	 In	more	 recent	 years	 studies	have	
focused	on	 insulin	and	cortisol	 interaction	 in	tissue-specific	 investigations.	For	example,	Gathercole	
et	al.2	detected	an	increase	in	lipogenesis	in	adipose	tissue	caused	by	insulin	while	GC	administration	






	In	 a	 separate	 study312	 synthetic	 GC	 administration	 (dexamethasone)	 has	 been	 linked	 to	 insulin	





effect	 may	 be	 due	 to	 an	 increased	 availability	 of	 NADPH	 (involved	 in	 lipogenesis)	 rather	 than	 an	
actual	overexpression	of	enzymes	involved	in	the	pathway.	Nevertheless	the	controversial	outcome	
of	 this	 study	 has	 been	 discussed	 in	 an	 editorial	 by	 Vienberg	 and	 Björnholm313	who	 addressed	 the	
unexpected	outcome	to	long	exposure	to	GC	administration.	
The	 studies	 discussed	 have	 been	 performed	 by	 investigating	 specific	 classes	 of	 metabolites	 with	
target-specific	assays	(for	example,	free	fatty	acids,	acyl	glycerides,	steroids).	However,	non-targeted	
metabolomics	 would	 be	 a	 suitable	 technique	 for	 the	 global	 assessment	 of	 a	 wide	 diversity	 of	
metabolic	classes	affected	by	insulin	and	cortisol.	Furthermore,	a	holistic	assessment	may	overcome	












The	 serum	 dataset	 derived	 from	 the	 positive	 ion	 mode	 acquisition	 consisted	 of	 7384	 metabolite	
features	which	was	 reduced	 to	6177	after	missing	 value	 filtering	 and	 to	5442	after	quality	 control	
filtering.	 The	 dataset	 derived	 from	 negative	 ion	 mode	 acquisition	 consisted	 of	 5897	 metabolite	
features	which	was	reduced	to	5098	after	missing	values	 filtering	and	to	4648	after	quality	control	









The	adipose	 tissue	dialysate	dataset	obtained	after	positive	 ion	mode	analysis	 consisted	of	14,486	








































After	 removing	 replicate	 metabolites	 features	 representing	 the	 same	 metabolite	 by	 keeping	 the	
feature	with	the	lowest	p-value	comparison	S1	–	S3	described	347	statistically	significant	metabolites	
(p<0.05)	 changing	when	moving	 from	 low	 to	 high	 insulin	 at	 basal	 cortisol	 (Appendix	 Table	 7	 and	
summarised	in	Table	13).	The	following	results	(increasing/decreasing)	always	refer	to	high	levels	of	
insulin	e.g.	3	acylglycerides	decreasing	(at	high	levels	of	insulin).	The	changing	metabolites	included	
12	acyl	 carnitines	 (decreased),	13	mono-	and	diacylglycerides	 (11	decreased),	7	 triacylglycerides	 (5	
increased),	3	amino	acids	(proline,	methionine	and	phenylalanine),	2	ceramides	(increased),	18	fatty	
acids	(decreased),	27	oxidised	fatty	acids	(24	decreased),	6	sphingolipids	(5	increased),	10	steroids	(8	
decreased)	 and	 60	 glycerophospholipids	 (41	 increased).	 Insulin	 induced	 activation	 of	 lipogenesis	
witnessed	by	 fatty	acids	 (and	 their	oxidised	 forms)	decreasing	probably	because	of	 their	usage	 for	




statistically	 significant	metabolites	 (Appendix	 Table	 8	 and	 summarised	 in	Table	 13).	 The	 following	
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results	 (increasing/decreasing)	always	refer	 to	high	 levels	of	 insulin.	These	metabolites	 included	16	



































































































































When	 comparing	 the	 effect	 of	 insulin	 at	 low	and	high	 cortisol	 levels,	 some	metabolic	 changes	 are	
induced	by	insulin	regardless	of	the	cortisol	level	(for	example,	diacylglycerides,	oxidised	fatty	acids).	
However,	 some	metabolite	 classes	 increase	when	 insulin	 is	 administered	at	basal	 levels	of	 cortisol	
and	decrease	at	high	levels	of	cortisol	(ceramides,	glycerophospholipids,	sphingomyelins)	(Figure	17.	
Boxplots	of	the	glog	transformed	concentrations	of	all	glycerophospholipids	(left)	and	sphingolipids	
(right).	 Concentrations	 in	 red:	 basal	 insulin	 and	 saline	 infusion	 (S1),	 green:	 high	 insulin	 and	 saline	
infusion	(S3),	magenta:	basal	 insulin	and	cortisol	 infusion	(HC1),	 light	blue:	high	 insulin	and	cortisol	
infusion	 (HC3).	 suggesting	 potential	 inhibition	 of	 glycerophospholipid	 and	 sphingolipid	 synthesis	
occurring	when	insulin	interacts	with	high	cortisol	levels.	Interestingly,	these	lipid	classes	have	been	
reported	 as	 mediators	 of	 insulin	 resistance314.	 Hence	 such	 an	 outcome	 suggests	 that	 insulin	




(right).	 Concentrations	 in	 red:	 basal	 insulin	 and	 saline	 infusion	 (S1),	 green:	 high	 insulin	 and	 saline	




322	 statistically	 significant	metabolite	 features	 (p<0.05)	 (Appendix	 Table	 9).	 The	 following	 results	
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relate	 to	 high	 levels	 of	 cortisol.	 These	metabolites	 included:	 6	 acylcarnitines	 (increased	by	 cortisol	
infusion),	 24	 di-	 and	 triacylglycerides	 (increased),	 8	 ceramides	 (6	 increased),	 7	 fatty	 alcohol	
(increased),	 62	 glycerophospholipids	 (57	 increased),	 12	 sphingomyelins	 (increased),	 tyrosine	 and	
dihydroxyphenyl-pyruvate	(increased).	The	final	two	metabolites	are	involved	in	tyrosine	metabolism	
which	 possibly	 highlights	 up-regulation	 of	 this	 pathway.	 While	 an	 increase	 in	 concentration	 of	
acylcarnitines	may	 indicate	 the	upregulation	of	 lipolysis	 (enhancement	of	 the	 long	 chain	 fatty	 acid	






trunk.	 Therefore,	 traces	 of	 both	mechanisms	 are	 expected	 in	 the	 global	metabolism	 imprinted	 on	
serum.	 Furthermore,	 all	 lipids	 species	 reported	 as	mediators	 of	 insulin	 resistance	 (diacylglycerols,	
sphingolipids,	ceramides	and	glycerophospholipids)	 increase	 in	concentration	after	cortisol	 infusion	
thus	suggesting	an	immediate	impairment	of	insulin	sensitivity.	
Some	biological	trends	appear	when	comparing	S1	–	HC1,	S2	–	HC2	and	S3	–	HC3	(Appendix	Table	9,	




Table	 14.	 Summary	 of	 statistically	 significant	 differences	 when	 comparing	 S1-HC1,	 S2-HC2	 and	 S3-HC3.	
Metabolites	 are	 grouped	 in	 classes	 of	 similar	 chemical	 structure.	 The	 arrows	 report	 up-	 or	 down-
























Acyl	carnitines	 6	 ↑	 13	 ↑	 10	 ↑	
Acyl	glycerides	 24	 ↑	 13	 MIX	 8	 MIX	
Ceramides	 8	 ↑	 1	 ↑	 3	 MIX	
Glycerophospholipids	 62	 ↑	 31	 MIX	 19	 MIX	






changed	 in	S3	–	HC3	with	24	of	 these	changed	uniquely	 in	S3	–HC3.	This	 trend	seems	to	suggest	a	
negating	 effect	 on	 cortisol	 operated	 by	 the	 increase	 of	 insulin.	 Some	 biochemical	 classes	 like	 acyl	
glycerides,	 ceramides	 and	 sphingolipids	 were	 observed	 to	 be	 significantly	 changed	 in	 S1	 –	 HC1	
(cortisol	 infusion	at	basal	 insulin)	but	not	at	 S2	–	HC2	and	S3	–	HC3	 (cortisol	 infusion	at	non-basal	
insulin).	This	is	shown	in	Figure	18.	As	already	noted,	these	classes	have	been	reported	as	mediators	
of	 insulin	resistance129.	 In	 fact	GCs	are	known	to	 induce	 insulin	resistance.	Hence	 it	 is	possible	that	











However,	 other	 metabolites	 including	 six	 acyl	 carnitines,	 four	 steroids	 as	 well	 as	 methionine	 and	
phenylalanine	 increased	only	when	cortisol	was	administered	at	non-basal	 levels	of	 insulin.	 In	 fact,	
the	increase	in	concentration	for	the	acyl	carnitines	may	indicate	a	cooperative	effect	of	insulin	and	
cortisol	(insulin	alone	induces	a	drop	in	concentration	for	acyl	carnitines).	This	is	shown	in	Figure	19.	









other	 three	 are	 sphingolipid	 synthesis,	 glycerophospholipid	 synthesis	 and	 acyl	 glycerides	
formation129.	 The	 cooperation	of	 the	 effects	 of	 insulin	 and	 cortisol	 is	 likely	 to	upregulate	 the	 fatty	
acid	β-oxidation	pathway	instead	of	sphingolipid	and	glycerophospholipid	synthesis.	It	must	be	noted	
that	 while	 the	 effect	 of	 increased	 acyl	 carnitines	 concentrations	 in	 serum	 is	 encountered	 when	
cortisol	 is	 administred	 in	 conditions	 of	 high	 levels	 of	 insulin	 (comparison	 S3	 –	 HC3),	 the	 opposite	
effect	(decreased	acyl	carnitine	concentrationss	decreasing)	is	displayed	when	insulin	is	administered	
Figure	 19.	 Boxplot	 of	 the	 glog	 transformed	 concentrations	 of	 all	 acyl	 carnitines.	 Concentrations	 in	 red:	 basal	




at	 non-basal	 levels	 of	 cortisol	 (comparison	 HC1-HC3).	 Therefore	 it	 is	 likely	 that	 the	 modality	 of	
cooperation	between	insulin	and	cortisol	is	dependent	on	the	order	of	administration.	
	
Figure	 20.	 Overview	 of	 three	 metabolic	 pathways	 and	 their	 behaviour	 in	 conjunction	 with	 insulin	 and	
cortisol129.	 On	 the	 left	 the	 pathway	 involving	 fatty	 acid	 β-oxidation	 and	 the	 citric	 acid	 cycle,	 in	 the	
center	 acylglycerides	 and	 glycerophospholipid	 synthesis,	 on	 the	 right	 sphingolipid	 and	 ceramide	
synthesis.	
The	 global	 effect	 of	 cortisol	 at	 increasing	 levels	 of	 insulin	 does	 not	 seem	 to	 highlight	 a	 precise	




Comparison	 S1	 –	 S3	 did	 not	 produce	 any	 separation	 in	 the	 PCA	 scores	 plot	 in	 positive	 ion	mode.	
However,	the	negative	ion	mode	data	showed	a	PCA	scores	plot	presenting	good	clustering	for	the	S1	
and	S3	group	(Figure	21)	and	clear	separation	between	the	groups	(PC1	vs	PC2).	Such	separation	is	
much	more	evident	 for	 the	comparison	HC1	–	HC3	which	 is	observed	for	positive	and	negative	 ion	








Analysing	 the	 multivariate	 outcomes	 for	 the	 effect	 of	 cortisol	 at	 increasing	 levels	 of	 insulin,	 the	





















































































worse	 estimates	 for	 S2–HC2	 and	 S3–HC3	 (Figure	 24).	 This	 result	 may	 be	 interpreted	 as	 a	
confirmation	 of	 what	 the	 univariate	 analysis	 highlighted,	 the	 effect	 of	 increasing	 insulin	 seems	 to	
negate	the	majority	of	changes	caused	by	cortisol	administration.		
































































acyl	 carnitines,	 which	 appeared	 as	 up-regulated	 by	 the	 interaction	 of	 insulin	 and	 cortisol,	 are	
observed	in	S2	-	HC2	as	expected.	Interestingly,	while	glycerophospholipids	drove	the	model	for	S1	–	
HC1,	 the	number	 of	 statistically	 significant	metabolite	 features	 decreases	 for	 the	 comparison	 S2	 –	
HC2	while	 the	number	of	 fatty	acids	 increase.	This	outcome	may	suggest	a	down-regulation	of	 the	
glycerophospholipid	 synthesis	 pathway	 which	 results	 in	 an	 increased	 number	 of	 ceramides,	 acyl	
glycerides	and	sphingolipids	being	synthesised	(univariate	comparison	S1	–	HC1).	
	
	 Number	 of	 statistically	 significant	
metabolite	 features	 for	 comparison	
S1	–	HC1	
Number	 of	 statistically	 significant	














The	 adipose	 tissue	 dialysate	 dataset	 was	 analysed	 according	 to	 the	 same	 comparisons	 that	 were	
explored	for	the	serum	dataset.	Generally,	the	number	of	statistically	significant	metabolite	features	




Comparison	 S1	 –	 S3	 highlighted	 106	 statistically	 significantly	 metabolite	 features	 (p<0.05)	 when	
comparing	 low	 and	 high	 insulin	 levels	 at	 basal	 cortisol.	 The	 following	 results	 refer	 to	 high	 insulin	
levels.	 29	 metabolite	 features	 were	 annotated	 (Appendix	 Table	 12	 and	 summary	 in	 Table	 16)	
including	4	amino	acids	and	amino	acid	derivatives	(decreasing),	1	ceramide	and	1	cholesterol	ester	
(increasing),	 3	 out	 of	 4	 fatty	 acids	 increasing,	 1	 fatty	 alcohol	 increasing,	 3	 oxidised	 fatty	 acids	
decreasing,	 2	 glycerophospholipids	 increasing	 and	 1	 sphingomyelin	 increasing.	 The	 trend	 reversal	





































































































Comparison	HC1	–	HC3	highlighted	155	 statistically	 significantly	metabolite	 features	 (p<0.05)	when	
comparing	low	to	high	insulin	at	high	cortisol	levels.		
The	 following	 results	 refer	 to	 high	 insulin	 levels.	42	 features	were	 annotated	 (Appendix	 Table	 13)	
including	4	out	of	5	amino	acids	and	amino	acid	derivatives	decreasing,	3	steroids	 increasing	and	8	
glycerophospholipids	presenting	a	mixed	trend.	Similar	to	what	occurred	in	the	serum	dataset,	insulin	
infusion	at	high	 cortisol	 levels	has	a	different	effect	on	 some	metabolic	 classes	when	 compared	 to	












































































































































Comparison	S2	–	HC2	 investigated	the	effect	of	cortisol	 infusion	at	 low	 insulin	 levels	and	described	





242	 statistically	 significant	metabolite	 features	 (p<0.05).	The	 following	 results	 refer	 to	high	 cortisol	
levels.	47	features	were	annotated	(Appendix	Table	16)	including	5	out	of	6	amino	acids	and	amino	
acid	derivatives	decreasing,	2	ceramides	decreasing,	3	oxidised	fatty	acids	and	3	fatty	acids	presenting	
a	 mixed	 trend,	 3	 nucleotides	 decreasing,	 7	 glycerophospholipids	 presenting	 a	 mixed	 trend	 and	 1	
sphingolipid	decreasing.	Results	are	summarised	in	Table	17.	
The	strong	effect	of	cortisol	that	was	highlighted	in	the	serum	dataset	is	not	detected	in	the	adipose	
tissue	 dialysate	 dataset.	 While	 insulin	 seemed	 to	 diminish	 the	 effect	 of	 cortisol	 in	 serum,	 here	 it	
seems	to	cooperate	at	some	level	as	observed	for	comparison	S3-HC3.	The	main	conclusion	drawn	for	
these	 three	 comparisons	 in	 the	 serum	 dataset	 was	 an	 occurrence	 of	 insulin	 resistance	 that	 was	
reduced	 by	 increasing	 levels	 of	 insulin.	 Conversely	 the	 adipose	 tissue	 dialysate	 dataset	 may	
demonstrate	no	observable	phenotype	of	this	mechanism	thus	complying	with	the	previous	finding	
of	glucocorticoids	failing	to	induce	insulin	resistance	in	adipose	tissue87.	




insulin	 and	 cortisol.	 This	 effect	 confirms	 the	 conclusion	 from	 the	 serum	 study.	 In	 fact	 the	 serum	
dataset	 showed	 an	 activation	 of	 fatty	 acid	 β-oxidation	which	 is	 a	 mechanism	 that	 competes	 with	
sphingolipid	 synthesis	 for	 fatty	 acids	 availability.	Here	 the	 data	 suggest	 that	 this	 activation	may	 be	





due	 to	 the	 low	number	of	metabolite	 features	 detected.	Also	 the	PLS-DA	models	 did	not	 produce	




















After	 signal	 correction	and	multi-batch	 integration	 the	dataset	derived	 from	the	positive	 ion	mode	
acquisition	consisted	of	5747	metabolite	 features	which	were	 reduced	 to	4862	after	missing	value	
filtering	 and	 to	 3860	 after	 quality	 control	 filtering.	 The	 dataset	 derived	 from	 negative	 ion	 mode	
acquisition	consisted	of	5055	metabolite	features	which	were	reduced	to	4222	after	missing	values	
filtering	and	to	3278	after	quality	control	filtering.	The	PCA	score	plot	of	the	datasets	showed	good	











1. In	 order	 to	 assess	 the	metabolic	 changes	 occurring	 due	 to	 diurnal	 rhythms	 comparison	 of	










3. The	 effects	 of	 cortisol	 administration	 through	 different	 modality	 in	 conjunction	 with	
dexamethasone	 (treatments	 3-5)	 were	 assessed	 comparing	 treatment	 2	 post	 (after	
dexamethasone	 administration)	 vs	 treatment	 3	 or	 4	 or	 5	 post	 (after	 dexamethasone	 and	
cortisol	administration).	This	comparison	should	therefore	highlight	metabolic	changes	which	
are	 triggered	 by	 cortisol.	 The	 resulting	 comparisons	 are	 indicated	 by	 [3],	 [4]	 and	 [5]	
respectively.	
After	 removing	 replicate	 metabolites	 features	 representing	 the	 same	 metabolite	 by	 keeping	 the	
metabolite	 feature	with	 the	 lowest	 p-value,	 comparison	 [1]	 highlighted	 195	 statistically	 significant	
metabolite	features	(p<0.05).	Results	are	shown	in	Appendix	Table	18	and	are	summarised	in	Table	
18.	The	following	results	refer	to	naturally	occurring	high	levels	of	cortisol.	The	significant	metabolite	
features	 included	 11	mono-,	 di-	 and	 triacylglycerides	 (decreased	 after	 naturally	 increasing	 cortisol	
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levels),	 5	 carbohydrates	 (4	 increased),	 20	 fatty	 acids	 (17	 decreased),	 17	 glycerophospholipids	 (12	
increased)	and	23	oxidised	fatty	acids	(decreased).		
	
Figure	 29.	 Boxplot	 of	 the	 glog	 transformed	 concentrations	 of	 all	 fatty	 acids	 (left)	 and	 glycerophospholipids	























































































































tetracosenoic	 acid)	 displayed	 a	 concentration	 decrease	 of	 more	 than	 4-fold.	 While	 the	 enhanced	
utilisation	of	fatty	acids	may	suggest	an	enhancement	of	lipogenic	mechanisms,	the	decrease	in	acyl	
glyceride	 concentrations	 does	 not	 suggest	 lipogenesis	 as	 a	 mechanism	 consuming	 fatty	 acids	 as	
cortisol	 levels	 increase.	 However,	 these	 results	 may	 indicate	 a	 precise	 mechanism	 in	 fatty	 acid	
metabolism.	In	fact,	intracellular	fatty	acids	can	undergo	three	separate	metabolic	pathways314:	they	
can	 be	 oxidised	 in	 order	 to	 produce	 ATP	 in	 the	 citric	 acid	 cycle	 following	 β	 oxidation	 feeding	 the	
resulting	acetyl-CoA	in	to	the	said	cycle,	they	can	be	converted	to	diacylglycerol	which	in	turn	may	be	
converted	to	triacylglycerides	or	glycerophospholipids	and	if	the	carbon	chain	is	sufficiently	long	they	
can	 be	 converted	 in	 to	 ceramides.	 Fatty	 acids	 are	 also	 involved	 in	 other	 metabolic	 pathways	
regulated	by	cyclooxygenase	(COX)	and	lipoxygenase	(LOX)	enzymes.	Hence,	the	results	shown	here	
provide	evidence	of	an	enhancement	of	the	metabolic	pathway	synthesising	glycerophopspholipids	
and	 suppression	 of	 fatty	 acid	 β-oxidation.	 This	 outcome	 complies	 to	 some	 extent	with	 the	 results	
related	 to	 the	 comparison	S1	–	HC1	 (effect	of	 cortisol)	 presented	 in	 the	 insulin	and	 cortisol	 study.	
Here	 60	 out	 of	 67	 statistically	 significant	 glycerophospholipids	 reported	 an	 increase	 after	 cortisol	
infusion.	 However,	 other	 metabolic	 classes	 demonstrate	 a	 different	 effect	 in	 these	 comparisons.	
Fatty	 acids	 and	 acyl	 glycerides	 which	 increased	 in	 concentration	 in	 the	 insulin	 and	 cortisol	 study	
moving	from	low	to	high	levels	of	exogenous	cortisol	in	serum	samples	(S1-HC1)	showed	a	decrease	
in	 concentration	 in	 this	 study	moving	 from	 low	 to	 high	 levels	 of	 endogenous	 cortisol	 (comparison	
[1]).	 It	 is	 possible	 that	 this	 effect	 is	 due	 to	 the	 different	 exposures	 to	 cortisol.	 The	 subjects	 in	 the	
insulin-cortisol	 study	underwent	a	 cortisol	 infusion,	whereas	 in	 the	present	 study	 the	effect	of	 the	
circadian	rhythm	of	endogenous	cortisol	is	measured.	It	must	be	noted	that	the	exogenous	levels	of	
cortisol	 reached	 in	 the	 insulin	cortisol	 study	are	much	higher	 than	 the	endogenous	overnight	peak	
measured	in	the	present	study	in	comparison	[1]	(1139.60	vs	405.42	nmol/L,	P	<.00001	vs	saline)87.	




metabolite	 features	 shown	 in	 Appendix	 Table	 19.	 The	 following	 results	 refer	 to	 high	 levels	 of	
dexamethasone.	These	metabolite	features	 included	9	acyl	carnitines	(increased),	14	acyl	glycerides	
(increased	after	dexamethasone	administration),	7	amino	acids	(decreased),	16	fatty	acids	(increased)	

















show	 any	 particular	 biological	 class	 trends.	 However,	 comparison	 [5]	 describes	 changes	 of	 15	 acyl	





number	of	 statistically	 significant	metabolite	 features	 in	 these	 comparisons,	 that	 administration	of	
intravenous	cortisol	has	a	more	striking	effect	compared	to	administration	of	 tablets	and	granules.	
This	 outcome	 may	 imply	 a	 major	 effect	 which	 is	 caused	 by	 the	 rapid	 bioavailability	 assured	 by	
intravenous	 administration	 as	 opposed	 to	 the	 slow	 release	 provided	 by	 tablets	 and	 granule	
administration.	
																											 	





Table	19.	 Summary	of	 statistically	 significant	differences	when	comparing	 [3],[4]	and	 [5].	Metabolite	 features	

































































































































Downregulation Downregulation Downregulation	 Downregulation	
Table	20.	Summary	of	the	metabolic	changes	occurring	after	insulin	administration	
	
The	 two	 studies	 described	 highlighted	 that	 insulin	 is	 a	 potential	 inducer	 of	 triglyceride	 and	
glycerophospholipid	synthesis	as	suggested	by	the	decrease	in	fatty	acid	concentrations	and	increase	
in	triacylglycerides	and	glycerophospholipid	concentrations.	These	findings	somehow	hint	at	a	similar	
direction	 pointed	 by	 studies	 proving	 insulin	 as	 a	 promoter	 of	 glycogenesis	 and	 suppressor	 of	





and	 ceramide	metabolism	 in	 serum	which	 inverts	 the	 trend	 shown	at	basal	 cortisol	 concentration.	
Effectively	while	 these	 classes	 appeared	 as	 increasing	 after	 insulin	 administration	 at	 basal	 cortisol	
levels,	 they	 showed	 downregulation	 after	 insulin	 administration	 at	 high	 cortisol	 levels.	 This	 result	
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infusion	 through	 comparison	 S1-HC1	 of	 the	 insulin/cortisol	 branch	 of	 the	 study	 and	 effect	 of	
naturally	occurring	high	levels	of	cortisol	in	comparison	[1]	of	the	cortisol/dexamethasone	branch	of	
the	study	was	performed.	 It	must	be	noted	 that	external	 infusion	of	 cortisol	 significantly	 increases	
the	 concentration	 of	 cortisol	 compared	 to	 the	 endogenous	 overnight	 peak	 (1139.60	 vs	 405.42	
nmol/L,	P	<.00001	vs	saline)87.	While	external	infusion	led	to	an	increase	in	the	concentrations	of	acyl	
carnitines,	 acylglycerides	 and	 glycerophospholipids,	 diurnal	 cortisol	 changes	 appeared	 to	 lead	 to	 a	
decrease	in	the	concentrations	of	fatty	acids	and	acylglycerides	and	an	increase	in	the	concentrations	
of	 carbohydrates	 and	 glycerophospholipids.	 None	 of	 the	 two	 effects	 can	 be	 clearly	 identified	 as	 a	
specific	metabolic	 pathway	which	 is	 perturbed	 even	 though	 (at	 least	 for	 diurnal	 changes)	 lipolytic	
activity	 was	 expected	 as	 described	 by	 Long41	 who	 reported	 suppression	 of	 lipogenesis	 after	 GC	
administration	 in	 the	 fasted	 state	 in	 humans.	 In	 fact,	 the	 effect	which	was	 observed	 in	 our	 study,	
seems	to	 lead	 to	a	similar	conclusion	as	suggested	by	 the	decrease	 in	concentration	of	 fatty	acids.	
The	 increase	 in	 concentration	 of	 glycerophospholipids	 however	 still	 requires	 further	 investigation.	
Notably,	 exogenous	 administration	 of	 cortisol	 appeared	 to	 increase	 (fold	 change	 	 1.7	 for	 6	
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ceramides	 and	 11	 sphingomyelins)	 some	 of	 the	 biochemical	 markers	 of	 insulin	 resistance	
immediately	 after	 cortisol	 infusion.	 This	 finding,	 albeit	 requiring	 further	 confirmation,	 offers	
clarification	regarding	the	time	scale	of	impaired	insulin	sensitivity.	Moreover	this	result	is	supported	
by	 the	 trends	 observed	 in	 comparisons	 S1-HC1,	 S2-HC2	 and	 S3-HC3.	 Specifically,	 while	 the	 insulin	
levels	 progressively	 increase,	 cortisol	 administration	 has	 a	 smaller	 impact	 on	 the	 global	 serum	
metabolome.	 Acyl	 glycerides,	 ceramides	 and	 sphingolipids	 (all	 insulin	 resistance	 mediators)	 are	
significantly	increased	only	at	basal	insulin	levels	suggesting	a	negating	effect	of	insulin	on	the	effects	
of	 these	metabolic	 classes.	Hence,	 it	 is	 probable	 that	 insulin	 infusion	 inhibits	 the	 enhancement	 of	
insulin	 resistance	 triggered	by	high	cortisol	 concentrations.	This	outcome	 is	 completely	 reverted	 in	
adipose	 tissue	 where	 the	 insulin	 resistance	 effect	 is	 severely	 blunted	 at	 high	 cortisol	 levels.	 This	
result	 complies	with	 the	 tissue	 specific	 study	performed	by	Halzhurst	et	 al.87	 that	 reported	 insulin	
sensitization	 in	 subcutaneous	 adipose	 tissue.	 However	 the	 tissue	 specific	 study	 highlighted	
deactivation	 of	 sphingolipid	 synthesis	 triggered	 by	 cooperation	 between	 cortisol	 and	 insulin	 and	
explains	the	activation	of	fatty	acid	β-oxidation	displayed	in	the	serum	study.	
Adipose	 tissue	 dialysate	 also	 showed	 differences	 between	 metabolic	 changes	 observed	 in	
comparisons	S1-S3	and	HC1-HC3.	The	latter	comparison	does	not	display	any	statistically	significant	
changes	 in	 ceramide	 and	 sphingolipid	metabolism	 and	 the	 glycerophospholipids	 do	 not	 appear	 to	
have	 a	 definite	 trend	 (some	 were	 increased	 and	 some	 were	 decreased	 in	 concentration	 at	 high	
insulin).	Moreover	it	is	notable	that	phosphethanolamines	are	shown	to	be	biologically	important	in	
both	the	univariate	and	multivariate	analysis	for	comparison	HC1-HC3	although	presented	different	




characterised	by	high	 levels	 of	GCs	do	not	 coincide	with	 the	effects	displayed	after	GC	 infusion	at	
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high	 levels	 of	 insulin.	 Hence	 interaction	 between	 insulin	 and	 cortisol	 does	 not	 seem	 to	 operate	
through	a	trivial	mechanism	but	is	dependent	on	the	concentrations	of	both	insulin	and	cortisol.	
Furthermore,	 it	 seems	 that	 amino	 acid	 metabolism	 in	 adipose	 tissue	 is	 particularly	 affected	 by	
cortisol	 administration	 regardless	of	 the	 concentration	of	 insulin.	 Specifically,	 the	 concentration	of	
amino	acids	decreased	after	cortisol	administration	possibly	hinting	impaired	protein	breakdown	or	
impaired	amino	acid	synthesis.	The	decreased	amino	acid	concentration	may	also	affect	later	feeding	
into	 gluconeogenesis.	 Notably	 this	 outcome	was	 detected	 through	 a	 spectroscopic	 analysis	 that	 is	
well	 suited	 to	 detect	 semi-polar	 and	 non-polar	 metabolites	 and	 therefore	 an	 analytical	 method	
targeted	to	investigate	polar	metabolites	may	describe	new	and	biologically	important	discoveries.		
On	the	other	hand,	dexamethasone	administration,	most	likely	through	suppression	of	endogenous	
GC	 synthesis,	 led	 to	 an	 enhancement	 of	 fatty	 acid	 β-oxidation	 and	 carnitine-mediated	 fatty	 acid	
transport.	Therefore	the	effect	which	is	displayed	by	cortisol	administration	is	not	only	suppressed	by	
dexamethasone	administration	but	completely	reverted.	This	consideration	sheds	light	on	the	effects	
that	may	arise	 after	dexamethasone	administration	 in	 conjunction	with	endogenous	or	 exogenous	
cortisol.	
For	 example	 this	 study	 highlighted	 that	 cortisol	 infusion,	 rather	 than	 tablet	 or	 granules	
administration	 may	 potentially	 display	 peculiar	 perturbations	 when	 administered	 with	
dexamethasone.	 It	 would	 be	 appropriate	 for	 future	 studies	 to	 assess	 the	 changes	 at	 the	
concentration	peak	of	cortisol.	 In	fact,	comparisons	[3],	[4]	and	[5]	 included	samples	taken	after	12	
hours	 from	 cortisol	 administration.	 If	 this	 result	 confirms	 on	 one	 side	 the	 fundamental	 biological	
difference	 between	 two	GCs	 as	 dexamethasone	 and	 cortisol,	 it	 also	 focuses	 on	 the	 importance	 of	










acts	 on	 different	 substrates	 including	 progesterone,	 androstenedione,	 aldosterone,	 corticosterone	
and	 cortisol	 through	 reduction	 of	 the	 steroidal	 A-ring316.	 All	 of	 the	 enzyme’s	 substrates	 are	
characterised	by	 the	presence	of	a	keto	group	on	carbon	C316.	The	products	of	5-αR	reduction	are	
known	 to	 undertake	 various	 roles	 in	 physiological	 conditions	 (Figure	 33).	 Dihydroprogesterone	
(synthesised	from	progesterone)	has	a	role	in	hormonal	balance	in	fertile	women317,	dihydrocortisol	
(synthesised	from	cortisol)	may	have	a	role	in	formation	of	the	aqueous	humour	in	the	human	eye318,	
dihydroaldosterone	 (synthesised	 from	 aldosterone)	 limits	 the	 amount	 of	 sodium	 excreted	 via	 the	
kidneys	in	to	urine319.	
One	 of	 5-αR’s	main	 substrates	 in	 terms	 of	 concentration	 and	 biological	 relevance	 is	 the	 androgen	
testosterone	(T)	which	is	reduced	to	dihydrotestosterone	(DHT).	Pregnenolone	and	progesterone	are	
converted	into	dihydroepiandrosterone	and	androstenedione,	respectively,	which	can	subsequently	
be	 converted	 into	 T	 and	 finally	 into	DHT.	 Testosterone	 is	 the	most	 abundant	 androgen	present	 in	
serum16.	 Almost	 the	 totality	 of	 it	 (97%)	 is	 bound	 to	 albumen	 and	 globulin	 thus	making	 the	 active	
fraction	just	3%	of	the	total16	which	can	be	converted	to	DHT.	The	structure	of	5-αR	bears	numerous	













the	 study	 of	 its	 metabolism.	 Steroids	 like	 T	 and	 DHT	 bind	 to	 androgen	 receptors	 (AR)	 triggering	
several	 AR-regulated	 transcriptions.	 Such	 modifications	 occur	 through	 binding	 of	 AR	 to	 hormone	
response	 elements	 which	 are	 particular	 sequences	 of	 DNA	 or	 through	 recruitment	 of	 other	




activity	 of	 AR	 has	 been	 also	 linked	 to	 biological	 mechanisms	 related	 to	 hyperplasia	 and	 prostate	
cancer324.	One	of	 the	most	 important	 steroid	metabolic	pathways	which	 involves	 the	activity	of	 5-
alpha	reductase	revolves	round	the	reduction	of	T	in	to	DHT.	The	obtained	DHT	binds	more	tightly	to	
AR	 compared	 to	 T	 (up	 to	 three	 times	 lower	 dissociation	 rate325	 and	 ten	 times	 higher	 signalling	
induction326)	showing	an	increased	effect	on	AR-regulated	transcription326.		
Three	different	 isoforms	of	5-alpha	reductase	have	been	identified.	5-αR1	is	mainly	present	 in	 liver	
and	skin;	5-αR2	is	present	in	prostate,	liver	and	genital	skin327,328;	5-αR3	has	been	recently	identified	




are	 often	 reported	 as	 an	 additional	 subfamily	 of	 the	 5-α	 reductases.	 Different	 isoforms	may	 play	
different	roles	in	physiological	and	diseased	conditions.	For	example,	prostate	cancer	displays	an	up-




in	prostate	cancer.	A	disease	which	 is	related	to	5-αR	activity	 is	5-αR2	deficiency.	Such	 impairment	
has	 been	 linked	 to	 potential	 pseudohermaphroditism,	 hypospadias	 and	 rudimentary	 prostate332.	
Moreover,	 lack	 of	 the	 5-αR2	 isoform	 is	 connected	 with	 decreased	 levels	 of	 circulating	 DHT	 and	
increased	 levels	of	 T324,332.	Diseases	 that	 affect	 the	endocrine	 system	often	have	an	 impact	on	 the	
role	of	5-αR	in	steroid	metabolism.		
Concentrations	of	T	and	DHT	may	vary	 significantly	 in	different	areas	of	 the	human	body.	DHT	 for	
instance	 is	 detected	 in	 the	 prostatic	 area	 with	 a	 concentration	 that	 is	 twice	 as	 high	 as	 the	 one	





as	 a	 treatment.	 Indeed	 treatments	have	 largely	been	developed	 focusing	on	 the	 inhibition	of	5-αR	
through	inhibitors	with	chemical	structures	that	are	similar	to	T	or	DHT.	In	fact,	binding	of	an	external	
compound	 to	 the	 active	 site	 of	 5-αR	 would	 prove	 efficient	 by	 decreasing	 the	 synthesis	 of	 DHT.	
Inhibitors	 of	 5-αR	 can	 be	 steroidal	 and	 non-steroidal.	 Since	 the	 primary	 substrates	 of	 5-αR	 are	
steroids	research	has	produced	a	higher	number	of	steroidal	inhibitors	compared	to	the	non-steroidal	





binding	 or	 they	 can	 bind	 to	 the	 NADP+-enzyme	 complex	 after	 completion	 of	 the	 reaction16.	 Two	





become	 largely	 applied	 in	 treatments	 against	 prostate	 cancer	 and	hyperplasia.	 After	 six	months	 of	
treatment	with	 finasteride	 the	concentration	of	 serum	DHT	decreases	by	71%335.	A	Pubmed	search	
(performed	 in	 May	 2016)	 with	 the	 term	 “finasteride”	 retrieved	 2684	 entries.	 Dutasteride	 was	
synthesised	 and	 commercialised	 later	 (late	 1990s)	 and	 displays	 tighter	 protein	 binding	 than	
finasteride	thus	gaining	large	application	in	treatment	of	prostatic	hyperplasia.	A	Pubmed	search	with	
the	term	“dutasteride”	(performed	in	May	2016)	retrieved	706	entries.	The	use	of	dutasteride	offers	




of	 treatment	 with	 dutasteride	 the	 DHT	 levels	 in	 serum	 decreased	 by	 95%	 (compared	 to	 71%	 for	
finasteride)338.	 Dutasteride	 also	 appears	 to	 inhibit	 isoform	 5-αR3	 much	 more	 efficiently	 than	



















these	 two	 drugs	 on	 sexual	 traits.	 An	 exhaustive	 review	 published	 by	 Traish	 et	 al.342	described	 the	
different	side	effects	of	5-αR	inhibitors,	mainly	focused	on	erectile	dysfunction,	decreased	libido	and	




Interestingly,	 Upreti	 et	 al.344	 investigated	 the	 effect	 of	 finasteride	 and	 dutasteride	 treatment	 on	
insulin	 sensitivity	monitoring	 glucose	 and	nonesterified	 fatty	 acid	disposal	 after	 insulin	 infusion	 for	
both	treatments.	While	finasteride	slightly	increased	glucose	disposal	(glucose	disposal	increased	by	
7.2	 ±	 3.0	µmol/kg	 fat-free	mass/min),	 dutasteride	was	 proven	 to	 severely	 impair	 glucose	 disposal	
(glucose	disposal	decreased	by	5.7	±	3.2	µmol/kg	fat-free	mass/min).	
These	findings	highlight	the	necessity	to	investigate	at	a	deeper	level	the	effects	of	such	inhibitors	of	




the	 effects	 of	 finasteride	 and	 dutasteride	 administration	 on	 global	 metabolism	 have	 not	 been	
investigated	 thoroughly,	 here	 we	 describe	 research	 which	 has	 taken	 advantage	 of	 non-targeted	
metabolomics	techniques	in	order	to	evaluate	the	metabolic	changes	occurring	during	inhibition	of	5-
αR.	 Serum	 and	 urine	 from	 patients	 treated	 with	 finasteride	 and	 dutasteride	 in	 conjunction	 with	
insulin	 infusion	 have	 been	 analysed	 applying	 UPLC-MS	 followed	 by	 univariate	 and	 multivariate	
analysis.		
5.2 Results	and	discussion	
Finasteride	 and	 dutasteride	 were	 detected	 and	 annotated	 in	 serum	 (positive	 ionisation	 mode).	
Finasteride	was	detected	as	 [M+H]+	at	m/z=373.2855	while	dutasteride	was	detected	as	 [M+H]+	at	




































insulin	 infusion	on	the	first	visit	 (effect	of	 insulin	only,	 i.e.	 fasted	to	fed	state),	 (2)	before	and	after	
insulin	 infusion	on	the	second	visit	 (effect	of	drug	on	response	to	 insulin,	 i.e.	 fed	state),	 (3)	before	




ion	mode	 contained	 11,278	metabolite	 features	 which	 were	 reduced	 to	 9096	 after	missing	 value	




to	 8331	 after	 missing	 value	 filtering	 and	 to	 7486	 after	 quality	 filtering.	 The	 dataset	 obtained	 by	
applying	 a	 monophasic	 extraction	 method	 and	 analysed	 in	 negative	 ion	 mode	 contained	 10,516	
metabolite	 features	 which	 were	 reduced	 to	 8951	 after	 missing	 value	 filtering	 and	 to	 7257	 after	
quality	 filtering.	 The	 dataset	 obtained	 by	 applying	 a	 biphasic	 extraction	 method	 and	 analysed	 in	
negative	 ion	mode	 contained	8359	metabolite	 features	which	were	 reduced	 to	7607	after	missing	
value	filtering	and	to	6805	after	quality	filtering.	
Following	 univariate	 analysis,	multiple	 features	 reporting	 the	 same	metabolite	were	 reduced	 to	 a	
single	metabolite	 feature	 (the	metabolite	 feature	 recorded	with	 the	 lowest	 p-value	was	 retained).	




Table	22.	Summary	 of	 statistically	 significant	 differences	 for	 comparison	 (1),	 (2),	 (3)	 and	 (4)	after	 finasteride	
































































































had	 not	 started.	 378	 metabolite	 features	 (Appendix	 Table	 23)	 were	 reported	 as	 statistically	
significant	(p<0.05).	The	biological	classes	involved	included	21	acyl	carnitines	generally	decreasing	at	
high	 insulin	 levels,	 12	 mono-	 and	 diacylglycerides	 decreasing	 at	 high	 insulin	 levels,	 12	
triacylglycerides	generally	increasing	at	high	insulin	levels,	14	ceramides	generally	decreasing	at	high	
insulin	 levels,	 25	 fatty	 acids	 most	 decreasing	 at	 high	 insulin	 levels,	 5	 phosphatidylcholines	 and	 9	
phosphatidylinositoles	increasing	at	high	insulin	levels,	6	lysoglycerophospholipids	decreasing	at	high	
insulin	levels	and	25	oxidised	fatty	acids	decreasing	at	high	insulin	levels.	This	outcome	may	suggest	
the	 occurrence	 of	 increased	 triacylglyceride	 synthesis	 rather	 than	 lipolysis.	 In	 fact,	 fatty	 acids	 and	
oxidised	 fatty	 acids	 decrease	 in	 concentration	 at	 high	 insulin	 levels	 implying	 an	 enhancement	 of	





Figure	40.	Boxplot	 of	 the	 glog	 transformed	 concentrations	 of	 all	 acyl	 carnitines	 (left)	 and	 fatty	 acids	 (right).	
Concentrations	 in	red:	 low	insulin	 level	and	no	drug	treatment,	green:	high	 insulin	 level	and	no	drug	
treatment,	magenta:	 low	insulin	level	after	dutasteride	administration,	yellow:	high	insulin	level	after	








insulin,	 167	metabolite	 features)	may	 indicate	 impaired	 insulin	 sensitivity	 development	 after	 drug	
administration.	 In	 fact	 drug	 administration	 suppresses	 several	 metabolic	 changes	 observed	 in	
comparison	(1).	Changes	significant	in	comparison	(1)	and	negated	after	drug	treatment	included:	10	
acyl	 carnitines,	 14	 ceramides,	 10	 fatty	 acids,	 33	 glycerophospholipids	 and	 17	 oxidised	 fatty	 acids.	
(Figure	 40).	 Metabolite	 features	 which	 were	 common	 between	 comparisons	 (1)	 and	 (2)	 were	
investigated	 as	 these	 features	 represent	 the	 metabolite	 features	 which	 change	 due	 to	 insulin	
administration	regardless	of	drug	administration.	88	metabolite	features	were	statistically	significant	
in	both	comparisons	 including	11	acyl	 carnitines	and	14	 fatty	acids.	The	metabolite	 features	which	
were	 significant	 in	 comparison	 (1)	 only	 represent	 the	 metabolite	 features	 which	 change	 due	 to	




in	 comparison	 (2)	 only.	 Therefore	 the	 drop	 in	 the	 number	 of	 significant	metabolite	 features	 from	
comparison	 (1)	 only	 to	 comparison	 (1)	 and	 comparison	 (2)	 (metabolite	 features	 common	 in	 both	
comparisons)	highlights	the	global	suppression	effect	of	finasteride	on	insulin	sensitivity.	
Comparison	 (3)	 investigated	 the	 changes	provoked	by	 the	drug	 treatment	without	any	effect	 from	
insulin	 (i.e.	 the	 effect	 of	 drug	 in	 a	 fasted	 state).	 The	 result	 described	 68	 statistically	 significant	
metabolite	features	(p<0.05;	Appendix	Table	25).	12	of	14	detected	glycerophospholipids	increased	





from	 testosterone.	 However,	 testosterone	 was	 not	 detected	 suggesting	 either	 a	 compensation	
mechanism	which	balances	the	steroid	concentration	or	an	inability	to	detect	the	metabolite	(which	
does	not	have	chemical	groups	that	could	be	ionised	easily).		
Comparison	 (4)	 described	 96	 statistically	 significant	 (p<0.05)	metabolite	 features	 (Appendix	 Table	
26)	which	represent	the	metabolic	changes	caused	by	finasteride	administration	 in	the	fed	state.	6	
acyl	glycerides	decreased	 in	concentration	at	high	 insulin	 levels,	14	out	of	18	glycerophospholipids	
decreased	 in	concentration	at	high	 insulin	 levels,	5	out	of	6	peptides	 increased	 in	concentration	at	
high	 insulin	 levels	 and	 7	 out	 of	 8	 steroids	 decreased	 in	 concentration	 at	 high	 insulin	 levels.	 Here,	
while	 the	drug	 administration	 appears	 to	 have	 a	marked	 impact	 on	 steroid	metabolism	 in	 general	
(affecting	 not	 only	 dihydrotestosterone),	 it	 seems	 that	 finasteride	 administration	 cooperated	with	
insulin	 resulting	 in	 a	 negation	 of	 fatty	 acid	 β-oxidation	 and	 glycerophospholipid	 synthesis.	 These	
effects	however,	need	to	be	confirmed	in	larger	cohort	studies.	
After	 removal	 of	 multiple	 metabolites	 features	 reporting	 the	 same	 metabolite	 (the	 metabolite	
feature	 recorded	 with	 the	 lowest	 p-value	 was	 retained),	 dutasteride	 described	 661	 metabolite	








Table	23.	Summary	of	 statistically	 significant	differences	 for	 comparison	 (1),	 (2),	 (3)	 and	 (4)	after	dutasteride	
































































































Comparison	 (1)	described	302	statistically	 significant	metabolite	 features	 (Appendix	Table	27).	The	
following	 results	 refer	 to	 high	 levels	 of	 insulin.	 The	 changing	 metabolite	 features	 included	 8	 acyl	
carnitines	 decreased,	 6	 amino	 acids	 increased,	 9	 ceramides	 increased,	 8	




finasteride,	 dutasteride	negates	 the	 effect	 of	 insulin	 on	metabolism.	 The	 following	 results	 refer	 to	
high	 levels	 of	 insulin.	 The	 metabolite	 features	 included	 8	 di-	 and	 triacylglycerides	 decreased,	 9	
ceramides	decreased,	13	fatty	acids	decreased,	24	glycerophospholipids	decreased,	11	oxidised	fatty	
acids	decreased	and	11	peptides	decreased.	 	36	metabolite	 features	were	statistically	significant	 in	
comparisons	 (1)	 and	 (2)	 including	 3	 glycerophosphoinositols.	 235	 metabolite	 features	 were	
statistically	 significant	 in	 comparison	 (1)	 only	 and	 143	 metabolite	 features	 were	 significant	 in	
comparison	 (2)	 only	 including	 7	 acyl	 carnitines	 and	 11	 ceramides.	 Notably,	 ceramides	 have	 been	
reported	as	mediators	of	insulin	resistance314.	The	difference	between	metabolite	features	significant	





Figure	 41.	 Boxplot	 of	 the	 glog	 transformed	 concentrations	 of	 all	 glycerophospholipids	 (left)	 and	 ceramides	
(right).	Concentrations	in	red:	low	insulin	level	and	no	drug	treatment,	green:	high	insulin	level	and	no	




Comparison	 (3)	 described	 132	 statistically	 significant	 metabolite	 features	 (Appendix	 Table	 29)	
affected	 by	 dutasteride	 administration	 at	 low	 insulin	 levels	 (fasted	 state).	 The	 fact	 that	 132	
metabolite	 features	were	 identified	 after	 dutasteride	 treatment	while	 only	 67	metabolite	 features	
were	described	after	finasteride	treatment	may	be	linked	to	the	inhibition	of	both	isoforms	of	5-αR	
by	dutasteride	whereas	finasteride	inhibits	the	5-αR1	isoform	only.	The	following	results	refer	to	the	
post-	 drug	 administration	 condition.	 Classes	 affected	 by	 dutasteride	 included:	 4	 di-	 and	
triacylglycerides	 increased,	 4	 amino	 acids	 increased,	 26	 glycerophospholipids	 increased	 and	 7	
peptides	 increased.	 Interestingly,	 the	 high	 number	 of	 glycerophospholipids	 increased	 in	
concentration	 corresponds	 to	 an	 enhancement	 of	 hepatic	 lipid	 accumulation	 as	 pointed	 out	 by	




Comparison	 (4)	described	188	statistically	 significant	 (p<0.05)	metabolite	 features	 (Appendix	Table	
30).	The	following	results	refer	to	the	post-	drug	administration	condition.	The	changing	metabolite	
features	 included	 7	 acyl	 glycerides	 decreased,	 11	 out	 of	 12	 ceramides	 decreased,	 6	 fatty	 acids	
decreased,	39	out	of	41	glycerophospholipids	decreased,	9	out	of	10	oxidised	fatty	acids	decreased,	5	
peptides	decreased	and	5	steroids	decreased.	Although	the	majority	of	changes	complied	with	 the	
results	 observed	 for	 finasteride,	 some	 differences	must	 be	 noted.	 First,	 the	 number	 of	 significant	










describe	 any	 biological	 trend,	 the	 biological	 classes	 detected	 as	 significant	 do	 not	 show	 uniform	
behaviour	 (no	 class	 is	 enriched).	However,	 dutasteride	 reported	 several	 classes	 as	being	 increased	
after	 administration	 including	 5	 amino	 acids,	 7	 metabolite	 features	 involved	 in	 carbohydrate	
metabolism,	 6	 glycerophopsholipids	 and	 5	 peptides.	 It	 appears	 that	 dutasteride	 affects	 global	
metabolism.	 Protein	 degradation	 appears	 to	 increase	 (peptides	 and	 amino	 acids	 are	 increased	 in	








much	 lower	when	 compared	 to	 serum.	Another	 reason	may	be	 the	 choice	 of	 a	 collection	method	
(spot	urine)	 that	 is	not	optimal	when	studying	global	metabolism;	 future	 studies	may	contemplate	
the	use	of	a	24-hour	urine	collection.	This	recommendation	reflects	the	need	to	include	the	array	of	




After	 QC	 filtering	 for	 biphasic	 extraction	 serum	 datasets,	 the	 PCA	 scores	 plots	 showed	 good	
clustering	 of	 QC	 samples	 indicating	 good	 technical	 reproducibility.	 No	 class	 separation	 based	 on	
insulin	administration	or	drug	treatment	was	observed	in	the	PCA	scores	plots	(Figure	42	and	Figure	
















Figure	43.	 PCA	 scores	 plots	 (biphasic/pos)	 comparing	 visit	 1	 and	 visit	 2	 for	 finasteride	 (top)	 and	 dutasteride	
(bottom).	The	QC	samples	are	clustered	
The	effect	of	drug	administration	and	 insulin	 infusion	was	 investigated	applying	PLS-DA	as	 follows.	
Firstly,	in	order	to	explore	the	effect	of	drug	administration,	PLS-DA	models	were	implemented	using	







Subsequently,	 insulin	 infusion	 was	 adopted	 as	 the	 explanatory	 variable	 and	 PLS-DA	 models	 were	
constructed.	Some	of	these	models	reported	acceptable	R2	and	Q2	values	 indicating	a	robust	cross-
validated	 model.	 The	 biphasic/positive	 dataset	 resulted	 in	 R2	 and	 Q2	 of	 0.6204	 and	 0.523,	
respectively	while	the	biphasic/negative	dataset	resulted	in	0.8126	and	0.4983,	respectively	(Figure	
44	 and	 Figure	 45).	 It	must	 be	 remarked	 that	 these	 values	were	 obtained	 using	 all	 of	 the	 samples	
present	 in	 the	 dataset	 (excluding	QCs),	 however	when	 the	 datasets	were	 separated	 in	 to	 samples	
administered	with	finasteride	and	samples	administered	with	dutasteride,	the	cross-validation	values	







































infusion	 rather	 than	drug	 administration.	 In	 fact,	 univariate	 analysis	 confirms	 this	 conclusion	 since	
the	majority	 of	 statistically	 significant	metabolite	 features	were	 observed	when	 comparing	 before	
and	 after	 insulin	 infusion.	 Although	 this	 seems	 to	 be	 the	main	 factor,	 univariate	 analysis	 revealed	
















After	 QC	 filtering	 the	 PCA	 scores	 plots	 showed	 good	 clustering	 of	 QC	 samples	 representing	 data	
reliability	 and	 instrument	 stability.	 PCA	 scores	 plots	 did	 not	 show	 any	 particular	 separation	 of	
samples	 according	 to	 drug	 administration.	 Furthermore,	 PLS-DA	 models	 constructed	 poor	 cross-
validatied	models,	probably	due	to	the	reduced	sample	size.	
5.3 Conclusion		




was	 obtained	 in	 chapter	 4	 after	 analysis	 of	 samples	 before	 and	 after	 insulin	 infusion.	
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of	 gluconeogenesis	 and	 glycogenolysis315	 in	 non-diabetic	 subjects.	 Furthermore,	 administration	 of	









Metabolite	 features	 influenced	 were	 acyl	 carnitines,	 fatty	 acids	 and	 glycerophopsholipids	 for	
finasteride	 treatment	 and	 acyl	 glycerides,	 glycerophospholipids,	 fatty	 acids	 and	 peptides	 for	
dutasteride	 treatment.	However,	 finasteride	 and	dutasteride	 administration	on	 its	 own	 seemed	 to	
achieve	 much	 fewer	 effects	 on	 the	 global	 metabolome	 as	 witnessed	 by	 the	 lower	 number	 of	
statistically	 significant	 metabolite	 features.	 Nonetheless,	 glycerophospholipids	 appeared	 to	 be	
increased	after	drug	administration	 independent	of	the	drug.	This	outcome	may	possibly	 link	to	an	
enhancement	 of	 hepatic	 lipid	 accumulation347,	 reported	 in	 the	 same	 study.	 It	 is	 peculiar	 that	
dihydrotestosterone,	 which	 was	 detected	 as	 decreasing	 after	 finasteride	 administration,	 is	 not	
observed	 to	 be	 statistically	 significant	 after	 dutasteride	 administration.	 However,	 dutasteride	
Drug	 	Visit	 1-pre	 vs	
Visit	1-post	
(insulin	only)	
Visit	 1-pre	 vs	 Visit	 2-
pre	
(drug	 at	 low	 insulin	
only)	
Visit	 1-post	 vs	 Visit	 2-
post	
(drug	 at	 high	 insulin	
only)	




Fin.	 378	 67	 36	 167	
Dut.	 271	 132	 166	 179	
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administration	 caused	a	higher	number	of	metabolite	 features	 to	 change	 compared	 to	 finasteride,	
probably	due	to	the	dual	inhibition	of	5-αR	isoforms.	
Other	interesting	observations	on	the	metabolic	effects	of	dutasteride	were	drawn	from	comparison	
(4)	 in	 serum	 and	 from	 the	 analysis	 of	 urine.	 Dutasteride	 appears	 to	 have	 an	 effect	 on	 protein	
degradation	 and	 possibly	 gluconeogenesis	 or	 glycolysis.	 While	 the	 analysis	 of	 urine	 highlights	 an	
enhancement	of	 this	 pathway	 (reporting	peptides	 and	 amino	 acids	 as	 increased	 in	 concentration),	
comparison	(4)	in	serum,	which	denotes	the	effect	of	dutasteride	in	a	fed	state,	reports	peptides	as	
decreased	 in	 concentration	 in	 serum	possibly	highlighting	a	 cooperative	mechanism	of	dutasteride	
with	insulin	to	protein	metabolism.	
These	 observations	 might	 introduce	 more	 awareness	 concerning	 finasteride	 and	 dutasteride	
prescription	since	these	drugs	trigger	mechanisms	with	a	wide	range	of	effects.	In	fact,	5-αR-related	
diseases	 proved	 to	 display	 potential	 links	 with	 insulin-resistance	 syndromes	 such	 as	 diabetes,	
Cushing’s	 syndrome	 and	 metabolic	 syndrome.	 Furthermore,	 the	 occurrence	 of	 lipogenesis	 and	
reduction	 of	 fatty	 acid	 beta-oxidation	 triggered	 by	 insulin	 infusion	 sheds	 light	 on	 the	 actual	 risks	
which	may	be	caused	by	drugs	provoking	insulin	resistance	i.e.	the	administration	of	such	drugs	may	
have	 a	 negative	 effect	 on	 the	 physiological	 occurrence	 of	 anabolic	 processes	 involving	 lipids	 (and	
possibly	carbohydrates).	
Concerning	 the	analytical	 aspects	of	 this	 study,	 it	 should	be	 remarked	 that	 the	biphasic	 extraction	
(non-polar	phase)	produced	datasets	bearing	a	 larger	number	of	 statistically	 significant	metabolite	
features	when	dealing	with	lipids	and	fatty	acids	which	in	this	case	proved	to	be	central	for	the	study.	
Therefore	 such	 an	 extraction	 method	 should	 be	 preferred	 when	 changes	 in	 lipid	 metabolism	 are	




to	 perform	 a	 biphasic	 extraction	 and	 integrate	 the	 data	 from	 the	 two	 extractions	 in	 a	
water/methanol	solution	for	reconstitution	so	to	have	the	maximum	coverage	of	metabolites348.	
Future	studies	may	focus	on	the	effect	of	5-αR	inhibitors	on	specific	classes	of	metabolites	or	specific	
indicators	of	 insulin-resistance.	 For	example,	 semi-targeted	 studies	on	 steroids	 could	 shed	 light	on	
the	 specific	 transformation	 occurring	 in	 the	 steroids	metabolic	 pathway.	 Furthermore,	 correlation	












The	 first	 part	 investigated	 an	 array	 of	 data	 pre-processing	 methods	 commonly	 used	 in	 UPLC-MS	
metabolomics	 and	 detected	 the	 most	 efficient	 permutations	 with	 respect	 to	 univariate	 and	
multivariate	 analysis.	 This	 study	 pointed	 out	 Random	 Forest	 imputation	 as	 the	 preferred	 missing	
value	imputation	method	since	it	outperforms	all	the	other	tested	methods.	However,	its	application	
must	 be	 evaluated	 case	 to	 case.	 In	 univariate	 analysis	 for	 example,	 it	 is	 advisable	 not	 to	 use	 any	
imputation	method	and	no	further	processing	methods.	When	dealing	with	multivariate	statistics	the	
conclusions	 change.	 Before	 performing	 PCA	 the	 recommended	 pre-processing	 methods	 to	 adopt	
would	be	PQN	normalisation,	Random	Forest	imputation	and	glog	transformation.	This	permutation	




to	 propose	 the	 aforementioned	 treatment	 permutations	 as	 the	 standard	 for	 untargeted	
metabolomics.		
Once	the	computational	method	was	tuned	and	set	up,	we	proceeded	to	investigate	the	second	part	
of	 the	 scientific	 question:	 how	 do	 glucocorticoids	 affect	 the	 global	 metabolism	 and	 how	 do	 they	






ceramides	 and	 sphingomyelins	 (mediators	 of	 insulin	 resistance)	 to	 increase,	 possibly	 suggesting	 a	
role	on	insulin	sensitivity	that	is	exerted	in	a	short	time	scale.	The	general	metabolic	changes	caused	
by	 cortisol	 also	 seem	 to	 blunt	 at	 high	 levels	 of	 insulin	 thus	 confirming	 a	 relation	 between	 cortisol	
induced	 changes	 and	 insulin	 sensitivity.	 The	 interaction	 between	 insulin	 and	 cortisol	 also	 caused	
glycerophospholipids	 and	 ceramides	 to	 decrease	 while	 they	 appeared	 as	 increasing	 after	 insulin	
administration.	 Furthermore,	 dexamethasone	 (commonly	 used	 as	 an	 exogenous	 GC	 in	 medical	
treatment)	displayed	enhanced	β-oxidation	and	contrasting	results	concerning	glycerophospholipids	
hence	 showing	 different	 behaviour	 when	 compared	 to	 cortisol.	 This	 part	 of	 the	 study	 not	 only	
provided	further	insight	to	the	known	effect	of	cortisol	and	insulin	but	also	defined	their	interaction	
and	 spotted	 affected	 metabolite	 classes	 that	 could	 be	 investigated	 in	 dedicated	 studies.	 It	 also	




differently	 in	 the	 presence	 of	 dexamethasone	 or	 cortisol	 and	 also	 β-oxidation,	which	 appeared	 as	
enhanced	after	dexamethasone	administration,	is	not	confirmed	at	high	levels	of	cortisol.	
After	 investigating	 the	 effects	 of	 GCs	 on	 global	 metabolism,	 the	 third	 part	 of	 the	 research	 study	
focused	on	the	interaction	between	other	steroidal	metabolic	pathways	and	the	global	metabolome.	
In	 order	 to	 do	 so,	 the	 inhibition	 of	 5-αR	was	 examined	 through	 administration	 of	 finasteride	 and	
dutasteride.	 In	 particular	 these	 drugs	 blunted	 the	 majority	 of	 the	 changes	 induced	 by	 insulin	 in	
serum.	Specifically	fatty	acids,	oxidised	fatty	acids	and	acyl	carnitines	were	the	metabolic	classes	that	
were	affected.	This	outcome	suggests	 that	steroidal	metabolic	pathways	and	their	 interaction	with	




fatty	 acids	 and	 acyl	 carnitines.	 However	 the	 5-αR	 inhibitors	 markedly	 diminished	 this	 effect	 thus	
proving	 a	 strong	 interdependency	between	different	 steroidal	 pathways.	 Furthermore,	 dutasteride	
displayed	 a	 larger	 effect	 on	 the	 global	 metabolome	 reflecting	 the	 greater	 drug	 potency	 when	
compared	to	finasteride.	These	findings	are	particularly	relevant	considering	the	large	application	of	
treatments	involving	administration	of	finasteride	and	dutasteride.	In	fact,	although	these	drugs	are	
commonly	 prescribed,	 to	 our	 knowledge	 no	 interaction	 with	 insulin	 has	 been	 reported	 yet.	 Thus	
while	the	effects	of	GCs	are	investigated	in	relation	with	insulin	resistance,	this	is	still	not	the	case	for	
other	 steroidal	 classes	 (e.g.	 androgens).	 Hopefully	 this	 study	 will	 raise	 awareness	 for	 this	 aspect,	
motivating	further	research	in	this	direction.	
In	 conclusion,	 this	 PhD	project	managed	 to	 close	 some	open	 topics	 (data	 treatment	 in	untargeted	
metabolomics)	 and	 provide	 further	 details	 for	 some	 complex	 or	 obscure	 topics	 (the	 interaction	
between	cortisol	and	insulin	and	the	role	of	steroidal	metabolic	pathways).	Some	of	the	findings	of	
the	 present	 work	 should	 therefore	 stir	 future	 investigations	 towards	 more	 narrow	 areas	 of	 the	
intricate	field	of	metabolomics.	Moreover,	it	is	worth	noting	how	metabolomics	is	gaining	more	and	
more	 importance	 in	clinical	 research	given	 its	ability	to	examine	biological	aspects	that	are	hard	to	
investigate	through	conventional	techniques.	Hopefully,	 this	and	other	works	will	contribute	to	the	
adoption	of	metabolomics	techniques	in	routine	medical	practice.	
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